WO2004063163A1

WO2004063163A1 - 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands

Info

Publication number: WO2004063163A1
Application number: PCT/US2003/040942
Authority: WO
Inventors: John Robert Proudfoot; John Robinson Regan; David S. Thomson; Daniel Kuzmich; Thomas Wai-Ho Lee; Abdelhakim Hammach; Mark Stephen Ralph; Renee Zindell; Younes Bekkali; Thomas Martin Kirrane, Jr.
Original assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
Priority date: 2003-01-03
Filing date: 2003-12-18
Publication date: 2004-07-29
Also published as: KR20050109922A; UY28157A1; MXPA05006872A; AR042875A1; JP2006516256A; PE20040927A1; MY135423A; EP1583745A1; JP4373926B2; US20040162321A1; RU2005124558A; TW200418815A; IL169477A0; AU2003297471A1; BR0317928A; US7579469B2; CA2512257A1

Abstract

Compounds of Formula (I) wherein R1, R2 R3, R4, R5, R6, and X are as defiend herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocoricoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

Description

-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS

Field of the Invention

5 The present invention relates to glucocorticoid mimetics or ligands, methods of making such compounds, their use in pharmaceutical compositions, and their use in modulating the glucocorticoid receptor function, treating disease-states or conditions mediated by the glucocorticoid receptor function in a patient in need of such treatment, and other uses.

10 Background of the Invention

Glucocorticoids, a class of corticosteroids_. are endogenous hormones with profound effects on the immune system and multiple organ systems. They suppress a variety of immune and inflammatory functions by inhibition of inflammatory cytokines such as IL-1, IL-2, IL-6, and TNF, inhibition of arachidonic acid metabolites including prostaglandins and leukotrienes,

15 depletion of T-lymphocytes, and reduction of the expression of adhesion molecules on endothehal cells (P.J. Barnes, Clin. Sci., 1998, 94, PP- 557-572; PJ. Barnes et al, Trends Pharmacol. Sci., 1993, 14, pp. 436-441). In addition to these effects, glucocorticoids stimulate glucose production in the liver and catabolism of proteins, play a role in electrolyte and water balance, reduce calcium absorption, and inhibit osteoblast function.

20

The anti-inflammatory and immune suppressive activities of endogenous glucocorticoids have stimulated the development of synthetic glucocorticoid derivatives including dexamethasone, prednisone, and prednisolone (L. Parente, Glucocorticoids. NJ. Goulding and RJ. Flowers (eds.), Boston: Birkhauser, 2001, pp. 35-54). These have found wide use in the treatment of

25 inflammatory, immune, and allergic disorders including rheumatic diseases such as rheumatoid arthritis, juvenile arthritis, and ankylosing spondylitis, dermatological diseases including psoriasis and pemphigus, allergic disorders including allergic rhinitis, atopic dermatitis, and contact dermatitis, pulmonary conditions including asthma and chronic obstructive pulmonary disease (COPD), and other immune and inflammatory diseases including Crohn disease,

30 ulcerative colitis, systemic lupus erythematosus, autoimmune chronic active hepatitis, osteoarthritis, tendonitis, and bursitis (J. Toogood, Glucocorticoids. NJ. Goulding and RJ. Flowers (eds.), Boston: Birkhauser, 2001, pp. 161-174). They have also been used to help prevent rejection in organ transplantation. Unfortunately, in addition to the desired therapeutic effects of glucocorticoids, their use is associated with a number of adverse side effects, some of which can be severe and life- threatening. These include alterations in fluid and electrolyte balance, edema, weight gain, hypertension, muscle weakness, development or aggravation of diabetes mellitus, and osteoporosis. Therefore, a compound that exhibited a reduced side effect profile while maintaining the potent anti-inflammatory effects would be particularly desirable especially when treating a chronic disease.

The effects of glucocorticoids are mediated at the cellular level by the glucocorticoid receptor (R.H. Oakley and J. Cidlowski, Glucocorticoids. N J. Goulding and RJ. Flowers (eds.), Boston: Birkhauser, 2001, pp. 55-80). The glucocorticoid receptor is a member of a class of structurally related intracellular receptors that when coupled with a ligand can function as a transcription factor that affects gene expression (R.M. Evans, Science, 1988, 240, pp. 889-895). Other members of the family of steroid receptors include the mineralocorticoid, progesterone, estrogen, and androgen receptors. In addition to the effects mentioned above for glucocorticoids, hormones that act on this receptor family have a profound influence on body homeostasis, mineral metabolism, the stress response, and development of sexual characteristics. Glucocorticoids. NJ. Goulding and RJ. Flowers (eds.), Boston: Birkhauser, 2001, is hereby incoφorated by reference in its entirety to better describe the state of the art.

A molecular mechanism which accounts for the beneficial anti-inflammatory effects and the undesired side effects has been proposed (e.g., S. Heck et al, EMBO J, 1994, 17, pp. 4087- 4095; H.M. Reichardt et al, Cell, 1998, 93, pp. 531-541; F. Tranche et al, Curr. Opin. in Genetics and Dev., 1998, 8, pp. 532-538). Many of the metabolic and cardiovascular side effects are thought to be the result of a process called transactivation., In transactivation, the translocation of the ligand-bound glucocorticoid receptor to the nucleus is followed by binding to glucocorticoid response elements (GREs) in the promoter region of side effect-associated genes, for example, phosphoenolpyruvate carboxy kinase (PEPCK), in the case of increased glucose production. The result is an increased transcription rate of these genes which is believed to result, ultimately, in the observed side effects. The anti-inflammatory effects are thought to be due to a process called transrepression. In general, transrepression is a process independent of DNA binding that results from inhibition of NF-kB and AP-1 -mediated pathways, leading to down regulation of many inflammatory and immune mediators. Additionally, it is believed that a number of the observed side effects may be due to the cross- reactivity of the currently available glucocorticoids with other steroid receptors, particularly the mineralocorticoid and progesterone receptors.

Thus, it may be possible to discover ligands for the glucocorticoid receptor that are highly selective and, upon binding, can dissociate the transactivation and transrepression pathways, providing therapeutic agents with a reduced side effect profile. Assay systems to detennine effects on transactivation and transrepression have been described (e.g., CM. Bamberger and H.M. Schulte, Eur. J. Clin. Invest., 2000, 30 (suppl. 3), pp. 6-9). Selectivity for the glucocorticoid receptor may be determined by comparing the binding affinity for this receptor with that of other steroid family receptors including those mentioned above.

Glucocorticoids also stimulate the production of glucose in the liver by a process called gluconeogenesis and it is believed that this process is mediated by transactivation events. Increased glucose production can exacerbate type II diabetes, therefore a compound that selectivity inhibited glucocorticoid mediated glucose production may have therapeutic utility in this indication (J.E. Freidman et al, J. Biol. Chem., 1997, 272, pp. 31475-31481).

Novel ligands for the glucocorticoid receptor have been described in the scientific and patent literature. For example, PCT International Publication No. WO 99/33786 discloses triphenylpropanamide compounds with potential use in treating inflammatory diseases. PCT International Publication No. WO 00/66522 describes non-steroidal compounds as selective modulators of the glucocorticoid receptor potentially useful in treating metabolic and inflammatory diseases. PCT International Publication No. WO 99/41256 describes tetracyclic modulators of the glucocorticoid receptor potentially useful in treating immune, autoimmune, and inflammatory diseases. U.S. Patent No. 5,688,810 describes various non-steroidal compounds as modulators of glucocorticoid and other steroid receptors. PCT International Publication No. WO 99/63976 describes a non-steroidal, liver-selective glucocorticoid antagonist potentially useful in the treatment of diabetes. PCT International Publication No. WO 00/32584 discloses non-steroidal compounds having anti-inflammatory activity with dissociation between anti-inflammatory and metabolic effects. PCT International Publication No. WO 98/54159 describes non-steroidal cyclically substituted acylanilides with mixed gestagen and androgen activity. U.S. Patent No. 4,880,839 describes acylanilides having progestational activity and EP 253503 discloses acylanilides with antiandrogenic properties. PCT International Publication No. WO 97/27852 describes amides that are inlnbitors of farnesyl-protein transferase.

A compound that is found to interact with the glucocorticoid receptor in a binding assay could be an agonist or an antagonist. The agonist properties of the compound could be evaluated in the transactivation or transrepression assays described above. Given the efficacy demonstrated by available glucocorticoid drugs in inflammatory and immune diseases and their adverse side effects, there remains a need for novel glucocorticoid receptor agonists with selectivity over other members of the steroid receptor family and a dissociation of the transactivation and transrepression activities. Alternatively, the compound may be found to have antagonist activity. As mentioned above, glucocorticoids stimulate glucose production in the liver. Increased glucose production induced by glucocorticoid excess can exacerbate existing diabetes, or trigger latent diabetes. Thus a ligand for the glucocorticoid receptor that is found to be an antagonist may be useful, inter alia, for treating or preventing diabetes.

Summary of the Invention

The instant invention is directed to compounds of Formula (IA)

wherein:

R¹ is an aryl, heteroaryl, or C₅-C₁₅ cycloalkyl group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently C₁-C₅ alkyl, C₂-Cs alkenyl, C₂-Cs alkynyl, C -C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-Cs alkenyloxy, C₂-C5 alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C1-C₅ alkanoyloxy, C₁-C₅ alkanoyl, aroyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C5 dialkylaminocarbonyloxy, C₃- C₅ cycloalkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C5 alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C5 alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, oxo, carboxy, cyano, trifluoromethyl, trifluoromethoxy, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl or C3-C₅ cycloalkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with one to four substituent groups selected from aryl or heterocyclyl wherein the heterocycle is optionally independently substituted with hydroxyl, halogen, methyl, or dialkyl amino; C₁-C₅ alkoxycarbonyl, methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino wherein the nitrogen atom is optionally independently mono- or di- substituted by C₁-C₅ alkyl or C_-C₃ dialkylamines or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; aminosulfonyl, or oxime wherein the oxygen atom is optionally substituted by C₁-C₅ alkyl or benzyl.

R² and R³ are each independently hydrogen, C₁-C₅ alkyl, or C₅-C₁₅ arylalkyl group, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-C₈ spiro cycloalkyl ring, or

R¹ and R² when taken together are a chromanyl or dihydrobenzo iranyl optionally substituted with C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C]-C₅ alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C5 alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C₁-C5 alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone;

R⁴ is carbonyl or methylene optionally independently substituted with one to two substituent groups selected from C,-C₃ alkyl, hydroxy, and halogen;

R⁵ is a pyrrolidine, morpholine, thiomoφholine, piperazine, piperidine, lH-pyridin-4-one, lH-pyridin-2-one, lH-pyridin-4-ylideneamine, lH-quinolin-4-ylideneamine, pyran, tetrahydropyran, 1,4-diazepane, 2,5-diazabicyclo[2.2.1]heptane, 2,3,4,5- tetrahydrobenzo[b][l,4]diazepine, dihydroquinoline, tetrahydroquinoline, 5,6,7,8- tetrahydro-lH-quinolin-4-one, tetrahydroisoquinoline, decahydroisoquinoline, 2,3- dihydro-lH-isoindole, 2,3-dihydro-lH-indole, chroman, 1,2,3,4-tetrahydroquinoxaline, l,2-dihydroindazol-3-one, 3,4-dihydro-2H-benzo[l,4]oxazine, 4H-benzo[l,4]thiazine, 3 ,4-dihydro-2H-benzo[ 1 ,4]thiazine, 1 ,2-dihydrobenzo[(i] [1,3] oxazin-4-one, 3 ,4- dihydrobenzo[l,4]oxazin-4-one, 3H-quinazolin-4-one, 3,4-dihydro-lH-quinoxalin-2-one, lH-cinnolin-4-one, lH-quinazolin-4-one, lH-[l,5]naphthyridin-4-one, 5,6,7,8-tetrahydro- lH-[l,5]naphthyridin-4-one, 2,3-dihydro-lH-[l,5]naphthyridin-4-one, 1,2- dihydropyrido [3 ,2-d] [ 1 ,3 ]oxazin-4-one, pyrrolo [3 ,4-c]pyridine- 1 ,3 -dione, 1 ,2- dihydropyrrolo[3_.4-c]pyridin-3-one, or tetrahydro[b][l,4]diazepinone, group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁵ is independently C₁-C₅ alkyl, C₂-Cs alkenyl, C-C₅ alkynyl, C₃-Cs cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C_-C₅ alkoxycarbonyl, C₁-C₅ alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C.-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C1-C5 alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R⁵ is optionally independently substituted with one to three substituent groups selected from C_.-C₃ alkyl, Cj-C₃ alkoxy, Cj-C₃ alkoxycarbonyl, acyl, aryl, benzyl, heteroaryl, heterocyclyl, halogen, hydroxy, oxo, cyano, amino wherein the nitrogen atom is optionally independently mono- or di- substituted by C₁-C5 alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl;, or trifluoromethyl; and

X is a hydroxy or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C5 alkyl,

or a tautomer, prodrug, solvate, or salt thereof.

Another aspect of the invention includes compounds of Formula (IA), wherein:

R¹ is phenyl, dihydrobenzofuranyl, benzofuranyl, dihydroindolyl, indolyl, benzo[l,3]dioxole, dihydrobenzothienyl, benzothienyl, benzoxazole, benzisoxazole, benzpyrazole, benzimidazole, thienyl, quinolinyl, tetrahydroquinolinone, tetrahydronaphthyridinone, dihydrochromene, pyridinyl, pyrimidinyl, or pyrazinyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently Cj-C₃ alkyl, C₂-C₃ alkenyl, C -C₃ alkynyl, Cι-C₃ alkoxy, C -C₃ alkenyloxy, C-C₃ alkanoyl, Cι-C₃ alkoxycarbonyl, C_.-C₃ alkanoyloxy, halogen, hydroxy, acyl, oxo, carboxy, cyano, trifluoromethyl, nitro, or Ci- C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with a substituent group selected from methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino; R² and R³ are each independently hydrogen, Q-C₃ alkyl, benzyl, or phenethyl, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-Cβ spiro cycloalkyl ring; and

R⁴ is CH₂,

or a tautomer, prodrug, solvate, or salt thereof.

Yet another aspect of the invention includes compounds of Formula (IA), wherein:

R¹ is phenyl, pyridyl, dihydrobenzofuranyl, or benzofuranyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo, hydroxy, trifluoromethyl, acyl, oxo, C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone, or cyano;

R² and R³ are each independently methyl, or R² and R³ together with the carbon atom they are commonly attached to form a spiro cyclopropyl ring; and

R⁴ is CH₂,

or a tautomer, prodrug, solvate, or salt thereof.

R¹ is phenyl, dihydrobenzofuranyl, or benzofuranyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently Cj-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cj-C₃ alkoxy, C₂-C₃ alkenyloxy, Cι-C₃ alkanoyl, Cj-C₃ alkoxycarbonyl, Cj-C₃ alkanoyloxy, halogen, hydroxy, carboxy, cyano, trifluoromethyl, nitro, or C_-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone; and

R² and R³ are each independently hydrogen or Cj-C₃ alkyl,

or a tautomer, prodrug, solvate, or salt thereof.

An aspect of the invention includes compounds of Formula (IA), wherein:

R⁵ is a moφholine, thiomoφholine, piperazine, piperidine, lH-pyridin-4-one, pyran, tetrahydropyran, dihydroquinoline, tetrahydroquinoline, chroman, 1,2,3,4- tetrahydroquinoxaline, 3,4-dihydro-2H-benzo[l ,4]oxazine, 3,4-dihydro-2H- benzo [ 1 ,4]thiazine, 1 ,2-dihydrobenzo[Jj [ 1 ,3]oxazin-4-one, 3 ,4-dihydrobenzo [ 1 ,4]oxazin- 4-one, 3,4-dihydro-lH-quinoxalin-2-one, 3,4-dihydro-2H-naphthalen-l-one, lH-cinnolin- 4-one, lH-quinazolin-4-one, lH-[l,5]naphthyridin-4-one, 2,3-dihydro-lH-

[ 1 ,5]naphthyridin-4-one, 3 ,4-dihydro-2H-isoquinolin- 1 -one, 1 ,2-dihydropyrido[ ,2- c?][l,3]oxazin-4-one, pyrrolo[3,4-c]pyridine-l,3-dione, tetrahydro[έ][l,4]diazepinone, or l,2-dihydropyrrolo[3,4-c]pyridin-3-one group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁵ is independently Cj-Cs alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-C₅ alkenyloxy, C₂-Cs alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C₁-C₅ alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C5 alkylsulfonylamino, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C_-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone, wherein each substituent group of R⁵ is optionally independently substituted with one to three substituent groups selected from Cι-C₃ alkyl, C_-C₃ alkoxy, halogen, hydroxy, oxo, cyano, amino, or trifluoromethyl,

or a tautomer, prodrug, solvate, or salt thereof.

The following are representative compounds of Formula (IA) according to the invention:

0

040

0

04 0

l-[2-Hydroxy-4-(5-methanesulfonyl-2,3- dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2- hydroxy-4-methyl-2- trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one

1 -[4-(5-Chloro-2,3 -dihydrobenzofuran-7- yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one

l-[4-(5-Fluoro-2-methylρhenyl)-2- hydroxy-4-methyl-2- trifluoromethylpentyl]-3 -methyl- 1H- quinolin-4-one

04/063163

l-[4-(5-Fluoro-2-hydroxyphenyl)-2- hydroxy-4-methyl-2- trifluoromethylpentyl]-3,3-dimethyl-2,3- dihydro- lH-quinolin-4-one

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7- yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3,3-dimethyl-2,3- dihydro- lH-quinolin-4-one

l-[2-Hydroxy-4-(5-methanesulfonyl-2,3- dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-3,3-dimethyl-2,3- dihydro- lH-quinolin-4-one

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2- hydroxy-4-methyl-2- trifluoromethylpentyl] -3 ,3 -dimethyl-2,3 - dihydro- lH-quinolin-4-one

l-[4-(5-Fluoro-2-methylphenyl)-2- hydroxy-4-methyl-2- trifluoromethylpentyl]-3,3-dimethyl-2,3- dihydro- lH-quinolin-4-one

040

4-[4-(5-Fluoro-2-methoxyphenyl)-2- hydroxy-4-methyl-2- trifluoromexhylpentyl]-3- methoxycarbonylmethylpiperazine- 1 - carboxylic acid tert-butyl ester

2-(4-tert-Butylpiperazin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol

2-(3 -Dimethylaminopyrrolidin- 1 - ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol

1,1,1 -Trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methyl-2-pyrrolidin- 1 - ylmethylpentan-2-ol

1,1,1 -Trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methyl-2-piperidin- 1 - ylmethylpentan-2-ol

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2- hydroxy-4-methyl-2- trifluoromethylpentyl]-3-methyl-lH- [ 1 ,5]naphthyridin-4-one

l-(4-Benzo[l,3]dioxol-4-yl-2-hydroxy-4- methyl-2-trifluoromethylpentyl)-3-methyl- lH-[ 1 ,5]naphthyridin-4-one

or a tautomer, prodrug, solvate, or salt thereof.

Preferred compounds of Formula (IA) include the following:

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,6- dimethylpiperazine- 1 -carbaldehyde;

2-( 1 , 1 -Dioxo-2,3 -dihydro- IH- 1 λ⁶-benzo [ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

2-(2,6-Dimethylmoφholin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-(2,3-Dihydrobenzo[ 1 ,4]oxazin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-xrifluoromethylpentyl]-3,5- dimethylpiperidin-4-one; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-cinnolin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,3-dihydro- lH-quinolin-4-one;

l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(3-Fluoro-4-methylphenyl)-2-hydroxy-4-mexhyl-2 -trifluoromethylpentyl]- lH-quinolin-4- one;

l-[4-(4-Fluoro-2-hyα roxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quirιolin-4- one;

l-[4-Phenyl-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Bromo-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -[4-(5-Methyl-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one; l-[4-(5-Chloro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2,3-Dihyάrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-2,4-dimethylpentyl]-3,5-dimethyl-lH-pyridin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-( 1 -oxo-2,3-dihydro- IH- lλ⁴- benzo[ 1 ,4]thiazin-4-ylmethyl)pentan-2-ol;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-2-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(6-Bromobenzo[l,3]dioxol-4-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3 -methyl- 1H- quinolin-4-one;

l-[2-Ηydroxy-4-(4-hydroxybiphenyl-3-yl)-4-methyl-2-xrifluoromethylpentyl]-lH-quinolin-4- one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-hydroxyphenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl} - lH-quinolin-4-one; l-[2-Hydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-methoxyphenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]- lH-[ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-methyl-4-(3-pyridin-3-ylphenyl)-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-moφholin-4-ylmethylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-moφholin-4-ylmethylphenyl)-4-methyl-2- trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-hydroxymethyl-2-methoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

4-Methoxy-3 -[4,4,4-trifluoro-3-hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzaldehyde;

l-[4-(5-[l,3]Dioxan-2-yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(5-Furan-3-yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- IH-quinazolin- 4-one;

l-[2-Ηydroxy-4-(4-methoxybiphenyl-3-yl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(5-Acetyl-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[3,3,3-Trifluoro-2-(6-fluoro-4-methylchroman-4-y]methyl)-2-hydroxypropyl]-lH-quinolin-4- one;

1 -(4- {3-[ 1 -(Benzyloxyimino)ethyl]phenyl} -2-hydroxy-4-methyl-2 -trifluoromethylpentyl)- 1H- quinolin-4-one;

l-[4-(3-Cyclopropanecarbonylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Acetyl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-(2-Ηydroxy-4-{3-[l-(methoxyimino)ethyl]phenyl}-4-methyl-2-trifluoromethylpentyl)-lH- quinolin-4-one;

l-[4-(5-Bromo-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one; l-(2-Hydroxy-4-{3-[l-(hydroxyimino)ethyl]phenyl}-4-methyl-2-trifluoromethylpentyl)-lH- quinolin-4-one;

l-[4-(5-Bromo-2-memoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(3,5-Difluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

1 - {2-Ηydroxy-4-methyl-4-[3 -(2-methyl-[ 1 ,3]dioxolan-2-yl)phenyl]-2-trifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

1 -[2-Ηydroxy-4-(3-hydroxymethylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4- one;

1 -[4-(3 -[ 1 ,3]Dioxan-2-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4- one;

l-[4-(3-Acetylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-{4-[3-(3,5-Dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5-dimethyl- lH-pyridin-4-one; l-{2-Hydroxy-4-[3-(l-hydroxyethyl)phenyl]-4-methyl-2-trifluoromethylpentyl}-lH-quinolin- 4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hyαjroxy-4-me yl-2-tjrifluoromethylpenxyl]-3,5-dimexhyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3 ,5-dimethyl- lH-pyridin-4-one;

3 -[4,4,4-Trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzaldehyde;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3 ,5-dimethyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- hydroxymethyl- lH-quinolin-4-one;

l-[4-(3-Bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydrox3φhenyl)-2-hydroxy-4-methyl-2-xrifluoromethylpentyl]-7-hydroxy-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-6-methyl-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- hydroxymethyl- lH-quinolin-4-one;

6-Chloro- 1 -[4-(5-fluoro-2-hydiOxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one; l-[-4-(2-Difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -(4-Biphenyl-3 -yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)- lH-quinolin-4-one;

6-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-methylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-{2-Ηydroxy-4-methyl-4-[3-(2-oxopropoxy)phenyl]-2-trifluoromethylpentyl}-lH-quinolin-4- one;

l-[2-Ηydroxy-4-(3-isopropoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(3 -Ethoxyphenyl)-2-hydiOxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

1 -[2-Ηydroxy-4-(2 -methoxy-5-methylphenyl)-4-methyl-2 -trifluoromethylpentyl]- IH-quinolin- 4-one;

l-[4-(2,5-Dimethylphenyl)-2-hy<rkoxy-4-memyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(3-hydroxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(3-methoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-l,2- dihydroindazol-3-one; 7-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5-dimethyl- lH-pyridin-4-one;

7-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -(2-Ηydroxy-4-methyl-4-phenyl-2-trifluoromethylhexyl)- lH-quinolin-4-one;

l-[4-(4-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

1 -[4-(3 ,4-Dimethylphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

8-Fluoro- 1 -[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-xrifluoromethylpentyl]- 1H- quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 - {4-[5-Fluoro-2-(2-oxopropoxy)phenyl]-2-hydroxy-4-methyl-2 -trifluoromethylpentyl} - 1H- quinolin-4-one;

7-Chloro- 1 -[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[4-(5-Fluoro-2-isopropoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(2-Benzyloxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(2-Ethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

8-Fluoro- 1 -[4-(5 -fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydiOxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηyαroxy-4-(5-methanesulfonyl-2,3-ώ^ydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfinyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl] - lH-quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7-yl)-2- trifluoromethylpentyl]- lH-quinolin-4-one;

7-Chloro- 1 -[4-(5-fluoro-2 -methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

1 -[4-(3-Fluoro-4-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-nitro-5- trifluoromethyl- lH-pyridin-2-one;

3-Chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-5- trifluoromethyl- lH-pyridin-2-one; 2-(2,3-Dihydroindol- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

1 -[2-Hydroxy-4-methyl-4-(3-moφholin-4-ylmethylphenyl)-2-trifluoromethylρentyl]- IH- quinolin-4-one;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]piperazin-l- yl} furan-2-ylmethanone;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl] -3 -methyl- lH-quinolin-4-one ;

2-[4-(3 -Chloro-5 -trifluoromethylpyridin-2-yl)piperazin- 1 -ylmethyl]- 1 ,1,1 -trifluoro-4-(5-fluoro- 2-methoxyphenyl)-4-methylpentan-2-ol;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]piperazin-l- yl} furan-2-ylmethanone;

l-[2-Ηydroxy-4-(2-methoxy-5-pyridin-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3-[l,3]Dioxan-2-yl-4-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l.[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(5-Fluoro-2-me ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(2,4-dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(4-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(3-Fluoro-4-memoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

1 -(4-Benzo[ 1 ,3]dioxol-4-yl-2-hydroxy-4-methyl~2-trifluoromethylpentyl)- lH-quinolin-4-one;

1 -[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1 ,2- dihydroindazol-3-one;

2-(3 ,4-Dihydro-2H-quinoxalin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5 -fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-methyl-3 ,4-dihydro-2H- quinoxalin- 1 -ylmethyl)pentan-2-ol;

2-(2,3-Dihydrobenzo[l ,4]thiazin-4-ylmethyl)-l , 1 , 1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl} ethanone; l-[2-Hydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyridin-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; and

Carbonic acid 4-fluoro-2-[4,4,4-trifluoro-3-hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]phenyl ester methyl ester,

or a tautomer, prodrug, solvate, or salt thereof.

More preferred compounds of Formula (IA) include the following:

2-(2,6-Dimethylmoφholin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-mexhoxyphenyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-memoxyphenyl)-2-hyαjroxy-4-methyl-2-teifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethylpiperidin-4-one; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

l-[4-(4-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-Phenyl-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2,3-dihy(lrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Bromo-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-xrifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Methyl-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -[4-(5-Chloro-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- IH- quinolin-4-one;

l-[4-(2,3-Dihyαjrobenzofuran-7-yl)-2-hyαjroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-2,4-dimethylpentyl]-3,5-dimethyl-lH-pyridin-4- one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(4-hydroxybiphenyl-3-yl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-hydroxyphenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl} - lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

4-Methoxy-3 -[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzaldehyde;

l-[2-Ηydroxy-4-(4-methoxybiphenyl-3-yl)-4-methyl-2-xrifluoromexhylpentyl]-lH-quinolin-4- one;

l-[4-(5-Acetyl-2-hydroxyphenyl)-2-hy(hOxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[3,3,3-Trifluoro-2-(6-fluoro-4-methylc]πoman-4-yhnethyl)-2-hydroxypropyl]-lH-quinolin-4- one;

l-(4-{3-[l-(Benzyloxj mino)ethyl]phenyl}-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-lH- quinolin-4-one;

1 -(2-Ηydroxy-4- { 3 -[ 1 -(methoxyimino)ethyl]phenyl } -4-methyl-2-trifluoromethylpentyl)- 1H- quinolin-4-one;

l-[4-(5-Bromo-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

1 -(2-Ηydroxy-4- {3 -[ 1 -(hydroxyimino)ethyl]phenyl} -4-methyl-2 -trifluoromethylpentyl)- 1H- quinolin-4-one;

l-[4-(5-Bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(3,5-Difluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one; l-[4-(3,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

1 - {2-Ηydroxy-4-methyl-4-[3-(2-methyl-[ 1 ,3]dioxolan-2-yl)phenyl]-2 -trifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(2,3-Dihydrobenzo&ran-7-yl)-2-hydroxy-4-methyl-2-xrifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

l-[4-(3-[l,3]Dioxan-2-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydiOxy-4-methyl-2-trifluoromethylpentyl]-3,5-dimethyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-metiιoxyphenyl)-2-hyάiOxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(3-Bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-qumolin-4-one;

6-Chloro-l-[4-(5-fluoro-2-hydiOxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[-4-(2-Difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-(4-Biphenyl-3-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-lH-quinolin-4-one;

1 -[2-Ηydroxy-4-(3 -isopropoxyphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(3-Ethoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-methylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(2,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-l,2- dihydroindazol-3 -one;

7-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3 ,5-dimethyl- lH-pyridin-4-one;

l-(2-Ηydroxy-4-methyl-4-phenyl-2-trifluoromethylhexyl)-lH-quinolin-4-one; l-[4-(4-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

8-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quirιolin-4-one;

l-[4-(5-Fluoro-2-isopropoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

8-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7-yl)-2- trifluoromethylpentyl]-lH-quinolin-4-one; 7-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one;

3-Chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-5- trifluoromethyl- lH-pyridin-2-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-3 -methyl- lH-quinolin-4-one;

l-[4-(3-[l,3]Dioxan-2-yl-4-fluorophenyl)-2-hydiOxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

2-( 1 , 1 -Dioxo-2,3 -dihydro- 1Η- lλ⁶-benzo[ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydiOxy-4-methyl-2-trifluoromethylpentyl]-lH- [l,5]naphthyridin-4-one; l-[4-(5-Fluoro-2-memylphenyl)-2-hydroxy-4-methyl-2-tiifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(3-Fluoro-4-methoxyphenyl)-2-hyαjroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-(4-Benzo[l,3]dioxol-4-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-lH-quinolin-4-one;

1 -[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1 ,2- dihydroindazol-3 -one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-( 1 -oxo-2,3-dihydro- IH- lλ⁴- benzo[l,4]thiazin-4-ylmethyl)pentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyτidin-4-one;

l-[2-Ηyαj-oxy-4-(2-methoxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyridin-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; and l-[2-Hyαj-oxy-4-(2-hydroxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one,

or a tautomer, prodrug, solvate, or salt thereof.

The invention also provides a method of making a compound of Formula (IA)

where R , R , R , R , and X are as defined above and R is -CΗ₂-, the method comprising:

(a) reacting an ester of Formula (II) with a suitable reducing agent in a suitable solvent to form a diol of Formula (III)

reduction

(b) reacting the diol of Formula (III) with a sulfonic acid chloride, R'S0₂C1 to form a sulfonic acid ester of Formula (IN)

in ιv ;

(c) reacting the intermediate of Formula (IN) with a suitable base to form the epoxide of Formula (N)

IV V ; and (d) reacting the epoxide of Formula (N) with the desired R⁵H to form the compound of Formula (IA)

V IA (R⁴ = CH₂ X = OH)

In addition, the invention also provides a method of making a compound of Formula (IA)

where R¹, R², R³, R⁵, and X are as defined above and R⁴ is -C(O)-, the method comprising:

(a) hydrolyzing the ester of Formula (II) to produce the carboxylic acid of Formula (X)

Hydrolysis

X and

(b) coupling the carboxylic acid of Formula (X) with R⁵H to provide the desired compound of Formula (I)

X IA (R⁴ = -C(O)-, X = OH)

The instant invention is directed to compounds of Formula (IB)

wherein:

R is an aryl, heteroaryl, or C₅-C₁₅ cycloalkyl group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently C₁-C5 alkyl, C-C5 alkenyl, C₂-C5 alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C5 alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, Q-C₅ alkoxycarbonyl, C1-C5 alkanoyloxy, C₁-C₅ alkanoyl, aroyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, Cj- C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, oxo, carboxy, cyano, trifluoromethyl, trifluoromethoxy, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C_.-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with one to three substituent groups selected from aryl or heterocyclyl wherein the heterocycle is optionally independently substituted with hydroxyl, halogen, methyl, dialkyl amino; methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl or Cι-C₃dialkylamines or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; aminosulfonyl, oxime wherein the oxygen atom is optionally substituted by C₁-C₅ alkyl or benzyl. R² and R³ are each independently hydrogen, C₁-C5 alkyl, or C₅-C_₅ arylalkyl group, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-Cs spiro cycloalkyl ring, or

R¹ and R² when taken together are a chromanyl or dihydrobenzofuranyl optionally substituted with C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-Cs alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C₁-C5 alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C1-C5 alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C5 alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C-C5 alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with Q-C₅ alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone;

R⁴ is carbonyl or methylene optionally independently substituted with one to two substituent groups selected from Cι-C alkyl, hydroxy, and halogen;

R⁵ is a pyrrolidine, moφholine, thiomoφholine, piperazine, piperidine, lH-pyridin-4-one, lH-pyridin-2-one, lH-pyridin-4-ylideneamine, lH-quinolin-4-ylideneamine, pyran, tetrahydropyran, 1,4-diazepane, 2,5-diazabicyclo[2.2.1]heptane, 2,3,4,5- tetrahydrobenzo[b][l,4]diazepine, dihydroquinoline, tetrahydroquinoline, 5,6,7,8- tetrahydro-lH-quinolin-4-one, tetrahydroisoquinoline, decahydroisoquinoline, 2,3- dihydro-lH-isoindole, 2,3 -dihydro- lH-indole, chroman, 1,2,3,4-tetrahydroquinoxaline, l,2-dihydroindazol-3-one, 3,4-dihydro-2H-benzo[l,4]oxazine, 4H-benzo[l,4]thiazine, 3,4-dihydro-2H-benzo[ 1 ,4]thiazine, 1 ,2-dihydrobenzo[fi] [ 1 ,3]oxazin-4-one, 3 ,4- dihydrobenzo[l,4]oxazin-4-one, 3H-quinazolin-4-one, 3,4-dihydro-lH-quinoxalin-2-one, lH-cinnolin-4-one, lH-quinazolin-4-one, lH-[l,5]naphthyridin-4-one, 5,6,7,8- tetrahydro- lH-[ 1 ,5]naphxhyridin-4-one, 2,3-dihydro- lH-[ 1 ,5]naphthyridin-4-one, 1 ,2- dihydropyrido [3 ,2-d] [ 1 ,3 ] oxazin-4-one, pyrrolo [3 ,4-c]pyridine- 1 ,3 -dione, 1,2- dihydropyrrolo[3,4-c]pyridin-3-one, or tetrahydro[έ][l,4]diazepinone, group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁵ is independently C₁-C₅ alkyl, C__.-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C1-C5 alkoxycarbonyl, C₁-C₅ alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, Q-C₅ alkylaminocarbonyloxy, C₁-C5 dialkylaminocarbonyloxy, C_.-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or Cj-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R⁵ is optionally independently substituted with one to three substituent groups selected from C_-C₃ alkyl, Cι-C₃ alkoxy, Cι-C₃ alkoxy carbonyl, acyl, benzyl, heteroaryl, heterocyclyl, halogen, hydroxy, oxo, cyano, amino wherein the nitrogen atom is optionally independently mono- or di- substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl, or trifluoromethyl; and

is hydrogen, Q-Cg alkyl, C₂-Cs alkenyl, C₂-Cs alkynyl, carbocycle, heterocyclyl, aryl, heteroaryl, carbocycle-Q-Cg alkyl, carboxy, alkoxycarbonyl, aryl-Cj-Cg alkyl, aryl-Cj-Cg haloalkyl, heterocyclyl-Cj-Cs alkyl, heteroaryl-Cj-Cg alkyl, carbocycle-C₂-Cg alkenyl, aryl-C₂-C₈ alkenyl, heterocyclyl-C₂-C₈ alkenyl, or heteroaryl-C₂-C₈ alkenyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁶ is independently C_-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, phenyl, C₁-C5 alkoxy, phenoxy, C₁-C₅ alkanoyl, aroyl, C₁-C₅ alkoxycarbonyl, C₁-C5 alkanoyloxy, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy,

C₁-C5 dialkylaminocarbonyloxy, aminocarbonyl, C₁-C₅ alkylaminocarbonyl, C₁-C₅ dialkylaminocarbonyl, C1-C5 alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, C_-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, cyano, oxo, trifluoromethyl, nitro, amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C5 alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with Cj-C₅ alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein R⁶ cannot be trifluoromethyl,

X is a hydroxy or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl,

or a tautomer, prodrug, solvate, or salt thereof.

Another aspect of the invention includes compounds of Formula (IB), wherein:

wherein each substituent group of R¹ is independently Cj-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cj-C₃ alkoxy, C₂-C alkenyloxy, Cj-C₃ alkanoyl, Cj-C₃ alkoxycarbonyl, Cι-C₃ alkanoyloxy, halogen, hydroxy, acyl, oxo, carboxy, cyano, trifluoromethyl, nitro, or Cj-

C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with a substituent group selected from methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino; R² and R³ are each independently hydrogen, Cι-C₃ alkyl, benzyl, or phenethyl, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-C₆ spiro cycloalkyl ring;

R⁴ is CH₂; and

R⁶ is C₁-C₅ alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl, phenyl, C₃-C₆ cycloalkyl-Cj-C₃ alkyl, phenyl-Cj-C₃ alkyl, phenyl-Cι-C₃ haloalkyl, C₃-C₆ cycloalkyl-C₂-C₃ alkenyl, phenyl-C₂- C₃ alkenyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁶ is independently C]-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cι-C alkoxy, aminocarbonyl, Cι-C₃ alkylaminocarbonyl, C_-C₃ dialkylaminocarbonyl, halogen, hydroxy, oxo, carboxy, cyano, trifluoromethyl, nitro, or Cι-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein R⁶ cannot be trifluoromethyl,

or a tautomer, prodrug, solvate, or salt thereof.

Yet another aspect of the invention includes compounds of Formula (IB), wherein:

R² and R³ are each independently methyl, or R² and R together with the carbon atom they are commonly attached to form a spiro cyclopropyl ring; and R⁴ is CH₂,

or a tautomer, prodrug, solvate, or salt thereof.

wherein each substituent group of R¹ is independently Cj-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cj-C₃ alkoxy, C₂-C₃ alkenyloxy, Cj-C₃ alkanoyl, Cj-C₃ alkoxycarbonyl, Cj-C₃ alkanoyloxy, halogen, hydroxy, carboxy, cyano, trifluoromethyl, nitro, or C_.-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone; and

R² and R³ are each independently hydrogen or Cι-C₃ alkyl,

or a tautomer, prodrug, solvate, or salt thereof.

An aspect of the invention includes compounds of Formula (IB), wherein:

R⁵ is a moφholine, thiomoφholine, piperazine, piperidine, lH-pyridin-4-one, pyran, tetrahydropyran, dihydroquinoline, tetrahydroquinoline, chroman, 1,2,3,4- tetrahydroquinoxaline, 3,4-dihydro-2H-benzo[l,4]oxazine, 3,4-dihydro-2H- benzo[l,4]thiazine, l,2-dihychobenzo[d][l,3]oxazin-4-one, 3,4-dihydrobenzo[l,4]oxazin- 4-one, 3,4-dihydro-lH-quinoxalin-2-one, 3,4-dihydro-2H-naphthalen-l-one, lH-cinnolin-

4-one, lH-quinazolin-4-one, lH-[l,5]naphthyridin-4-one, 2,3-dihydro-lH-

[ 1 ,5]naphthyridin-4-one, 3 ,4-dihydro-2H-isoquinolin- 1 -one, 1 ,2-dihydropyrido[3 ,2- d][l,3]oxazin-4-one, pyrrolo[3,4-c]pyridine-l,3-dione, tetrahydro[b][l,4]diazepinone, or l,2-dihydropyrrolo[3,4-c]pyridin-3-one group, each optionally independently substituted with one to three substituent groups, wherein each substituent group of R is independently C₁-C5 alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C5 alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C]-C₅ alkoxycarbonyl, C1-C5 alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C5 dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, Cj-C₅ alkylsulfonylamino, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R⁵ is optionally independently substituted with one to three substituent groups selected from Cj-C₃ alkyl, Cj-C₃ alkoxy, halogen, hydroxy, oxo, cyano, amino, or trifluoromethyl; and

R⁶ is C₁-C₅ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkylmethyl-, or benzyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁶ is independently methyl, methoxy, fluoro, chloro, bromo, cyano, trifluoromethyl, or hydroxy,

wherein R⁶ cannot be trifluoromethyl,

or a tautomer, prodrug, solvate, or salt thereof.

The following are representative compounds of Formula (IB) according to the invention:

Preferred compounds of Formula (IB) include:

l-[2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin-4- one; and

l-[2-Difluoromethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin-4- one,

or a tautomer, prodrug, solvate, or salt thereof.

The invention also provides a method of making a compound of Formula (IB)

where R¹, R², R³, R⁵, R⁶, and X are as defined above and R⁴ is -CH₂-, the method comprising:

(a) reacting a compound of Formula (IA) with a suitable base in a suitable solvent to form a ketone of Formula (IIB)

IA IIB

(b) reacting the ketone of Formula (IIB) with a organometallic reagent to form a compound of Formula (IB)

IIB IB (R⁴ = CH₂; X = OH)

In another aspect of the invention, the compounds according to the invention are formulated into pharmaceutical compositions comprising an effective amount, preferably a pharmaceutically effective amount, of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof, and a pharmaceutically acceptable excipient or carrier.

The invention also provides a method of modulating the glucocorticoid receptor function in a patient, the method comprising administering to the patient an effective amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.

The invention further provides a method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.

In addition, the invention also provides a method of treating a disease-state or condition selected from: type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof.

The invention provides a method of treating a disease characterized by inflammatory, allergic, or proliferative processes, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof. In a preferred embodiment of the invention, the disease characterized by inflammatory, allergic, or proliferative processes is selected from: (i) lung diseases; (ii) rheumatic diseases or autoimmune diseases or joint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft-versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis. In another preferred embodiment of the invention, the disease characterized by inflammatory, allergic, or proliferative processes is selected from: type I diabetes, osteoarthritis, Guillain- Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone resoφtion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis, and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.

The invention further provides methods of treating the disease-states or conditions mentioned above, in a patient in need of such treatment, the methods comprising sequentially or simultaneously administering to the patient: (a) an effective amount of a pharmaceutically acceptable compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) a pharmaceutically acceptable glucocorticoid.

The invention further provides a method of assaying the glucocorticoid receptor function in a sample, comprising: (a) contacting the sample with a selected amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) detecting the amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof bound to glucocorticoid receptors in the sample. In a preferred embodiment of the invention, the compound according to the invention or a tautomer, prodrug, solvate, or salt tiiereof is labeled with a detectable marker selected from: a radiolabel, fluorescent tag, a chemiluminescent tag, a chromophore, and a spin label.

The invention also provides a method of imaging the glucocorticoid receptor distribution in a sample or patient, the method comprising: (a) contacting the sample or administering to a patient a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker; (b) detecting the spatial distribution and amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker bound to glucocorticoid receptors in the sample or patient using an imaging means to obtain an image; and (c) displaying an image of the spatial distribution and amount of the compound according to the invention or a tautomer, prodrug, solvate, or salt thereof having a detectable marker bound to glucocorticoid receptors in the sample. In a preferred embodiment of the invention, the imaging means is selected from: radioscintigraphy, nuclear magnetic resonance imaging (MRI), computed tomography (CT scan), or positron emission tomography (PET).

The invention also provides a kit for the in vitro diagnostic determination of the glucocorticoid receptor function in a sample, comprising: (a) a diagnostically effective amount of a compound according to the invention or a tautomer, prodrug, solvate, or salt thereof; and (b) instructions for use of the diagnostic kit. Detailed Description of the Invention Definition of Terms and Conventions Used

Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification and appended claims, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

A. Chemical Nomenclature, Terms, and Conventions

In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, C_J-C_JO alkyl means an alkyl group or radical having

1 to 10 carbon atoms. The term "lower" applied to any carbon-containing group means a group containing from 1 to 8 carbon atoms, as appropriate to the group (i.e., a cyclic group must have at least 3 atoms to constitute a ring). In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for example, "alkylaryl" means a monovalent radical of the formula Alk-Ar-, while "arylalkyl" means a monovalent radical of the formula Ar-Alk- (where Alk is an alkyl group and Ar is an aryl group). Furthermore, the use of a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa. Unless otherwise specified, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.

The terms "alkyl" or "alkyl group" mean a branched or straight-chain saturated aliphatic hydrocarbon monovalent radical. This term is exemplified by groups such as methyl, ethyl, n- propyl, 1-methylethyl (isopropyl), «-butyl, «-pentyl, 1,1-dimethylethyl (tert-butyl), and the like. It may be abbreviated "Alk".

The terms "alkenyl" or "alkenyl group" mean a branched or straight-chain aliphatic hydrocarbon monovalent radical containing at least one carbon-carbon double bond. This term is exemplified by groups such as ethenyl, propenyl, n-butenyl, isobutenyl, 3-methylbut-2-enyl, λz-pentenyl, heptenyl, octenyl, decenyl, and the like. The terms "alkynyl" or "alkynyl group" mean a branched or straight-chain aliphatic hydrocarbon monovalent radical containing at least one carbon-carbon triple bond. This term is exemplified by groups such as ethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n- pentynyl, heptynyl, octynyl, decynyl, and the like.

The terms "alkylene" or "alkylene group" mean a branched or straight-chain saturated aliphatic hydrocarbon divalent radical having the specified number of carbon atoms. This term is exemplified by groups such as methylene, ethylene, propylene, rc-butylene, and the like, and may alternatively and equivalently be denoted herein as -(alkyl)-.

The terms "alkenylene" or "alkenylene group" mean a branched or straight-chain aliphatic hydrocarbon divalent radical having the specified number of carbon atoms and at least one carbon-carbon double bond. This term is exemplified by groups such as ethenylene, propenylene, H-butenylene, and the like, and may alternatively and equivalently be denoted herein as -(alkylenyl)-.

The terms "alkynylene" or "alkynylene group" mean a branched or straight-chain aliphatic hydrocarbon divalent radical containing at least one carbon-carbon triple bond. This term is exemplified by groups such as ethynylene, propynylene, /z-butynylene, 2-butynylene, 3- methylbutynylene, H-pentynylene, heptynylene, octynylene, decynylene, and the like, and may alternatively and equivalently be denoted herein as -(alkynyl)-.

The terms "alkoxy" or "alkoxy group" mean a monovalent radical of the formula AlkO-, where Alk is an alkyl group. This term is exemplified by groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentoxy, and the like.

The terms "aryloxy", "aryloxy group", mean a monovalent radical of the formula ArO-, where Ar is aryl. This term is exemplified by groups such as phenoxy, naphthoxy, and the like.

The term "oxo" means a double-bonded divalent oxygen radical of the formula (=0), For instance, one example of an alkyl group substituted by an "oxo" would be a group of the formula Alk-C(0)-Alk, wherein each Alk is an alkyl. The terms "alkylcarbonyl", "alkylcarbonyl group", "alkanoyl", or "alkanoyl group" mean a monovalent radical of the formula AlkC(O)-, where Alk is alkyl or hydrogen.

The terms "arylcarbonyl", "arylcarbonyl group", "aroyl" or "aroyl group" mean a monovalent radical of the foπnula ArC(O)-, where Ar is aryl.

The terms "acyl" or "acyl group" mean a monovalent radical of the formula RC(O)-, where R is a substituent selected from hydrogen or an organic substituent. Exemplary substituents include alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, and the like. As such, the terms comprise alkylcarbonyl groups and arylcarbonyl groups.

The terms "acylamino" or "acylamino group" mean a monovalent radical of the formula RC(0)N(R)-, where each R is a substituent selected from hydrogen or a substituent group.

The terms "alkoxycarbonyl" or "alkoxycarbonyl group" mean a monovalent radical of the formula AlkO-C(O)-, where Alk is alkyl. Exemplary alkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl, tert-butyloxycarbonyl, and the like.

The terms "aryloxycarbonyl" or "aryloxycarbonyl group" mean a monovalent radical of the formula ArO-C(O)-, where Ar is aryl.

The terms "alkylcarbonyloxy" or "alkylcarbonyloxy group" or "alkanoyloxy" or "alkanoyloxy group" mean a monovalent radical of the formula AlkC(0)0-, where Alk is alkyl.

The terms "arylcarbonyloxy" or "arylcarbonyloxy group" or "aroyloxy" or "aroyloxy group" mean a monovalent radical of the formula ArC(0)0-, where Ar is aryl.

The terms "alkylaminocarbonyloxy" or "alkylaminocarbonyloxy group" mean a monovalent radical of the formula R₂NC(0)0-, where each R is independently hydrogen or lower alkyl. The term "alkoxycarbonylamino" or "alkoxycarbonylamino group" mean a monovalent radical of the formula ROC(0)NH-, where R is lower alkyl.

The terms "alkylcarbonylamino" or "alkylcarbonylamino group" or "alkanoylamino" or "alkanoylamino groups" mean a monovalent radical of the formula AlkC(0)NH-, where Alk is alkyl. Exemplary alkylcarbonylamino groups include acetamido (CH₃C(0)NH-).

The terms "alkylaminocarbonyloxy" or "alkylaminocarbonyloxy group" mean a monovalent radical of the formula AlkNHC(0)0-, where Alk is alkyl.

The terms "amino" or "amino group" mean an -NH₂ group.

The terms "alkylamino" or "alkylamino group" mean a monovalent radical of the formula (Alk)NH-, where Alk is alkyl. Exemplary alkylamino groups include methylamino, ethylamino, propylamino, butylamino, tert-butylamino, and the like.

The terms "dialkylarnino" or "dialkylarnino group" mean a monovalent radical of the formula (Alk)(Alk)N-, where each Alk is independently alkyl. Exemplary dialkylarnino groups include dimethylamino, methylethylamino, diethylamino, dipropylamino, ethylpropylamino, and the like.

The terms "substituted amino" or "substituted amino group" mean a monovalent radical of the formula -NR₂, where each R is independently a substituent selected from hydrogen or the specified substituents (but where both Rs cannot be hydrogen). Exemplary substituents include alkyl, alkanoyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, and the like.

The terms "alkoxycarbonylamino" or "alkoxycarbonylamino group" mean a monovalent radical of the formula AlkOC(0)NH-, where Alk is alkyl.

The terms "ureido" or "ureido group" mean a monovalent radical of the formula R₂NC(0)NH-, where each R is independently hydrogen or alkyl. The terms "halogen" or "halogen group" mean a fluoro, chloro, bromo, or iodo group.

The term "halo" means one or more hydrogen atoms of the group are replaced by halogen groups.

The terms "haloalkyl" or "haloalkyl group" mean a branched or straight-chain saturated aliphatic hydrocarbon monovalent radical, wherein one or more hydrogen atoms thereof are each independently replaced with halogen atoms. This term is exemplified by groups such as chloromethyl, 1,2-dibromoethyl, 1,1,1-trifluoropropyl, 2-iodobutyl, l-chloro-2-bromo-3- fluoropentyl, and the like.

The terms "sulfanyl", "sulfanyl group", "thioether", or "thioether group" mean a divalent radical of the formula -S-.

The terms "alkylthio" or "alkylthio group" mean a monovalent radical of the formula AlkS-, where Alk is alkyl. Exemplary groups include methylthio, ethylthio, «-propylthio, isopropylthio, rc-butylthio, and the like.

The terms "arylthio" or "arylthio group" mean a monovalent radical of the formula ArS-, where Ar is aryl.

The terms "sulfinyl", "sulfinyl group", "thionyl", or "thionyl group" mean a divalent radical of the formula -SO-.

The terms "sulfonyl" or "sulfonyl group" mean a divalent radical of the formula -S0₂-.

The terms "sulfonylamino" or "sulfonylamino group" mean a divalent radical of the formula -S0₂NR-, where R is a hydrogen or a substituent group.

The terms "aminosulfonyl" or "aminosulfonyl group" mean a monovalent radical of the formula NR₂SO₂-, where R is each independently a hydrogen or a substituent group. The terms "carbocycle" or "carbocyclic group" mean a stable aliphatic 3- to 15-membered monocyclic or polycyclic monovalent or divalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7- membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the carbocycle may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. The term comprises cycloalkyl (including spiro cycloalkyl), cycloalkylene, cycloalkenyl, cycloalkenylene, cycloalkynyl, and cycloalkynylene, and the like.

The terms "cycloalkyl" or "cycloalkyl group" mean a stable aliphatic saturated 3- to 15- membered monocyclic or polycyclic monovalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7- membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornanyl, adamantyl, tetrahydronaphthyl (tetralin), 1-decalinyl, bicyclo[2.2.2]octanyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2- methylcyclooctyl, and the like.

The terms "cycloalkenyl" or "cycloalkenyl group" mean a stable aliphatic 3- to 15-membered monocyclic or polycyclic monovalent radical having at least one carbon-carbon double bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkenyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary cycloalkenyl groups include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, norbornenyl, 2- methylcyclopentenyl, 2-methylcyclooctenyl, and the like. The terms "cycloalkynyl" or "cycloalkynyl group" mean a stable aliphatic 8- to 15-membered monocyclic or polycyclic monovalent radical having at least one carbon-carbon triple bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 8- to 10-membered monocyclic or 12- to 15-membered bicyclic ring. Unless otherwise specified, the cycloalkynyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary cycloalkynyl groups include, cyclooctynyl, cyclononynyl, cyclodecynyl, 2-methylcyclooctynyl, and the like.

The terms "cycloalkylene" or "cycloalkylene group" mean a stable saturated aliphatic 3- to 15- membered monocyclic or polycyclic divalent radical consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7- membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkyl ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary cycloalkylene groups include cyclopentylene, and the like.

The terms "cycloalkenylene" or "cycloalkenylene group" mean a stable aliphatic 5- to 15- membered monocyclic or polycyclic divalent radical having at least one carbon-carbon double bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring. Unless otherwise specified, the cycloalkenylene ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary cycloalkenylene groups include cyclopentenylene, cyclohexenylene, cycloheptenylene, cyclooctenylene, cyclononenylene, cyclodecenylene, norbornenylene, 2-methylcyclopentenylene, 2- methylcyclooctenylene, and the like.

The terms "cycloalkynylene" or "cycloalkynylene group" mean a stable aliphatic 8- to 15- membered monocyclic or polycyclic divalent radical having at least one carbon-carbon triple bond and consisting solely of carbon and hydrogen atoms which may comprise one or more fused or bridged ring(s), preferably a 8- to 10-membered monocyclic or 12- to 15-membered bicyclic ring. Unless otherwise specified, the cycloalkynylene ring may be attached at any carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary cycloalkynylene groups include cyclooctynylene, cyclononynylene, cyclodecynylene, 2-methylcyclooctynylene_. and the like.

The terms "aryl" or "aryl group" mean an aromatic carbocyclic monovalent or divalent radical of from 6 to 14 carbon atoms having a single ring (e.g., phenyl or phenylene) or multiple condensed rings (e.g., naphthyl or anthranyl). Unless otherwise specified, the aryl ring may be attached at any suitable carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable carbon atom which results in a stable structure. Exemplary aryl groups include phenyl, naphthyl, anthryl, phenanthryl, indanyl, indenyl, biphenyl, and the like. It may be abbreviated "Ar".

The terms "heteroaryl" or "heteroaryl group" mean a stable aromatic 5- to 14-membered, monocyclic or polycyclic monovalent or divalent radical which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic radical, having from one to four heteroatoms in the ring(s) independently selected from nitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms may optionally be oxidized and any nitrogen heteroatom may optionally be oxidized or be quaternized. Unless otherwise specified, the heteroaryl ring may be attached at any suitable heteroatom or carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable heteroatom or carbon atom which results in a stable structure. Exemplary and preferred heteroaryls include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolizinyl, azaindolizinyl, indolyl, azaindolyl, diazaindolyl, dihydroindolyl, dihydroazaindoyl, isoindolyl, azaisoindolyl, benzofuranyl, furanopyridinyl, furanopyrimidinyl, furanopyrazinyl, furanopyridazinyl, dihydrobenzofuranyl, dihydrofuranopyridinyl, dihydrofuranopyrimidinyl, benzothienyl, thienopyridinyl, thienopyrimidinyl, thienopyrazinyl, thienopyridazinyl, dihydrobenzothienyl, dihydrothienopyridinyl, dihydrothienopyrimidinyl, indazolyl, azaindazolyl, diazaindazolyl, benzimidazolyl, imidazopyridinyl, benzthiazolyl, thiazolopyridinyl, thiazolopyrimidinyl, benzoxazolyl, oxazolopyridinyl, oxazolopyrimidinyl, benzisoxazolyl, purinyl, chromanyl, azachromanyl, quinolizinyl, quinolinyl, dihydroquinolinyl, tetrahydroquinolinyl, isoquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, cinnolinyl, azacinnolinyl, phthalazinyl, azaphthalazinyl, quinazolinyl, azaquinazolinyl, quinoxalinyl, azaquinoxalinyl, naphthyridinyl, dihydronaphthyridinyl, tetrahydronaphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, benzo[l,3]dioxane, dihydrobenzimidazolone, and the like.

The terms "heterocycle", "heterocycle group", "heterocyclyl", or "heterocyclyl group" mean a stable non-aromatic 5- to 14-membered monocyclic or polycyclic, monovalent or divalent, ring which may comprise one or more fused or bridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclic ring, having from one to three heteroatoms in the ring(s) independently selected from nitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms may optionally be oxidized and any nitrogen heteroatom may optionally be oxidized or be quaternized. Unless otherwise specified, the heterocyclyl ring may be attached at any suitable heteroatom or carbon atom which results in a stable structure and, if substituted, may be substituted at any suitable heteroatom or carbon atom which results in a stable structure. Exemplary and preferred heterocycles include pyrrolinyl, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, moφholinyl, thiomoφholinyl, piperazinyl, tetrahydropyranyl, tetrahydrotliiopyranyl, tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl, and the like.

The term "compounds of the invention" and equivalent expressions are meant to embrace compounds of Formula (I) as herein described, including the tautomers, the prodrugs, the salts, particularly the pharmaceutically acceptable salts, and the solvates and hydrates thereof, where the context so permits. In general and preferably, the compounds of the invention and the formulas designating the compounds of the invention are understood to only include the stable compounds thereof and exclude unstable compounds, even if an unstable compound might be considered to be literally embraced by the compound formula. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits. The terms "optional" or "optionally" mean that the subsequently described event or circumstances may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.

The terms "stable compound" or "stable structure" mean a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent. For example, a compound which would have a "dangling valency" or is a carbanion is not a compound contemplated by the invention.

The term "substituted" means that any one or more hydrogens on an atom of a group or moiety, whether specifically designated or not, is replaced with a selection from the indicated group of substituents, provided that the atom's normal valency is not exceeded and that the substitution results in a stable compound. If a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound, then such substituent may be bonded via any atom in such substituent. For example, when the substituent is piperazinyl, piperidinyl, or tetrazolyl, unless specified otherwise, such piperazinyl, piperidinyl, or tetrazolyl group may be bonded to the rest of the compound of the invention via any atom in such piperazinyl, piperidinyl, or tetrazolyl group. Generally, when any substituent or group occurs more than one time in any constituent or compound, its definition on each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0 to 2 R⁵, then such group is optionally substituted with up to two R⁵ groups and R⁵ at each occurrence is selected independently from the defined list of possible R⁵. Such combinations of substituents and/or variables, however, are permissible only if such combinations result in stable compounds.

In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%, and more preferably within 5% of a given value or range. The yield of each of the reactions described herein is expressed as a percentage of the theoretical yield.

B. Salt, Prodrug, Derivative, and Solvate Terms and Conventions The terms "prodrug" or "prodrug derivative" mean a covalently-bonded derivative or carrier of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s). In general, such prodrugs have metabolically cleavable groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood, and generally include esters and amide analogs of the parent compounds. The prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability, prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased hydrosolubility), and/or decreased side effects (e.g., toxicity). In general, prodrugs themselves have weak or no biological activity and are stable under ordinary conditions. Prodrugs can be readily prepared firom the parent compounds using methods known in the art, such as those described in A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: "Design and Applications of Prodrugs"; Design of Prodrugs. H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drug Delivery. K.B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology. K. Widder et al. (eds.), Nol. 42, Academic Press, 1985, particularly pp. 309-396; Burger's Medicinal Chemistry and Drug Discovery. 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995, particularly Nol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems. T. Higuchi and V. Stella (eds.), Am. Chem. Soc, 1975; Bioreversible Carriers in Drug Design. E.B. Roche (ed.), Elsevier, 1987, each of which is incoφorated herein by reference in their entireties.

The term "pharmaceutically acceptable prodrug" as used herein means a prodrug of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible. The term "salt" means an ionic form of the parent compound or the product of the reaction between the parent compound with a suitable acid or base to make the acid salt or base salt of the parent compound. Salts of the compounds of the present invention can be synthesized from the parent compounds which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid parent compound with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

The term "pharmaceutically acceptable salt" means a salt of a compound of the invention which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use. The term includes pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts. As the compounds of the present invention are useful in both free base and salt form, in practice, the use of the salt form amounts to use of the base form. Lists of suitable salts are found in, e.g., S.M. Birge et al, J. Pharm. Sci., 1977, 66, pp. 1-19, which is hereby incoφorated by reference in its entirety.

The term "pharmaceutically-acceptable acid addition salt" means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cirmamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid

(isethionic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid, pectinic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, _o-toluenesulfonic acid, undecanoic acid, and the like.

The term "pharmaceutically-acceptable base addition salt" means those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically-acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2- diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N- methylmoφholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1- ephenamine, NN-dibenzylethylenediamine, polyamine resins, and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

The term "solvate" means a physical association of a compound with one or more solvent molecules or a complex of variable stoichiometry formed by a solute (for example, a compound of Formula (I)) and a solvent, for example, water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incoφorated in the crystal lattice of the crystalline solid. In general, the solvents selected do not interfere with the biological activity of the solute. Solvates encompasses both solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like. The term "hydrate" means a solvate wherein the solvent molecule(s) is/are H₂0.

The compounds of the present invention as discussed below include the free base or acid thereof, their salts, solvates, and prodrugs and may include oxidized sulfur atoms or quaternized nitrogen atoms in their structure, although not explicitly stated or shown, particularly the pharmaceutically acceptable forms thereof. Such forms, particularly the pharmaceutically acceptable forms, are intended to be embraced by the appended claims.

C. Isomer Terms and Conventions

The term "isomers" means compounds having the same number and kind of atoms, and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.

The terms "stereoisomer" or "optical isomer" mean a stable isomer that has at least one chiral atom or restricted rotation giving rise to peφendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the invention which may give rise to stereoisomerism, the invention contemplates stereoisomers and mixtures thereof. The compounds of the invention and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. As discussed in more detail below, individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereomers followed by separation or recrystalhzation, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well-known in the art. The term "enantiomers" means a pair of stereoisomers that are non-superimposable mirror images of each other.

The terms "diastereoisomers" or "diastereomers" mean optical isomers which are not mirror images of each other.

The terms "racemic mixture" or "racemate" mean a mixture containing equal parts of individual enantiomers.

The term "non-racemic mixture" means a mixture containing unequal parts of individual enantiomers.

The term "geometrical isomer" means a stable isomer which results from restricted freedom of rotation about double bonds (e.g., cz^'s-2-butene and tr««s-2-butene) or in a cyclic structure (e.g., cfs-l,3-dichlorocyclobutane and trø7ω-l,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, cyclic structures, and the like may be present in the compounds of the invention, the invention contemplates each of the various stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these cyclic structures. The substituents and the isomers are designated using the cisltrans convention or using the E or Z system, wherein the term "E" means higher order substituents on opposite sides of the double bond, and the term "Z" means higher order substituents on the same side of the double bond. A thorough discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions. Mechanisms, and Structure. 4th ed., John Wiley & Sons, 1992, which is hereby incoφorated by reference in its entirety. Several of the following examples represent single E isomers, single Z isomers, and mixtures of E/Z isomers. Determination of the E and Z isomers can be done by analytical methods such as x-ray crystallography, ^lτJ NMR, and ¹³C NMR.

Some of the compounds of the invention can exist in more than one tautomeric form. As mentioned above, the compounds of the invention include all such tautomers. It is well-known in the art that the biological and pharmacological activity of a compound is sensitive to the stereochemistry of the compound. Thus, for example, enantiomers often exhibit strikingly different biological activity including differences in pharmacokinetic properties, including metabolism, protein binding, and the like, and pharmacological properties, including the type of activity displayed, the degree of activity, toxicity, and the like. Thus, one skilled in the art will appreciate that one enantiomer may be more active or may exhibit beneficial effects when enriched relative to the other enantiomer or when separated from the other enantiomer. Additionally, one skilled in the art would know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the invention from this disclosure and the knowledge of the prior art.

Thus, although the racemic form of drug may be used, it is often less effective than administering an equal amount of enantiomerically pure drug; indeed, in some cases, one enantiomer may be pharmacologically inactive and would merely serve as a simple diluent. For example, although ibuprofen had been previously administered as a racemate, it has been shown that only the S-isomer of ibuprofen is effective as an anti-inflammatory agent (in the case of ibuprofen, however, although the R-isomer is inactive, it is converted in vivo to the S- isomer, thus, the rapidity of action of the racemic form of the drug is less than that of the pure S-isomer). Furthermore, the pharmacological activities of enantiomers may have distinct biological activity. For example, S-penicillamine is a therapeutic agent for chronic arthritis, while R-penicillamine is toxic. Indeed, some purified enantiomers have advantages over the racemates, as it has been reported that purified individual isomers have faster transdermal penetration rates compared to the racemic mixture. See U.S. Pat. Nos. 5,114,946 and 4,818,541.

Thus, if one enantiomer is pharmacologically more active, less toxic, or has a preferred disposition in the body than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially. In this way, the patient undergoing treatment would be exposed to a lower total dose of the drug and to a lower dose of an enantiomer that is possibly toxic or an inhibitor of the other enantiomer. Preparation of pure enantiomers or mixtures of desired enantiomeric excess (ee) or enantiomeric purity are accomplished by one or more of the many methods of (a) separation or resolution of enantiomers, or (b) enantioselective synthesis known to those of skill in the art, or a combination thereof. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective host- guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and nonenzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are disclosed generally in Chiral Separation Techniques: A Practical Approach (2nd Ed.), G. Subramanian (ed.), Wiley-NCH, 2000; T.E. Beesley and R.P.W. Scott, Chiral Chromatography. John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography. Am. Chem. Soc, 2000. Furthermore, there are equally well-known methods for the quantitation of enantiomeric excess or purity, for example, GC, HPLC, CE, or ΝMR, and assignment of absolute configuration and conformation, for example, CD ORD, X-ray crystallography, or ΝMR.

In general, all tautomeric forms and isomeric forms and mixtures, whether individual geometric isomers or stereoisomers or racemic or non-racemic mixtures, of a chemical structure or compound is intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.

D. Pharmaceutical Administration and Diagnostic and Treatment Terms and Conventions

The term "patient" includes both human and non-human mammals.

The term "effective amount" means an amount of a compound according to the invention which, in the context of which it is administered or used, is sufficient to achieve the desired effect or result. Depending on the context, the term effective amount may include or be synonymous with a pharmaceutically effective amount or a diagnostically effective amount.

The terms "pharmaceutically effective amount" or "therapeutically effective amount" means an amount of a compound according to the invention which, when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue, system, or patient that is sought by a researcher or clinician. The amount of a compound of according to the invention which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the invention, and the age, body weight, general health, sex, and diet of the patient. Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.

The term "diagnosticaUy effective amount" means an amount of a compound according to the invention which, when used in a diagnostic method, apparatus, or assay, is sufficient to achieve the desired diagnostic effect or the desired biological activity necessary for the diagnostic method, apparatus, or assay. Such an amount would be sufficient to elicit the biological or medical response in a diagnostic method, apparatus, or assay, which may include a biological or medical response in a patient or in a in vitro or in vivo tissue or system, that is sought by a researcher or clinician. The amount of a compound according to the invention which constitutes a diagnosticaUy effective amount will vary depending on such factors as the compound and its biological activity, the diagnostic method, apparatus, or assay used, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of administration, drugs and other compounds used in combination with or coincidentally with the compounds of the invention, and, if a patient is the subject of the diagnostic administration, the age, body weight, general health, sex, and diet of the patient. Such a diagnosticaUy effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.

The term "modulate" means the ability of a compound to alter the function of the glucocorticoid receptor by, for example, binding to and stimulating or inhibiting the glucocorticoid receptor functional responses. The term "modulator" in the context of describing compounds according to the invention means a compound that modulates the glucocorticoid receptor function. As such, modulators include, but are not limited to, agonists, partial agonists, antagonists, and partial antagonists.

The term "agonist" in the context of describing compounds according to the invention means a compound that, when bound to the glucocorticoid receptor, enhances or increases the glucocorticoid receptor function. As such, agonists include partial agonists and full agonists.

The term "full agonist" in the context of describing compounds according to the invention means a compound that evokes the maximal stimulatory response from the glucocorticoid receptor, even when there are spare (unoccupied) glucocorticoid receptors present.

The term "partial agonist" in the context of describing compounds according to the invention means a compound that is unable to evoke the maximal stimulatory response from the glucocorticoid receptor, even at concentrations sufficient to saturate the glucocorticoid receptors present.

The term "antagonist" in the context of describing compounds according to the invention means a compound that directly or indirectly inhibits or suppresses the glucocorticoid receptor function. As such, antagonists include partial antagonists and full antagonists.

The term "full antagonist" in the context of describing compounds according to the invention means a compound that evokes the maximal inhibitory response from the glucocorticoid receptor, even when there are spare (unoccupied) glucocorticoid receptors present.

The term "partial antagonist" in the context of describing compounds according to the invention means a compound that is unable to evoke the maximal inhibitory response from the glucocorticoid receptor, even at concentrations sufficient to saturate the glucocorticoid receptors present. The terms "treating" or "treatment" mean the treatment of a disease-state in a patient, and include:

(i) preventing the disease-state from occurring in a patient, in particular, when such patient is genetically or otherwise predisposed to the disease-state but has not yet been diagnosed as having it; (ii) inhibiting or ameliorating the disease-state in a patient, i.e., arresting or slowing its development; or (iii) relieving the disease-state in a patient, i.e., causing regression or cure of the disease- state.

General Synthetic Methods for Making Compounds of Formula (IA)

The invention also provides processes for making compounds of Formula (I). In all schemes, unless specified otherwise, R¹ to R⁵ in the formulas below shall have the meaning of R¹ to R⁵ in the Formula (I) of the invention described hereinabove. Intermediates used in the preparation of compounds of the invention are either commercially available or readily prepared by methods known to those skilled in the art.

Optimum reaction conditions and reaction times may vary depending on the particular reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions may be readily selected by one of ordinary skill in the art. Specific procedures are provided in the Experimental Examples section. Typically, reaction progress may be monitored by thin layer chromatography (TLC), if desired, and intermediates and products may be purified by chromatography on silica gel and/or by recrystalhzation.

Compounds of Formula (IA) may be prepared by the method outlined in Scheme I.

Compounds of Formula (IA) in which R⁴ is -CH₂- may be prepared by the method outlined in Scheme I. ^R'^: so₂cι

II

IV V IA (R⁴ = -CH₂-, X=0H)

Scheme I As illustrated in Scheme I, an ester intermediate of Formula (II) where R' is Me or Et, is reduced with a suitable reducing agent, such as lithium aluminum hydride (LiAlH ), in a suitable solvent, such as tetrahydrofuran (THF) or diethyl ether (Et₂0), to produce the 1,2-diol of Formula (III). The diol is then reacted with a reagent, for example R'S0₂C1 (R' = methyl or _σ-tolyl) that will form a leaving group L, with the primary alcohol of Formula (III) A suitable leaving group would be, for example, a sulfonic acid ester such as a mesylate or tosylate (IN, L is -S0₂CH₃ or -S0₂ (p-tolyl)). Intermediate (IN) may be isolated or reacted in situ with a base such as potassium carbonate to produce epoxide (N). Reaction of epoxide (N) with the desired R⁵H, provides the desired product of Formula (IA). The reaction may take place by heating R⁵H and epoxide (N) in a suitable solvent such as DMF, or by heating R⁵H and epoxide (N) together in a solvent in the presence of a suitable base such as sodium ethoxide in EtOH.

Intermediates of Formula (II) may be prepared by methods known in the art. Two procedures are illustrated in Scheme II.

s Acid

VI IX "

Scheme II

For an R¹ group which will undergo a Friedel-Crafts alkylation, one may react a pyruvate (VI) bearing CF₃ and where R' is Me or Et, with a bromomethyl olefin (VII) bearing an R² and an olefin group (=CH-R") that will become R³, in the presence of manganese and a Lewis acid, such as zinc chloride, in a suitable solvent, such as THF, to produce a 2-hydroxy ester (VIII). Friedel-Crafts alkylation of R¹ with this intermediate (VHT) in the presence of a suitable Lewis acid, such as aluminum chloride, provides compound (II) (R³ = -CH₂R"). Alternatively, one may perform a Grignard reaction with a pyruvate bearing CF₃ (VI) and an ethyl magnesium halide (IX) bearing R¹, R², and R³ to provide the desired intermediate of Formula (II).

Compounds in which R⁴ is -C(O)- may be prepared readily from intermediate (II) as illustrated in Scheme III.

Hydrol ^'yssiis

X

IA (R⁴ = -C(O)-, X=OH) Scheme III

As illustrated in Scheme III, hydrolysis of intermediate (II), for example, by refluxing with an aqueous base such as potassium hydroxide with a suitable co-solvent such as methanol, provides carboxylic acid (X). The resulting carboxylic acid (X) may be coupled with R⁵H under standard coupling conditions well-known in the art (see, for example, M. Bodanszky, The Practice of Peptide Synthesis (Springer- Verlag: 1984), which is hereby incoφorated by reference in its entirety). For example, one may couple carboxylic acid (X) and R⁵H by treating with l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) followed by 1- hydroxybenzotriazole hydrate (HOBT) in a suitable solvent such as DMF.

Compounds of Formula (IB) may be prepared by the method outlined in Scheme IN below,

where R , R , R , R , R , and X are as defined above and R is -CH₂-, the method comprising:

IA IIB ; and

IIB IB (R⁴ = CH₂; X = OH)

In order that this invention be more fully understood, the following examples are set forth. These examples are for the puφose of illustrating embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way since, as recognized by one skilled in the art, particular reagents or conditions could be modified as needed for individual compounds. Starting materials used are either commercially available or easily prepared from commercially available materials by those skilled in the art.

Experimental Examples

Example 1: Synthesis of 2-(2,6-dimethylmorphoIin-4-ylmethyl)-l,l,l-trifluoro-4-(5-fluoro- 2-methoxyphenyl)-4-methylpentan-2-ol hydrochloride

To a mixture of 8.5 g (49.9 mmol) of ethyl trifluoromethylpyruvate, 6.6 g (120 mmol) of manganese, and 0.65 g (4.8 mmol) of zinc chloride in 40 mL of THF warmed to reflux was added 200 μL (2 mmol) of l-bromo-2-methylpropene. After 30 minutes, 9.13 mL (90.5 mmol) of l-bromo-2-methylpropene in 30 mL of THF was added dropwise over a 1 hour period. The mixture was refluxed for 1 hour after the addition and was then cooled to 0°C and diluted with 150 mL of saturated aqueous ammonium chloride and 100 mL of ethyl acetate (EtOAc). The organic phase was separated and the aqueous layer extracted with three 100 mL portions of EtOAc. The combined organic layers were washed with two 50 mL portions of saturated aqueous ammonium chloride, followed by two 50 mL portions of brine, dried over magnesium sulfate (MgS0 ), filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography eluting with EtOAc-hexanes (5:95) to afford 5.9 g (52%) of 2-hydroxy-4- methyl-2-trifluoromethylpent-4-enoic acid ethyl ester.

To a mixture of 5.9 g (26.1 mmol) of the above 2-hydroxy-4-methyl-2-trifluoromethylpent-4- enoic acid ethyl ester in 30 mL of 4-fluoroanisole was added in several portions 5.2 g (39.4 mmol) of aluminum chloride. The mixture became exothermic and turned black with the first addition and was cooled with an ice-water bath. The mixture was stirred for 3 days and was then poured into 200 mL of ice-cold IN aqueous HCl and extracted with three 150 mL portions of EtOAc. The combined organic layers were washed with 50 mL of IN aqueous hydrochloric acid, three 50 mL portions of brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by silica gel chromatography eluting with EtOAc- hexanes (1:9, then 2:8, then 3:7, then 4:6) to afford 6.6 g (71%) of 4-(5-fluoro-2- methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentanoic acid ethyl ester.

To 4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-xrifluoromethylpentanoic acid ethyl ester (10.07 g) in 100 mL of anhydrous THF at 0°C-5°C was added 1.3 g of lithium aluminum hydride portionwise. The mixture slowly warmed to room temperature and was stirred for two days. The reaction was quenched with 1.3 mL of water, 1.3 mL of 15% aqueous NaOH, and 3.9 mL of water. The mixture was filtered through diatomaceous earth, diluted with diethyl ether, washed with water and brine, and dried over magnesium sulfate. The volatiles were removed in vacuo. The product 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2- trifluoromethylpentane- 1 ,2-diol was taken forward without further purification.

To a solution of 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-trifluoromethylpentane-l,2-diol (8.15 g) and pyridine (21.2 mL) in 50 mL of methylene chloride (CH₂C1₂) at 0°C-5°C was added dropwise methanesulfonyl chloride (2.63 mL). The mixture was warmed to room temperature, stirred overnight and methanol (80 mL) and K₂C0₃ (36.2 g) were added. The mixture was stirred 4 hours, diluted with diethyl ether, washed with water, dilute HCl, and brine, and dried over magnesium sulfate. Removal of the volatiles in vacuo provided a residue that was purified by flash silica gel chromatography using 5% EtOAc in hexanes as the eluent. The product-rich fractions were collected and the volatiles removed in vacuo to provide 2-[2- (5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane.

A mixture of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (0.219 g) and 2-6-dimethylmoφholine (0.26 mL) in 2 mL anhydrous DMF was heated at 100°C for 2 hours, cooled to room temperature, diluted with diethyl ether, washed with water and brine, and dried over magnesium sulfate. Removal of the volatiles in vacuo provided an oil which was dissolved in approximately 15 mL diethyl ether and HCl in dioxane was added. The volatiles were removed in vacuo and the resulting solid was triturated with diethyl ether and dried in vacuo to give the title compound, m.p. 133°C-135°C

Example 2: Synthesis of 2-(2,3-dihydrobenzo[l,4]oxazin-4-yImethyl)-l,l,l-trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-oI hydrochloride

A mixture of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (see Example 1) (0.139 g) and 3,4-dihydro-2H-benzo[l,4]oxazine (0.76 g) was dissolved in approximately 5 mL of methylene chloride and 0.55 g of flash silica gel was added. The volatiles were removed in vacuo and the residue was microwaved for 60 seconds at 150°C and applied to a column of flash silica gel. Elution with EtOAc-hexanes (1: 10) and concentration in vacuo of the product-rich fractions provided a residue which was dissolved in diethyl ether. ΗC1 in dioxane was added. The volatiles were removed in vacuo and the residue triturated with diethyl ether. The resulting solid was dried in vacuo to provide the title compound, m.p. 98°C- 99°C.

Example 3: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyI]-lH-quinoIin-4-one

A mixture of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromefhyloxirane (see Example 1) (0.21 g) and 4-hydroxyquinoline (0.105 g) and sodium ethoxide (21 wt.% in EtOΗ) in 4 mL anhydrous EtOΗ was heated at 85°C for 6 hours, cooled to room temperature, diluted with EtOAc and acetic acid, washed with water and brine, and dried over magnesium sulfate. Removal of the volatiles in vacuo provided a residue which was purified with flash silica gel using EtOAc as the eluent. Concentration in vacuo of the product-rich fractions provided the title compound, m.p. 170°C-172°C.

Example 4: Synthesis of 2-(3,4-dihydro-2H-quinoxalin-l-ylmethyl)-l,l,l-trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-ol

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromexhyloxirane (see Example 1) (54.4 mg) and tetrahydroquinoxaline (124.8 mg) in DMF (0.6 mL) was heated at 100°C for 6 hours. The resulting mixture was diluted with diethyl ether, washed with water and brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (eluted with 25% diethyl ether-benzene) to give the title compound as a clear oil (31.2 mg).

Example 5: Synthesis of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4- methyl-3,4-dihydro-2H-quinoxalin-l-ylmethyl)pentan-2-ol

To a solution of 2-(3,4-dihydro-2H-quinoxalin-l-ylmethyl)-l,l,l-trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol (Example 4) (18.6 mg) in acetonitrile (3 mL) was added formaldehyde solution (37% w/w aqueous, 300 μL) followed by sodium cyanoborohydride (13.8 mg). After 30 minutes at room temperature, acetic acid (50.4 μL) was added. The resulting mixture was stirred for 3 hours, quenched with saturated aqueous sodium bicarbonate solution and extracted three times with methylene chloride. The combined organic phases were dried over sodium sulfate, filtered, and the volatiles removed in vacuo. The residue was purified by preparative TLC (eluted with 25% EtOAc-hexanes) to give the title compound as a pale yellow oil (16.6 mg).

Example 6: Synthesis of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2- thiomorpholin-4-ylmethyIpentan-2-ol

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (see Example 1) (130 mg) and thiomoφholine (84.6 μL) in dimexhylformamide (1 mL) was heated at 100°C for 15 hours. The resulting mixture was diluted with diethyl ether, washed with water and brine, dried over sodium sulfate, filtered, and the volatiles removed in vacuo. The residue was purified by silica gel column chromatography using 2% EtOAc-hexanes as the eluent. The product-rich fractions were concentrated in vacuo to provide the title compound as a clear oil (161 mg).

Example 7: Synthesis of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(l-oxo- lλ⁴-thiomorpholin-4-ylmethy!pentan-2-ol

To a solution of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-thiomoφholin-4- ylmethylpentan-2-ol (Example 6) (34 mg) in MeOH (1.5 mL) was added a solution of sodium periodate (20 mg) in water (1.5 mL). After 21 hours at room temperature, an additional portion of sodium periodate (7 mg) was added to the incomplete reaction. The resulting mixture was allowed to stir for 15 hours, concentrated in vacuo, diluted with water and extracted two times with diethyl ether. The combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 50% to 70% ethyl acetate-hexanes to give the title compound as a white solid (29 mg), m.p. 135°C-136°C.

Example 8: Synthesis of 2-(l,l-dioxo-lλ⁶-thiomorpholin-4-yImethyl)-l,l,l-trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-oI

To a solution of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-thiomoφholin-4- ylmethylpentan-2-ol (Example 6) (65 mg) in CH₂C1₂ (2 mL) was added a solution of hydrogen peroxide (30% w/w aqueous, 46.8 μL) in trifluoroacetic acid (0.5 mL). The resulting mixture was stirred for 3.5 days, quenched with saturated aqueous sodium bicarbonate, and extracted two times with diethyl ether. The combined organic phases were washed with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (eluted with 50% ethyl acetate-hexanes plus 0.2% triethylamine) to give the title compound as a clear oil (13.1 mg).

Example 9: Synthesis of 2-(2,3-dihydrobenzo[l,4]thiazin-4-yImethyl)-l,l,l-trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-oI

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (118 mg) and 3,4-dihydro-2H-l,4-benzothiazine (Η.I. El-Subbagh et al, Arch. Pharm. Med. Chem.,

1999, 332, pp. 19-24) (122 mg) in dimethylformamide (1 mL) was heated at 140°C for 73 hours. The resulting mixture was diluted with diethyl ether, washed with saturated aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by radial chromatography with a chromatotron (eluted with 0% to 1% ethyl acetate-hexanes) to give the title compound as a white solid (53.5 mg), m.p. 103°C-104°C.

Example 10: Synthesis of 2-(3,5-dimethylpiperazin-l-ylmethyl)-l,l,l-trifluoro-4-(5-fluoro- 2-methoxyphenyl)-4-methylpentan-2-ol

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (98.7 mg) and 2,6-dimethylpiperazine (77.2 mg) in dimethylformamide (1 mL) was heated at 100°C for 5 hours. The resulting mixture was diluted with diethyl ether, washed with water and brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 1:98.5:0.5 methanol-methylene chloride- triethylamine) to give the title compound as a white solid (97.3 mg), m.p. 61°C-62°C

Example 11: Synthesis of l-{4-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-2,6-dimethylpiperazin-l-yl}ethanone

To a solution of 2-(3,5-dimethylpiperazin-l-ylmethyl)-l,l,l-trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol (18 mg) in methylene chloride (1 mL) was added pyridine (55.8 μL) followed by acetic anhydride (43.4 μL). The resulting mixture was stirred overnight, quenched with saturated aqueous sodium bicarbonate solution and extracted twice with methylene chloride. The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 50% ethyl acetate-hexanes) to give the title compound as a clear oil (20 mg).

Example 12: Synthesis of 4-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-2,6-dimethylpiperazine-l-carbaldehyde

To a solution of 2-(3,5-dimethylpiperazin-l -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol (20 mg) in methylene chloride (1 mL) at 0°C was added pyridine (60.7 μL) followed by formic anhydride (2M in methylene chloride, 0.5 mL). (Formic anhydride was freshly prepared by slow addition of one equivalent of 1,3- diisopropylcarbodiimide to 2 equivalents of formic acid in methylene chloride. The resulting suspension was stirred for 1 hour, and filtered). The resulting mixture was stirred overnight for 20 hours, filtered tlirough a cotton plug, poured into half-saturated aqueous sodium bicarbonate solution, and extracted twice with methylene chloride. The combined organic phases were dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by chromatography on silica gel (eluted with 5% methanol-methylene chloride) to give the title compound as a clear oil (19.3 mg).

Example 13: Synthesis of 4-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyI-2- trifluoromethylpentyl]-3,4-dihydro-lH-quinoxalin-2-one

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (105 mg) and 3,4-dihydro-lH-quinoxalin-2-one (R.E. TenBrink et al, J. Med. Chem., 1994, 37, pp. 758-768) (267 mg) in dimethylformamide (0.75 mL) was heated at 140°C for 45 hours. The resulting mixture was poured into water and extracted twice with diethyl ether. The combined organic phases were washed with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 30% ethyl acetate-hexanes) to give the title compound as a pale yellow solid (67.8 mg), m.p. 69°C-71°C.

Example 14: Synthesis of 4-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-l-methyl-3,4-dihydro-lH-quinoxalin-2-one

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (98.8 mg) and l-methyl-3,4-dihydro-lH-quinoxalin-2-one (prepared as the minor regioisomer following a similar procedure described for 3,4-dihydro-lH-quinoxalin-2-one; R.E. TenBrink et al, J. Med. Chem., 1994, 37, pp. 758-768) (165 mg) in dimethylformamide (0.75 mL) was heated at 140°C for 60 hours. The resulting mixture was poured into saturated aqueous sodium bicarbonate solution and extracted twice with diethyl ether. The combined organic phases were dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 20% ethyl acetate-hexanes) to give the title compound as a pale yellow solid (16.2 mg), m.p. 132°C-134°C. Example 15: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyI]-3-hydroxymethyl-lH-quinolin-4-one

A mixture of 4-hydroxyquinoline (5.0 g), aqueous sodium hydroxide solution (IM, 42 mL) and formaldehyde solution (37% in water, 6 irL) was heated at 45°C for 18.5 hours. The reaction mixture was filtered, acidified with 2N HCl (21 mL) and extracted with ethyl acetate. The aqueous layer was chilled to afford 4-hydroxy-3-hydroxymethylquinoline (2.0 g) as a white solid.

To a suspension of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (344 mg) and 4-hydroxy-3-hydroxymethylquinoline (412 mg) in anhydrous ethanol (2.5 mL) was added sodium ethoxide (21 wt.% solution in ethanol, 439 μL). After heating at 85°C for 17 hours, the reaction mixture was poured into saturated aqueous sodium bicarbonate and extracted twice with ethyl acetate. The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 80%- 100% ethyl acetate-hexanes) to give the title compound as a white solid (405 mg), m.p. 183°C-184°C

Example 16: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyI-2- trifluoromethylpentyl]-3-methoxymethyI-lH-quinoIin-4-one

To a suspension of l-[4-(5-fluoro-2-methoxyphenyl)-2~hydroxy-4-methyl-2- trifluoromethylpentyl]-3-hydroxymethyl-lH-quinolin-4-one (51.5 mg) and silver(I) oxide (127 mg) in acetonitrile (3 mL) was added methyl iodide (68.5 μL). After heating at 50°C for 15 hours, the reaction mixture was filtered and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 50%-70% ethyl acetate-hexanes) to give tlie title compound as a white solid (37.5 mg).

Example 17: Synthesis of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-(4-imino-4H- quinoIin-l-ylmethyI)-4-methylpentan-2-ol (Ph)₃

A mixture of 4-aminoquinoline (H. Shinkai et al, J. Med. Chem., 2000, 43, pp. 4667-4677) (251 mg), chlorotriphenylmethane (533 mg), and triethylamine (266 μL) in methylene chloride (5 mL) was stirred at room temperature for 24 hours. The reaction mixture was then poured into saturated aqueous sodium bicarbonate solution and extracted twice with methylene chloride. The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 50% ethyl acetate-hexanes) to give quinolin-4-yltritylamine as a pale yellow foam (610 mg).

To a suspension of quinolin-4-yltritylamine (428 mg) in anhydrous dimethylsulfoxide (3.4 mL) and tetrahydrofuran (0.6 L) was added sodium hydride (60% dispersion in mineral oil, 44.3 mg) in one portion. After 30 minutes, 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2- trifluoromethyloxirane (292 mg) was added and the mixture stirred for 3 hours. The mixture was poured into half-saturated aqueous ammonium chloride and extracted twice with ethyl acetate. The combined organic phases were washed with water, brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 0.2% triethylamine-ethyl acetate) to give a 2: 1 mixture of quinolin-4-yltritylamine and product, l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)- 4-methyl-2-[4-(tritylimino)-4H-quinolin-l-ylmethyl]pentan-2-ol (480 mg), which was used without further purification.

To a solution of l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-[4-(tritylimino)-4H- quinolin-l-ylmethyl]pentan-2-ol (470 mg) in methylene chloride (50 mL) was added trifluoroacetic acid (2 mL). After 2 hours, another portion of trifluoroacetic acid (1 mL) was added and the mixture was stirred for another 4 hours. The reaction was quenched by slow addition of saturated aqueous sodium bicarbonate solution and was extracted twice with ethyl acetate. The combined organic phases were dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 8 to 10% methanol-methylene chloride) to give the title compound (84.2 mg), m.p. 137°C-140°C.

Example 18: Synthesis of l-[2-hydroxy-4-methyl-4-(3-morpholin-4-ylmethylphenyI)-2- trifluoromethylpentyl]-lH-quinolin-4-one

To a solution of 3-[4,4,4-trifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin-l- ylmethyl)butyl]benzaldehyde (0.05 g, 0.12 mmol), dichloroethane (3.0 mL), and acetic acid (0.09 mL, 1.46 mmol) in an ice bath was added moφholine (0.26 mL, 3.00 mmol). The solution was warmed to room temperature and stirred for 0.5 hours. Triacetoxy sodium borohyride (0.06 g. 0.30 mmol) was added and the reaction stirred at room temperature. After 3.0 hours, the solution was partitioned between EtOAc and 3% NΗ₄OΗ (3 mL). The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and the solvent was evaporated in vacuo. The product was eluted from a flash chromatography column with EtOAc/hexanes, and concentrated in vacuo to afford 1 -[2-hydroxy-4-methyl-4-(3 -moφholin-4-ylmethylphenyl)-2-xrifluoromethylpentyl]- 1H- quinolin-4-one as a colorless solid (0.03 g, 45%).

Example 19: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyI-2- trifluoromethyIpentyI]-lH-quinazolin-4-one

A solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxhane (500 mg) and 2-aminobenzamide (1.17 g) in dimethylformamide (2.5 mL) was heated at 140°C for 19.5 hours. The resulting mixture was diluted with diethyl ether, washed with water and brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 15 to 30% ethyl acetate-hexanes) to give 2- [4-(5-fluoro-2-memoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentylamino]benzamide as a white foam (447 mg).

To a solution of 2-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentylamino]benzamide (106 mg) in frimethylorthoformate (6 mL) was added trifluoroacetic acid (0.1 mL). After 1.5 hours, the reaction mixture was concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 70% ethyl acetate-hexanes) to give the title compound as a white solid (82 mg), m.p. 118°C-121°C.

Example 20: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-cinnolin-4-one

To a suspension of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (216 mg) and cinnolin-4-ol (N.G. Chapoulaud et al, Tetrahedron, 2000, 56, pp. 5499-5507) (216 mg) in anhydrous ethanol (1.2 mL) was added sodium ethoxide (21 wt.% solution in ethanol, 276 μL). After heating at 85°C for 16 hours, the reaction mixture was diluted with ethyl acetate, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (eluted with 40% ethyl acetate-hexanes) to give the title compound as a pale yellow solid (26 mg), m.p. 122°C-123°C.

Example 21: Synthesis of l-[4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-mefhyl-2- trifluoromethylpentyl]-2-hydroxymethyI-3,5-dimethyl-lH-pyridin-4-one

A mixture of (4-methoxy-3,5-dimethylpyridin-2-yl)methanol (1.0 g) and anhydrous lithium chloride (0.76 mg) in dimethylformamide (10 mL) was heated at reflux for 43 hours. Sodium hydroxide solution (10% w/v, 30 mL) was then added and the resulting solution was extracted twice with diethyl ether. The aqueous phase was neutralized with IN HCl (21 mL) and the volatiles were removed in vacuo. The resulting solid was purified by column chromatography with silica gel (eluted with 10% methanol-methylene chloride). Product-rich fractions were combined, concentrated in vacuo, and triturated with chloroform-acetonitrile (4:1) to afford the product, 2-hydroxymethyl-3,5-dimethylpyridin-4-ol, as a white solid (0.78 g).

To a suspension of 7-[l,l-dimethyl-2-(2-trifluoromemyloxiranyl)ethyl]-2,3-dmydrobenzofuran (30.0 mg) and 2-hydroxymethyl-3,5-dimethylpyridin-4-ol (32.2 mg) in anhydrous ethanol (0.25 mL) was added sodium ethoxide (21 wt.% solution in ethanol, 39.0 μL). After heating at 85°C for 18 hours, the reaction mixture was diluted with ethyl acetate, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 4% to 7% methanol-methylene chloride) to give the title compound as a white solid (10.4 mg), m.p. 160°C-162°C

Example 22: Synthesis of l-[2-hydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7- yl)-4-methyl-2-trifluoromethylpentyl]-3,5-dimethyl-lH-pyridin-4-one

To a suspension of trimethylsulfoxonium iodide (1.36 g) in anhydrous dimethylsulfoxide (7.7 mL) was added sodium hydride (60% dispersion in mineral oil, 246 mg). The resulting solution was stirred at room temperature for 30 minutes and was then added dropwise to a solution of 1 , 1 , l-trifluoro-4-methyl-4-(5-methylsulfanyl-2,3 -dihydrobenzofuran-7-yl)pentan-2- one (1.63 g) in anhydrous dimethylsulfoxide (6.5 mL). After 2 hours, water (100 mL) was added and the resulting mixture was extracted with three 100 mL portions of diethyl ether. The combined organic phases were washed twice with water, washed with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to afford 7-[l,l-dimethyl-2-(2- trifluoromethyloxiranyl)ethyl]-5-methylsulfanyl-2,3-dihydrobenzofuran as a clear oil (1.64 g) which was used without further purification.

To a solution of 7-[l,l-dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]-5-methylsulfanyl-2,3- dihydrobenzofuran (535 mg) in acetonitrile (30 mL) and water (10 mL) was added sodium periodate (1.03 g) followed by ruthenium (III) chloride (1 mg). After 2 hours, the reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic phases were dried over magnesium sulfate, filtered, and concentrated to afford 7-[l,l-dimethyl-2-(2- trifluoromethyloxiranyl)ethyl]-5-methanesulfonyl-2,3-dihydrobenzofuran as a tan solid (568 mg) which was used without further purification.

To a suspension of 7-[l,l-dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]-5-methanesulfonyl-2,3- dihydrobenzofuran (51.0 mg) and 3,5-dimethylpyridin-4-ol (B. Boduszek et al, Synthesis, 1979, pp. 452-453) (34 mg) in anhydrous ethanol (0.40 mL) was added sodium ethoxide (21 wt.% solution in ethanol, 52.0 μL). After heating at 85°C for 16 hours, the reaction mixture was diluted with ethyl acetate, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by column chromatography with silica gel (eluted with 4% methanol- methylene chloride) to give the title compound as a white solid (47 mg), m.p. 150°C-152°C.

Example 23: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyI-2- trifluoromethyIpentyl]-l,2-dihydroindazol-3-one

To a solution of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (0.29 g) and l,2-dihydroindazol-3-one (0.17 g) in anhydrous dimethylsulfoxide (1 mL) was added sodium bis(trimethylsilyl)amide (1.0M in tetrahydrofuran, 1.0 mL). After 14 days, the reaction mixture was diluted with ethyl acetate and washed twice with water. The organic phase was dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by preparative TLC (eluted with 1% ethanol-methylene chloride) to give l-[4-(5- fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-l,2-dihydroindazol-3- one as a white solid (91 mg), m.p. 141°C-144°C.

Example 24: Synthesis of l-[2-cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4- methylpentyl]-lH-quinolin-4-one

To a solution of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one (2.25 g, 5.14 mmol) in DMF (40 mL) was added potassium carbonate (2.13 g, 15.4 mmol) followed by heating to 120°C in a sealed reaction vessel for 14 hours. The solution was diluted with 300 mL of diethyl ether, washed with one 200 mL portion of saturated aqueous sodium bicarbonate, three 100 mL portions of water, one 100 mL portion of brine, dried over anhydrous sodium sulfite (Na₂S0₃), and concentrated in vacuo. The crude material was purified by flash column chromatography (5% MeOH/CH₂Cl₂) to give l-[4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxopentyl]-lH-quinolin-4-one as a brown foam (1.07 g, 57%).

An oven-dried round-bottomed flask charged with cerium chloride (0.27 g, 1.08 mmol) was dried under vacuum and at 140°C for 1 hour followed by vacuum at room temperature for an additional 14 hours. The flask was sealed with a septum, evacuated under vacuum, and charged with argon. TΗF (3 mL) was added and the slurry was sonicated for 1 hour to give a yellow suspension. To this slurry was added l-[4-(5-fluoro-2-mexhoxyphenyl)-4-methyl-2-oxopentyl]- lH-quinolin-4-one (0.20 g, 0.54 mmol) dissolved in 1 mL of TΗF resulting in the formation of a dark brown solution. This was stirred for 1 hour at room temperature followed by the addition of the cyclopropylmagnesium bromide (2.18 mL, 0.5 mol/L) at 0°C The reaction was allowed to stir at this temperature for 3 hours followed by quenching through the addition of saturated ammonium chloride (10.0 mL) resulting in the formation of a white precipitate. The biphasic system was filtered and the aqueous layer was separated. The organic layer was washed with one 25 mL portion of brine, dried over anhydrous sodium sulfite, filtered, and the solvent was evaporated in vacuo to give a yellow oil. The pure product, l-[2-cyclopropyl-4-(5- fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin-4-one (2.0 mg, 1%) was obtained by flash chromatography on silica gel using mixtures of EtOAc-hexanes as the eluent.

Example 25: Synthesis of l-[2-hydroxy-4-(3-hydroxymethylphenyl)-4-methyI-2- trifluoromethyIpentyI]-lH-quinoIin-4-one

To a solution of the 3-[4,4,4-trifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin-l- ylmethyl)butyl]benzaldehyde (20.0 mg, 0.05 mmol) in methanol (0.50 rnL) and TΗF (0.50 mL) was added NaBΗ (20.0 mg, 0.48 rnmol). The reaction vessel was sealed and stirred for 45 minutes. The solvent was evaporated in vacuo and the off-white solid was re-dissolved in EtOAc and water and transferred to a separatory funnel. The aqueous layer was extracted with two 10 mL portions of EtOAc and the combined organic layers were washed with one 10 mL portion of brine, dried over magnesium sulfate, filtered, and the solvent was evaporated in vacuo to give a white foam. The material was chromatographed (6% Me0H/CH₂Cl₂, 0.5% NK_.OH) to give the desired compound, l-[2-hydroxy-4-(3-hydroxymethylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one as a white foam (6.6 mg, 36%).

Example 26: Synthesis of l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethyIpentyl]-3-methyl-lH-quinoIin-4-one

A mixture of aniline (10.7 g) and diethyl oxalpropionate (21.7 mL) in 75 mL of methylene chloride was heated at reflux overnight, cooled to room temperature, washed with IN ΗC1, water, brine, and dried over magnesium sulfate. The volatiles were removed in vacuo and the residue (2-methyl-3-(phenylimino)succinic acid diethyl ester) was taken forward without additional purification.

A mixture of 2-methyl-3-(phenylimino)succinic acid diethyl ester (2.42 g) in silicon oil (7 mL) was heated at 240°C-245°C for 20 minutes with removal of ethanol by distillation, cooled to room temperature, diluted with hexanes, and filtered. The solid (3-methyl-4-oxo-l,4- dihydroquinoline-2-carboxylic acid ethyl ester) was dried in vacuo. Yield: 0.91 g.

A mixture of 3-methyl-4-oxo-l,4-dihydroquinoline-2-carboxylic acid ethyl ester (1.42 g) and aqueous NaOH (18.4 mL of a IN solution) was heated at reflux for 3 hours, cooled to room temperature, acidified with concentrated HCl, filtered, and the solid dried in vacuo. The solid (1.1 g) was suspended in 10 mL of silicon oil and heated at 260°C-265°C for 10 minutes, cooled to room temperature, diluted with hexanes, and filtered. The solid (3-methyl-lH-quinolin-4- one) was dried in vacuo.

A mixture of 3-methyl-lH-quinolin-4-one (0.76 g), 2-[2-(5-fluoro-2-methoxyphenyl)-2- methylpropyl]-2-trifluoromethyloxirane (0.089 g) and sodium ethoxide in ethanol (0.18 mL of a 21 wt.% solution) in 2 mL of anhydrous ethanol was heated at 85°C for 12 hours, cooled to room temperature, and most of the volatiles removed in vacuo. The residue was diluted with diethyl ether and methanol and washed with water and brine, and dried over magnesium sulfate. The residue was purified by flash silica gel chromatography using ethyl acetate as the eluent. The product-rich fractions were concentrated in vacuo and dried to afford l-[4-(5-fluoro-2- methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl-lH-quinolin-4-one, m.p. >225°C.

Example 27: Synthesis of l-[4-(2-ethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one

A mixture of l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one (0.053 g), iodoethane (0.011 L) and powdered potassium carbonate (0.090 g) in 1 mL of anhydrous DMF was heated at 80°C for 18 hours, cooled to room temperature, and diluted with water and filtered. The solid was purified with flash silica gel chromatography using ethyl acetate as the eluent. The product rich fraction were concentrated in vacuo and provided l-[4-(2-ethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one, m.p. 195°C-196°C.

Example 28: Synthesis of l-[4-(2-difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyI-2- trifluoromethylpentyl]-lH-quinolin-4-one

A mixture of l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one (0.05 g), methyl 2-chloro-2,2-difluoroacetate (0.014 mL) and cesium carbonate (0.195 g) in 1.5 mL of DMF was heated at 60°C for 20 hours, cooled to room temperature, diluted with ethyl acetate, and washed with aqueous acetic acid, water, and brine. The residue was purified by reverse-phase ΗPLC using acetonitrile/water as the eluent. The product rich fractions were concentrated in vacuo and provided l-[4-(2-difluoromethoxy-5- fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one, m.p. 150°C- 155°C.

Example 29: Synthesis of l-[2-hydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2- trifluoromethyIpentyl]-lH-quinolin-4-one

To a solution of 2-methoxyphenylmagnesium bromide (131 mL, 65.7 mmol, 0.5M solution in THF) at 0°C was added Cul (12.5 g, 65.7 mmol). The reaction mixture was warmed to room temperature and stirred for 1 hour. A solution of 4-methyl-l,l,l-trifluoropent-3-en-2-one (10.0 g, 65.74 mmol) (made via procedure in PCT international application WO03/082280, Example 10), in diethyl ether (200 mL) was added and the reaction mixture was stirred overnight. The reaction was quenched with saturated aqueous ammonium chloride (50 mL) and extracted with three 300 mL portions of ethyl acetate. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel chromatography using 0%-5% ethyl acetate in hexanes as the eluent. Concentration in vacuo of the product-rich fractions gave 14 g (82%) of l,l,l-trifluoro-4-(2- methoxyphenyl)-4-methylpentan-2-one.

A mixture of N-bromosuccinimide (6.84 g, 38.42 mmol), benzoylperoxide (catalytic amount) and l,l,l-trifluoro-4-(2-methoxyphenyl)-4-methylpentan-2-one (10.0 g, 38.42 mmol) in carbon tetrachloride (120 mL) and was refluxed for two days. After cooling, the solution was washed with water (60 mL) and 1.0M NaOH (60 mL), dried over sodium sulfate (Na₂S0₄), and concentrated in vacuo giving l,l,l-trifluoro-4-(5-bromo-2-methoxyphenyl)-4-methylpentan-2- one and the starting material as 3:1 mixture (13.0 g).

Preparation of ylide Stock Solution:

To trimethylsulfoxonium iodide (8.0 g, 36.3 mmol) in 30 mL of anhydrous DMSO was added NaH (1.46 g, 36.35 mmol; 60% dispersion in mineral oil) in portions. The mixture was stirred 30 minutes.

Epoxide Formation:

To a solution of l,l,l-trifluoro-4-(5-bromo-2-methoxyphenyl)-4-methylpentan-2-one (5 g, 14.7 mmol) in 5 mL of anhydrous DMSO at room temperature was added 14.6 mL of the ylide stock solution (17.3 mmol) over 5 minutes. The reaction was quenched after 2 hours with water and diethyl ether. The aqueous layer was extracted with diethyl ether. The combined organic layers were washed with water and brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to afford 2-[2-(5-bromo-2-methoxyphenyl)-2-methylpropyl]-2- trifluoromethyloxirane as a dark yellow oil.

A mixture of 2-[2-(5-bromo-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane (5.0 g, 14.2 mmol), 4-hydroxyquinoline (3.08 g, 21.2 mmol) and sodium ethoxide (21 wt.% solution in ethanol, 5.3 mL, 14.2 mmol) in ethanol (120 mL) was heated at 85°C for 14 hours. The reaction was quenched with water and concentrated in vacuo to remove most of the ethanol. The residue was diluted with methylene chloride and washed with half saturated sodium bicarbonate (NaHC0₃), dried over magnesium sulfate, filtered, and concentrated in vacuo. The product was precipitated from diethyl ether-hexanes to afford l-[4-(5-bromo-2- methoxyphenyl)-2 -hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one (5.2 g, 73% yield).

A mixture of l-[4-(5-bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one (0.2 g, 0.4 mmol), 3-thiopheneboronic acid (77 mg, 0.6 mmol), sodium carbonate (Na₂C0₃; 85 mg, 0.8 mmol) in DME-MeOΗ-DMF (1:1.5:0.5; 3.0 mL) was stirred for 10 minutes and Pd(PPh₃)₄ (46.2 mg, 0.04 mmol) was added. The mixture was microwaved for 15 minutes at 120°C, cooled to room temperature, and filtered through CELITE® filter aid. The residue was diluted with EtOAc (20 mL) and washed with aqueous NaOΗ (1.0M, 10 mL), water, and brine, and dried over sodium sulfate, and the volatiles removed in vacuo. The residue was purified by silica gel chromatography and then by reverse phase ΗPLC to yield 60 mg (30%) of l-[2-hydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one as a white foam.

Example 30: Synthesis of l-[2-hydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyI-2- trifluoromethylpentyl]-lH-quinoIin-4-one

To a solution of l-[2-hydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one (32 mg, 0.06 mmol) in methylene chloride (1 mL) at 0°C under an argon atmosphere was added BBr₃ (0.06 mL, 0.6 mmol). The mixture was warmed to room temperature, stirred 3 hours, cooled to 0°C, stirred 2 days, and quenched with methanol (5 mL). The volatiles were removed in vacuo and the residue diluted with ethyl acetate (10 mL), washed with saturated aqueous sodium bicarbonate (5 mL), and brine (5 mL), and dried over magnesium sulfate. The volatiles were removed in vacuo and the residue purified by reverse phase HPLC to afford l-[2-hydroxy-4-(2-hy(iroxy-5-thiophen3-ylphenyl)-4- methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one (20 mg, 68%).

Example 31: Synthesis of l-[2-hydroxy-4-(4-methoxybiphenyl-3-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one

A mixture of l-[4-(5-bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one (200 mg, 0.4 mmol), Pd(OAc)₂ (9 mg, 0.04 mmol), DCyBPP ((2- dicyclohexylphosphino)biphenyl, 28 mg, 0.08 mmol), KF (93 mg, 1.6 mmol) in toluene/TΗF (3/2 mL) at room temperature was treated with phenylboronic acid (98 mg, 0.8 mmol). The reaction mixture stirred overnight at room temperature and filtered through CELITE® filter aid. The residue was diluted with EtOAc (20 mL), washed with aqueous NaOΗ (1.0M, 10 mL), water, and brine (10 mL). The organic phase was dried over sodium sulfate, filtered, and solvent was evaporated in vacuo. The residue was purified silica gel chromatography and then by reverse phase ΗPLC to provide l-[2-hydroxy-4-(4-methoxybiphenyl-3-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one as white solid.

Example 32: Synthesis of l-[4-(5-Acetyl-2-methoxyphenyI)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one

A mixture of l-[4-(-bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one (200 mg, 0.4 mmol), 1-vinyloxybutane (0.26 mL, 2.0 mmol), Pd(OAc)₂ (5 mg, 0.02 mmol), l,3-bis(diphenylphosphino) propane (DPPP) (10.5 mg, 0.03 mmol), K₂C0₃ (66.34 mg, 0.48 mmol), and water (0.1 mL) in DMF (1 mL) was microwaved for 1 hour at 122°C After cooling, the mixture was poured into 5 mL of 5% HCl, stirred for 30 minutes and extracted with three 10 mL portions of ethyl acetate. The combined organic layers were washed with 10% aqueous K₂C0₃ and dried. The residue was purified silica gel chromatography and then by reverse phase HPLC to yield 50 mg (27% yield) of l-[4-(5-acetyl- 2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one as white solid.

Example 33: Synthesis of 3-chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl- 2-trifluoromethylpentyl]-5-trifluoromethyl-lH-pyridin-2-one

A mixture of 3 -chloro-5 -trifluoromethylpyridin-2-ol (135 mg, 0.68 mmol) in 1 mL of EtOΗ was added to 0.13 mL of a IM sodium ethoxide solution in ethanol and was heated to 85°C for 5 minutes in a sealed vial. The mixture was cooled to room temperature, 2-[2-(5-fluoro-2- methoxyphenyl)-2-methylpropyl]-2-xrifluoromethyloxirane was added, and the mixture heated to 85°C overnight in a sealed vial. The volatiles were removed in vacuo and the residue diluted with water and extracted with EtOAc. The organic extracts were combined, dried over sodium sulfate and concentrated in vacuo. The residue was purified on PLC plate (hexanes-EtOAc (8:2)) to give 125 mg of 3-chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromexhylpentyl]-5-trifluoromethyl-lH-pyridin-2-one as a solid.

Example 34: Synthesis of l-{4-[3-(3,5-dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl- 2-trifluoromethylpentyI}-lH-quinolin-4-one

A solution of 3-bromoacetophenone (9.9 mL, 0.075 mol), methylcyanoacetate (9.8 mL, 0.112 mmol, 1.5 equiv.), benzylamine (0.87 mL, 0.008 mol, 0.1 equiv.), and acetic acid (4.3 mL) in 110 mL of toluene was refluxed overnight with azeotropic removal of water. The reaction was concentrated in vacuo and purified via flash chromatography using a hexanes/ethyl acetate gradient to elute product (Z)-3-(3-bromophenyl)-2-cyanobut-2-enoic acid methyl ester. Yield: 14.13 g (67%).

To a chilled (0°C) suspension of Soxhlet-extraction-purified Cul (14.28 g, 0.075 mol, 1.5 equiv.) in 150 mL of anhydrous diethyl ether, was added a 1.6M solution of methyl lithium (84.4 mL, 0.135 mol,. 2.7 equiv.) in diethyl ether. The mixture was stirred for 10 minutes, cooled to -25°C and a solution of (Z)-3-(3-bromophenyl)-2-cyanobut-2-enoic acid methyl ester (14.13 g, 0.05 mol) in 150 mL of anhydrous diethyl ether was added dropwise. The mixture was stirred at -25 °C for 30 minutes, warmed to room temperature, and stirred overnight. The reaction was quenched with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The combined organics were washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo to afford a brown oil. The oil was purified via flash chromatography using a hexanes-ethyl acetate gradient to afford 3-(3-bromophenyl)-2-cyano-3- methylbutyric acid methyl ester. Yield: 8.88 g (60%).

A mixture of 3-(3-bromophenyl)-2-cyano-3-methylbutyric acid methyl ester (8.88 g, 28.6 mmol) and sodium chloride (4.69 g, 80.2 mmol, 2.8 equiv.) in 74 mL of dimethyl sulfoxide with 3.5 mL of water was refluxed overnight. The reaction was cooled and diluted with brine and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford an oil which was purified via flash chromatography. A hexanes-ethyl acetate gradient was used to elute product. The product fractions were pooled and concentrated in vacuo to afford a dark brown oil, 3-(3- bromophenyl)-3-methylbutyronitrile. Yield: 5.1 g (75%)

To a mixture of 3-(3-bromophenyl)-3-methylbutyronitrile (5.1 g, 21 mmol) in anhydrous methylene chloride (94 mL) at -78°C was added diisobutylaluminum hydride (IM in dichloromethane) dropwise. The reaction was stirred 1 hour, slowly warmed to room temperature, and quenched with saturated aqueous solution of Rochelle's salt and extracted with ethyl acetate. The combined organics were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford as an oil. The oil was purified via flash chromatography using a hexanes-ethyl acetate gradient to elute 3-(3-bromophenyl)-3- methylbutyr aldehyde.

To 3-(3-bromophenyl)-3-methylbutyraldehyde (3.1 g, 12.8 mmol) in a 0.5M solution of trimethyl(trifluoromethyl)silane in THF (25.7 mL, 12.8 mmol) was added over a 2 minutes tetrabutyl ammonium fluoride (2.6 mL of a IM solution in THF). The mixture stirred for 30 minutes and an additional 10.3 mL of a IM solution of tetrabutyl ammonium fluoride was added. The mixture was diluted with water and extracted with ethyl acetate. The combined organics were washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo. The residue was purified via flash chromatography using a hexanes-ethyl acetate gradient to elute 4-(3-bromophenyl)-l,l,l-trifluoro-4-methylpentan-2-ol. Yield: 2.048 g (51%).

To a solution of 4-(3-bromophenyl)-l,l,l-trifluoro-4-methylpentan-2-ol (2.05 g, 6.58 mmol) in dichloromethane (33 mL) was added the Dess-Martin periodinane (3.9 g, 9.2 mmol). The mixture stirred for 48 hours and was then concentrated in vacuo. The residue was diluted with hexanes and filtered. The filtrate was concentrated in vacuo and purified via flash chromatography using a hexanes-ethyl acetate gradient to elute product 4-(3-bromophenyl)- l,l,l-trifluoro-4-methylpentan-2-one. Yield: 68 mg (34%)

To a solution of 4-(3-bromophenyl)- 1,1,1 -trifluoro-4-methylpentan-2-one (68 mg, 2.2 mmol) in 2.9 mL of anhydrous DMSO was added over 5 minutes a solution the ylide of trimethylsulfoxonium iodide (3.3 mL of a 0.8M DMSO solution prepared from 2.66 g (12.1 mmol) of trimethylsulfoxonium iodide in 15 mL of anhydrous DMSO and 483 mg of 60% NaH in mineral oil (12.1 mmol) added in portions and aged for 30 minutes). The mixture stirred 2 hours and quenched with water and ethyl acetate. The organic phase was washed with water and brine, and dried over sodium sulfate. Removal of the volatiles in vacuo afforded the yellow oil 2-[2-(3-bromophenyl)-2-methylpropyl]-2-trifluoromethyloxfrane which was used without further purification.

A mixture of 2-[2-(3-bromophenyl)-2-methylpropyl]-2-trifluoromethyloxirane, 4- hydroxyquinoline (2 equiv.), and sodium ethoxide (21 wt.% solution in ethanol, 1 equiv.) in ethanol was heated at 85°C for 14 hours, quenched with water, and concentrated in vacuo to remove most of the ethanol. The residue was diluted with half saturated aqueous sodium bicarbonate solution and methylene chloride. The organic phase was dried over sodium sulfate, filtered, and concentrated in vacuo. Purification of the residue by flash chromatography using ethyl acetate-hexanes gradient and concentration of the product-rich fractions afforded l-[4-(3- bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one.

A mixture of l-[4-(3-bromophenyl)-2-hydrOxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one (30 mg, 0.064 mmol), 3,5-dimethylisoxazole-4-boronic acid (9 mg, 0.064 mmol, 1 equiv.), bisdichlorotriphenylphosphinopalladium (II) (catalytic amount) and cesium carbonate (21 mg, 0.064 mmol) in 1.1 mL of ethylene glycol dimethyl ether-water-ethanol (7:3:2) was degassed, sealed in a vial, and irradiated twice (microwave) at 160°C for 300 seconds. The reaction was cooled to room temperature and filtered through CELITE® filter aid. The filtrate was diluted with water and extracted with diethyl ether. The combined organic layers were washed with brine and dried with sodium sulfate. Removal of the volatiles in vacuo provided a residue which was purified by ΗPLC to give l-{4-[3-(3,5-dimethylisoxazol-4-yl)phenyl]-2- hydroxy-4-methyl-2-trifluoromethylpentyl} - lH-quinolin-4-one.

Example 35: Synthesis of l-[4-(3-cyclopropanecarbonylphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one

35

To a solution of the Grignard reagent derived from 2-(3-bromophenyl)-[l,3]dioxane (52.6 mL of 0.25M in THF, 13.1 mmol) at 0°C was added copper (I) iodide (25 g, 13.1 mmol). After 45 minutes, l,l,l-trifluoro-4-methylpent-3-en-2-one (2 g, 13.1 mmol) was added and the reaction mixture slowly warmed to room temperature and stirred overnight. The mixture was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried with sodium sulfate, and concentrated in vacuo. The residue was triturated with hexanes and filtered. The filtrate was concentrated in vacuo to give 4-(3-[l,3]dioxan-2-ylphenyl)- 1,1,1 - trifluoro-4-methylpentan-2-one.

To a solution of 4-(3-[l,3]dioxan-2-ylphenyl)-l,l,l-trifluoro-4-methylpentan-2-one (1 g, 3 mmol) in 4.1 mL of anhydrous DMSO was added the sodium ylide of trimethylsulfoxonium iodide (3.0 mL of a 0.8M solution in DMSO) over 5 minutes. The reaction was stirred 2 hours and quenched with water and ethyl acetate. The organic layer was washed with water and brine, and dried over sodium sulfate. Removal of the volatiles in vacuo afforded 2-{3-[l,l- dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]phenyl}-[l,3]dioxane as a yellow oil.

A mixture of 2-{3-[l,l-dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]phenyl}-[l,3]dioxane (0.910 g, 2.75 mmol), 4-hydroxyquinoline (806 mg, 5.55 mmol) and sodium ethoxide (21 wt.% solution in ethanol, 1.03 mL, 2.7 mmol) in ethanol (7.7 mL) was capped and heated at 85°C for 14 hours. The mixture was quenched with water and concentrated in vacuo to remove most of the ethanol. The residue was diluted with half saturated aqueous sodium bicarbonate solution and methylene chloride. The organic layer was dried over sodium sulfate and concentrated in vacuo. Purification of the residue by flash chromatography using ethyl acetate-hexanes as the eluent. The product-rich fractions were concentrated in vacuo to l-[4-(3-[l,3]dioxan-2- ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one.

A mixture of l-[4-(3-[l,3]dioxan-2-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one (0.99 g, 2.09 mmol), ethanol (66 mL), water (13.2 mL), and pyridinium p- toluenesulfonic acid (262 mg, 1.04 mmol) was heated at reflux for 3 hours, cooled to room temperature and concentrated in vacuo to remove ethanol. The residue was diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, and dried over sodium sulfate. Removal of the volatile in vacuo afforded 3-[4,4,4-trifluoro-3-hydroxy-l,l- dimethyl-3-(4-oxo-4H-quinolin-l-ylmethyl)butyl]benzaldehyde. Yield: 77 mg (89%).

To a solution of 3-[4,4,4-trifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin-l- ylmethyl)butyl]benzaldehyde (0.10 g, 0.24 mmol) in anhydrous tetrahydrofuran (5 mL) and cooled in a ice/isopropanol bath was added dropwise cyclopropylmagnesium bromide (0.71 mL of a 0.84M solution in TΗF, 0.6 mmol). The mixture was slowly warmed to room temperature, quenched with saturated aqueous ammonium chloride solution, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. A mixture of the residue and hydrazine resin in TΗF was agitated for several hours and filtered. Removal of the volatiles in vacuo afforded alcohol l-{4-[3- (cyclopropylhydroxymethyl)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-lH- quinolin-4-one.

A mixture of l-{4-[3-(cyclopropylhydroxymethyl)phenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl }-lH-quinolin-4-one (26 mg, 0.057 mmol) and Mn0₂ (5 mg, 0.57 mmol) in methylene chloride (2 mL) was stirred for 48 hours at room temperature under an atmosphere of argon and filtered over CELITE® filter aid. The filtrate was concentrated in vacuo and the residue purified by reversed phase ΗPLC to afford l-[4-(3- cyclopropanecarbonylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one. Yield: 9 mg (35%). Example 36a and 36b: Synthesis of l-(2-Hydroxy-4-{3-[l-(hydroxyimino)ethyl]phenyl}-4- methyl-2-trifluoromethylpentyl)-lH-quinolin-4-one and l-(2-Hydroxy-4-{3-[l-

(methoxyimino)ethyl]phenyl}-4-methyl-2-trifluoromethylpentyl)-lH-quinolin-4-one

A mixture of 3-bromoacetophenone (10 mL, 75.6 mmol), ethylene glycol (10.1 mL, 181 mmol), and _»-toluenesulfonic acid hydrate in toluene (120 mL) was heated with azeotropic removal of water. After 4 hours, a second portion of ethylene glycol was added and the mixture heated at refluxed for 48 hours. The reaction was cooled to room temperature and washed with saturated aqueous sodium bicarbonate solution and brine, and dried over sodium sulfate. Removal of the volatiles in vacuo provided a residue that was purified by flash chromatography. Concentration of the product-rich fractions afforded 2-(3-bromophenyl)-2- methyl-[l,3]dioxolane as a clear oil. Yield: 2.44 g.

To a solution of 2-(3-bromophenyl)-2-methyl-[l,3]dioxolane (1 g) in THF (5 mL) was added portionwise magnesium metal (0.2 g) and the reaction heated at refluxed for 30 minutes. The mixture was cooled to room temperature and CuBr-DMS complex (846 mg, 4.11 mmol) was added. The mixture was stirred 3 minutes at room temperature, cooled to 0°C and 1,1,1- trifluoro-4-methylpent-3-en-2-one (62 mg, 4.11 mmol) in 20 mL of THF was added dropwise. The mixture was stirred for 30 minutes at 0°C, warmed to room temperature, stirred overnight and quenched with aqueous ammonium chloride solution and ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo to afford a residue that was purified by flash chromatography. Concentration in vacuo of the product-rich fractions afforded 0.56 g of l,l,l-trifluoro-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2- yl)phenyl]pentan-2-one.

To a solution of l,l,l-trifluoro-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2-yl)phenyl]pentan-2- one (0.56 g, 1.8 mmol) in anhydrous DMSO (2.3 mL) was added the sodium ylide of trimethylsulfoxonium iodide (2.6 mL of a 0.8M solution in DMSO) over 5 minutes. The mixture was stirred 2 hours, quenched with water, and extracted with ethyl acetate. The combined organic layers were washed with water and brine, and dried over sodium sulfate. The solution was concentrated in vacuo to afford the yellow oil, 2-{3-[l,l-dimethyl-2-(2- trifluoromethyloxiranyl)ethyl]phenyl}-2-methyl-[l,3]dioxolane, which was used without further purification.

A mixture of 2-{3-[l,l-dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]phenyl}-2-methyl- [l,3]dioxolane (0.514 g, 1.55 mmol), 4-hydroxyquinoline (0.433 g, 2.98 mmol), and sodium ethoxide (21 wt.% solution in ethanol, 0.55 mL, 1.49 mmol) in ethanol (4.2 mL) was heated at 85°C for 14 hours, cooled to room temperature, quenched with water, and concentrated in vacuo to remove most of the ethanol. The residue was diluted with half saturated aqueous sodium bicarbonate solution and extracted with methylene chloride. The organic layers were combined, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography using ethyl acetate-hexanes as the eluent. The product-rich fractions were concentrated in vacuo to afford l-{2-hydroxy-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2- yl)phenyl]-2-trifluoromethylpentyl}-lH-quinolin-4-one. Yield: 0.35 g.

A mixture of l-{2-hydroxy-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2-yl)phenyl]-2- trifluoromethylpentyl}-lH-quinolin-4-one (0.35 g, 0.75 mmol), ethanol (24 mL), water (4.8 mL), and pyridinium _z?-toluenesulfonic acid (95 mg, 0.37 mmol) was heated to reflux for 3 hours, cooled to room temperature, and concentrated in vacuo to remove most of the ethanol. The residue was diluted with ethyl acetate and water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with saturated aqueous sodium bicarbonate and brine, and dried over sodium sulfate. Removal of the volatiles in vacuo afforded l-[4-(3-acetylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one. Yield: 0.27 g (84%).

A mixture of l-[4-(3-acetylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one (60 mg, 0.14 mmol), potassium carbonate (79 mg, 0.57 mmol), and hydroxylamine hydrochloride (39 mg, 0.55 mmol) in methanol (1 mL) was heated at 65°C for 3 hours, cooled to room temperature, and concentrated in vacuo. The residue was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography to afford l-(2-hydroxy-4-{3-[l-(hydroxyimino)ethyl]phenyl}-4-methyl-2- trifluoromethylpentyl)- lH-quinolin-4-one. Yield: 38 mg.

A mixture of l-[4-(3-acetylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one (55 mg, 0.12 mmol), potassium carbonate (72 mg, 0.52 mmol), and methoxyamine hydrochloride (42 mg, 0.51 mmol) in 1 mL of methanol was heated at 65°C for 3 hours, cooled to room temperature, and concentrated in vacuo. The residue was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by flash chromatography to afford 1 -(2-hydroxy-4- {3-[l -(methoxyimino)ethyl]phenyl} -4-methyl-2-trifluoromethyl- pentyl)-lH-quinolin-4-one. Yield: 48 mg.

Example 37: Synthesis of l-[2-hydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7- yl)-4-methyl-2-trifluoromethyIpentyl]-lH-quinolin-4-one

To a solution of 10 g (29 mmol) of 4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentanoic acid ethyl ester in 20 mL of acetic acid (HOAc) was added dropwise a solution of 1.55 mL (30 mmol) of bromine in 10 mL of HOAc. The reaction was monitored by proton NMR. An additional 0.5 mL of Br₂ was added. The mixture was diluted with saturated aqueous sodium bicarbonate and extracted with diethyl ether. The organic layer was dried over magnesium sulfate and concentrated in vacuo to afford 11.7 g (95%) of 4-(5-bromo-2,3- dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentanoic acid ethyl ester.

To a suspension of 1.25 g (33 mmol) of lithium aluminum hydride in 50 mL of THF at 0°C was added dropwise a solution of 11.7 g (27.5 mmol) of 4-(5-bromo-2,3-dihydrobenzofuran-7-yl)- 2-hydroxy-4-methyl-2-trifluoromethylpentanoic acid ethyl ester in 20 mL of THF. The reaction was warmed to room temperature, stirred 2 hours, cooled to 0°C, carefully quenched with water, followed by IN HCl, and extracted with EtOAc. The organic layers were combined, dried over magnesium sulfate, and concentrated in vacuo. The residue was triturated with hexanes and the solid collected by filtration to afford 7.6 g (72%) of 4-(5-bromo-2,3- dihydrobenzofuran-7-yl)-4-methyl-2-xrifluoromethylpentane-l,2-diol.

A mixture of 7.6 g (20 mmol) of 4-(5-bromo-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentane-l,2-diol and 0.754 g (4 mmol) of_σ-toluenesulfonic acid monohydrate in 200 mL of acetone was stirred at room temperature for 6 days and the volatiles removed in vacuo. The residue was dissolved in EtOAc, washed with saturated aqueous sodium bicarbonate, dried over magnesium sulfate, and concentrated in vacuo. The residue was extracted with diethyl ether and the filtrate concentrated in vacuo to afford 6.3 g (75%) of 5- bromo-7-[2-(2,2-dimethyl-4-trifluoromethyl-[ 1 ,3]dioxolan-4-yl)- 1 , 1 -dimethylethyl]-2,3 - dihydrobenzofuran.

To a solution of 1 g (2.4 mmol) of 5-bromo-7-[2-(2,2-dimethyl-4-trifluoromethyl- [l,3]dioxolan-4-yl)-l,l-dimethylethyl]-2,3-dihydrobenzofuran in 20 mL of THF at -78°C was added 1.05 mL (2.6 mmol) of 2.5M solution «-BuLi in hexanes. After 20 minutes, 0.255 mL (2.8 mmol) of methyl disulfide was added and the reaction was warmed to room temperature. The reaction was monitored by TLC. The mixture was cooled to -78°C and quenched with saturated ammonium chloride, and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate, and concentrated in vacuo to afford 0.89 g of an oil which was purified by silica gel chromatography using 5% to 40% methylene chloride in hexanes as the eluent. Concentration in vacuo of the product-rich fractions gave 0.31 g (34%) of 7-[2-(2,2- dimethyl-4-trifluoromethyl-[l ,3]dioxolan-4-yl)- 1 , 1 -dimethylethyl]-5-methylsulfanyl-2,3- dihydrobenzofuran.

A solution of 0.31 g of 7-[2-(2,2-dimethyl-4-xrifluoromethyl-[l,3]dioxolan-4-yl)-l,l- dimethylethyl]-5-methylsulfanyl-2,3-dihydrobenzofuran and 0.015 g of _σ-toluenesulfonic acid (p-TsOH) monohydrate in methanol (10 mL) was stirred at room temperature for 7 days, heated to reflux for 1 minute, and the volatiles removed in vacuo. The residue was diluted with saturated aqueous sodium bicarbonate and filtered. The solid was washed with water and hexanes, and dried to give 0.235 g of 4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7- yl)-2-trifluoromethylpentane- 1 ,2-diol.

To a solution of 0.313 g (0.8 mmol) of 4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7- yl)-2-trifluoromethylpentane-l,2-diol and 0.06 mL of methanesulfonyl chloride in 10 mL of MeQHCH₂Cl₂ at 0°C was added 0.015 g (0.08 mmol) of ^-TsOH monohydrate. The mixture was warmed to room temperature, stirred overnight, and additional (0.01 g) _σ-TsOH monohydrate was added. The mixture was stirred 3 days and concentrated in vacuo. The residue was diluted with saturated aqueous sodium bicarbonate and the solid was collected by filtration. The solid was washed with water and hexanes, and dried to afford 0.235 g (84%) of a solid which was dissolved in 10 mL of THF and cooled to 0°C. NaH (0.064 g of 60% oil dispersion) was added and the mixture warmed to room temperature and stirred overnight. The mixture was quenched with saturated aqueous ammonium chloride (NH CI) and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on PLC plate (hexanes-EtOAc (95:5)) to give 0.145 g of 7-[l,l-dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]-5-methylsulfanyl-2,3- dihydrobenzofuran.

7-[l,l-dimethyl-2-(2-trifluoromemyloxiranyl)ethyl]-5-methylsulfanyl-2,3-dihydrobenzofuran was reacted with 4-hydroxyquinoline and sodium ethoxide according to Example 35 to give 1- [2-hydroxy-4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7-yl)-2- trifluoromethylpentyl]-lH-quinolin-4-one.

To a solution of 0.03 g (0.06 mmol) of l-[2-hydroxy-4-methyl-4-(5-methylsulfanyl-2,3- dihydrobenzofuran-7-yl)-2-trifluoromethylpentyl]-lH-quinolin-4-one and 0.04 g (0.18 mmol) of NaI0₄ in 3 mL of acetonitrile and 1 mL of water at room temperature was added a catalytic amount of RuCl₃. The mixture was stirred 30 minutes, diluted with water, and extracted with EtOAc. The organic layers were combined, dried over sodium sulfate, and concentrated in vacuo. The residue was purified on a PLC plate eluting with dichloromethane-methanol (CΗ₂Cl₂/Me0Η, 95:5) to afford 0.008 g (27%) of l-[2-hydroxy-4-(5-methanesulfonyl-2,3- dihydrobenzofuran-7-yl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one.

Example 38: Synthesis of l,l,l-trifluoro-3-(6-fluoro-4-methylchroman-4-yl)propan-2-one

A mixture of 10.0 g (60 mmol) of 6-fluorochroman-4-one, 7.9 mL (90 mmol) of methyl cyanoacetate, 0.54 mL (5 mmol) of benzylamine, and 3 mL of acetic acid in 100 mL of toluene was heated to reflux with azeotropic removal of water. After 18 hours, additional methyl cyanoacetate and acetic acid was added. The reaction was monitored by TLC and then the reaction was concentrated under a stream of nitrogen. The residue was passed through a pad of silica gel using EtOAc-hexanes (1:9) to afford 3.4 g (22%) of cyano-[6-fluorochroman-(4E/Z)- ylidenejacetic acid methyl ester which was a mixture of geometric isomers.

To a chilled (0°C) suspension of 4.3 g (22.6 mmol) of copper (I) iodide in 75 mL of diethyl ether was added 26 mL (41.6 mmol) of a 1.6M solution of methyl lithium in diethyl ether. After 5 minutes, the mixture was cooled to -20°C and a solution of 3.36 g (13.6 mmol) of cyano-[6-fluorochroman-(4E/Z)-ylidene]acetic acid methyl ester in 20 mL of diethyl ether was added. The mixture slowly warmed to room temperature, and was monitored by proton NMR. The reaction was cooled -78°C and quenched with saturated aqueous ammonium chloride and warmed to room temperature. The mixture was then filtered through diatomaceous earth and the aqueous layer was separated and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to afford 3.1 g (86%) of cyano- (6-fluoro-4-methylchroman-4-yl)acetic acid methyl ester as a mixture of diastereomers which was used without further purification.

A mixture of 3.1 g (11.8 mmol) of cyano-(6-fluoro-4-methylchroman-4-yl)acetic acid methyl ester and 2.47 g (42.4 mmol) of sodium chloride in 30 mL of wet DMSO was warmed to reflux. The reaction was monitored by TLC. After 4 hours, the reaction was cooled and diluted with water and extracted with diethyl ether. The combined organic layers were washed with four portions of water, brine, dried over magnesium sulfate, and concentrated in vacuo to afford 2.1 g (87%) of (6-fluoro-4-memylchroman-4-yl)acetonifrile as an oil.

To a chilled (-40°C) solution of 2.1 g (10.2 mmol) of (6-fluoro-4-methylchroman-4- yl)acetonitrile in 30 mL of dichloromethane was added 11.4 mL (11.4 mmol) of a IM solution of diisobutylaluminum hydride in dichloromethane. The mixture was warmed to room temperature. After 1 hour, the mixture was cautiously quenched with minimal water, dried over magnesium sulfate, filtered through diatomaceous earth, and concentrated in vacuo to afford 1.7 g (80%) of (6-fluoro-4-methylchroman-4-yl)acetaldehyde as an oil which was used without further purification. To 1.7 g (8.16 mmol) of (6-fluoro-4-methylchroman-4-yl)acetaldehyde and 1.69 mL (11.4 mmol) of trimethyl(trifluoromethyl)silane in 15 mL of tefrahydrofuran was added 1 mL (1 mmol) of a IM solution of tefrabutylammonium fluoride in tefrahydrofuran. The mixture stirred for 1 hour and then an additional 9 mL (9 mmol) of a IM solution of tefrabutylammonium fluoride in tefrahydrofuran was added. After 18 hours, the mixture was concentrated in vacuo and diluted with IN aqueous HCl and extracted with three 50 mL portions of diethyl ether. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to afford 2.4 g of crude l,l,l-frifluoro-3-(6-fluoro-4-methylchroman-4- yl)propan-2-ol as a mixture of diastereomers. The crude oil was used without further purification.

To a solution of 2.4 g (8.62 mmol) of l,l,l-trifluoro-3-(6-fluoro-4-methylchroman-4- yl)propan-2-ol in 20 mL of dichloromethane was added 11.8 mmol of Dess-Martin periodinane. After 18 hours, the mixture was adsorbed onto silica gel and passed through a pad of silica gel, washing with EtOAc-hexanes (1:9) to afford 1.05 g (44%) of the title compound as an oil.

The following trifluoromethyl ketones were also prepared by the method of Example 34:

1,1,1 -Trifluoro-3 -( 1 -methylindan- 1 -yl)propan-2-one;

1,1,1 -Trifluoro-3 -(6-fluorochroman-4-yl)propan-2-one (prepared by foregoing the methyl cuprate step and reducing the double bond under standard hydrogenation conditions (Pd/C, H₂ atmosphere);

3 -Chroman-4-yl- 1,1,1 -trifluoropropan-2-one; and

4-Benzo[ 1 ,3]dioxol-4-yl- 1,1,1 -trifluoro-4-methylpentan-2-one.

Example 39: Synthesis of l-benzo[l,3]dioxol-4-ylethanone

To a chilled (-78°C) solution of 10 g of benzo[l,3]dioxole-4-carbaldehyde in 200 mL of THF was added by addition funnel 43.7 mL of a 1.6M MeLi solution in diethyl ether. The reaction was slowly warmed to room temperature and stirred overnight. The reaction was monitored by TLC. The mixture was then cooled to -78°C and quenched with saturated aqueous ammonium chloride and concentrated in vacuo. The residue was extracted with EtOAc. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to give 11 g of 1- benzo[l,3]dioxol-4-ylethanol as a brown oil that crystallized upon standing.

To a solution of 11 g of l-benzo[l,3]dioxol-4-ylethanol in 100 mL of THF was added 17.26 g of Mn0₂ in one portion and reaction was monitored by TLC. After several hours, TLC showed a new product and starting material. Additional Mn0₂ was added. TLC indicated still the reaction was incomplete. The mixture was filtered through CELITE® filter aid and concentrated in vacuo to afford an oil that partially crystallized. To a chilled (-60°C) solution of 9.24 mL of oxalyl chloride in 120 mL of methylene chloride was added a solution of 15 mL of DMSO in 20 mL of methylene chloride. After 10 minutes, a solution of above alcohol/ketone mixture (53 mmol) in 20 mL of methylene chloride was added. After 15 minutes, 44.3 mL of triethylamine was added. The reaction was allowed to slowly warm to room temperature overnight and was then poured onto ice. The organic layer was separated and washed with five 100 mL portions of water, washed with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a tan solid. Trituration with hexanes gave 9.33 g of the title compound.

l-Benzo[l,3]dioxol-4-ylethanone was converted to the corresponding trifluoromethyl ketone according to Example 34.

Example 40: Synthesis of 2-Hydroxy-4-methyI-4-phenyI-2-trifluoromethylhexanoic acid ethyl ester

To a solution of 5 g (38 mmol) of 2-phenylpropionitrile in 50 mL of DMSO was added 42 mL of a IM solution of NaHMDS in THF. After 15 minutes, the reaction was cooled to 0°C and 4.6 mL of ethyl iodide was added. The reaction was monitored by TLC. After 30 minutes, the mixture was poured into water and extracted with diethyl ether. The combined organics were washed with four portions of water, washed with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to afford 6.1 g of 2-methyl-2-phenylbutyronitrile as an oil.

To a solution of 6.1 g of 2-methyl-2-phenylbutyronitrile in 50 mL of methylene chloride at room temperature was added dropwise 57 mL of a IM solution of DIBAl in methylene chloride. The reaction was monitored by TLC. After 30 minutes, the reaction was carefully poured into 100 mL of IN aqueous HCl and the organic layer separated and concentrated in vacuo. The residue was diluted with diethyl ether, combined with the aqueous layer, and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on silica gel column eluting with ethyl acetate-hexanes (0-2%) to afford 4.2 g of 2-methyl-2-phenylbutyraldehyde as a colorless oil.

To a chilled (0°C) solution of 7.4 g of (diethoxyphosphoryl)ethoxy acetic acid ethyl ester in 30 mL of THF was added 16 mL of a 1.8M solution of LDA. After 30 minutes, 4.2 g of 2-methyl- 2-phenylbutyraldehyde in 30 mL of THF was added dropwise by syringe. The mixture was warmed to room temperature, quenched with saturated aqueous ammonium chloride, and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo to afford 8.3 g of 2-ethoxy-4-methyl-4-phenylhex-2-enoic acid ethyl ester as an orange oil and a mixture of geometric isomers (2: 1). To a solution of 8.3 g of 2-ethoxy-4-methyl-4-phenylhex-2-enoic acid ethyl ester in 25 mL of acetic acid was added 116 mL of IM aqueous sulfuric acid (H₂S0 ). The reaction was stirred at room temperature for several hours. The reaction was monitored by TLC. The reaction was warmed at 100°C overnight. An additional 2 mL of concentrated sulfuric acid and 20 mL of acetic acid was added. After 1 hour, the reaction was cooled to room temperature and extracted with diethyl ether. The combined organics were washed with four portions of water, washed with brine, dried over magnesium sulfate, filtered, and concenfrated in vacuo to afford 2.5 g of an orange oil. A proton NMR indicated 1 : 1 mixture of minor isomer and aldehyde. The aqueous layer was extracted with EtOAc. The combined ethyl acetate layers were dried over magnesium sulfate and concentrated in vacuo to afford a brown liquid. NMR showed a mixture of the desired product as the ketoacid. The mixture was diluted with 200 mL of ethanol, 1 mL of concentrated HCl was added, and the mixture was refluxed overnight. The reaction was cooled to room temperature and concentrated in vacuo. The residue was diluted with water and extracted with diethyl ether. The combined organics were dried over magnesium sulfate, filtered, and concenfrated in vacuo to afford 4.3 g of 4-methyl-2-oxo-4-phenylhexanoic acid ethyl ester as an orange oil.

To a solution of 4.3 g of 4-methyl-2-oxo-4-phenylhexanoic acid ethyl ester and 3.6 mL of frifluoromethyltrimethylsilane in 50 mL of THF was added 1.5 mL (0.1 equiv.) of IM TBAF in THF. The reaction stirred until ketoester was consumed by TLC. After 30 minutes, 17.5 mL of TBAF was added. After 1 hour, the mixture was concentrated in vacuo and the residue was diluted with IN aqueous HCl and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a brown oil. The residue was diluted with hexanes (cloudy), treated with activated charcoal, filtered through CELITE® filter aid, and concenfrated in vacuo to afford 3.8 g of 2-hydroxy-4-methyl-4- phenyl-2-trifluoromethylhexanoic acid ethyl esters as a mixture of diastereomers as a light green oil.

The diastereomeric mixture of esters was converted to the corresponding epoxides according to Example 1. Example 41: Synthesis of 6-bromo-4-[l,l-dimethyI-2-(2- trifiuoromethyloxiranyl)ethyl]benzo[l,3]dioxole

To a solution of 0.1 g (0.35 mmol) of 4-[l,l-dimethyl-2-(2- trifluoromethyloxiranyl)ethyl]benzo[l,3]dioxole in 5 mL of THF was added 0.06 g (0.35 mmol) of N-bromosuccinimide. The reaction was monitored by TLC. After stirring overnight, TLC showed starting material and a new slightly more polar spot. The reaction was concenfrated in vacuo and the residue was diluted with hexanes. The resulting suspension was filtered to remove insoluble material and the filtrate was purified by chromatography over silica gel eluting with ethyl acetate-hexanes (0-10%) to afford an oil as a mixture of starting material and product (3.5:1) by proton ΝMR. The residue was dissolved in 3 mL of acetonitrile and 0.06 g (0.35 mmol) of N-bromosuccinimide was added. After 3 hours, a TLC indicated the reaction was complete and it was worked up as above to afford 0.07 g (54%) of 6-bromo-4- [l,l-dimethyl-2-(2-trifluoromethyloxiranyl)ethyl]benzo[l,3]dioxole as a yellow oil.

Example 42: Synthesis l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyI]-l,3-dihydroindol-2-one

To a solution of 42 mg (0.31 mmol) of oxindole in 1 mL of DMF was added 10 mg (0.39 mmol) of 60% sodium hydride in mineral oil. After hydrogen evolution ceased, 50 mg (0.17 mmol) of 2-[2-(5-fluoro-2-methoxyphenyl)-2-methylpropyl]-2-trifluoromethyloxirane was added and the mixture was warmed to 75 °C. The reaction was monitored by TLC (ethyl acetate-hexanes (15:85)). After 40 minutes, the mixture was cooled and diluted with saturated aqueous ammonium chloride and extracted with three 5 mL portions of ethyl acetate. The combined organic layers were washed with three 5 mL portions of brine, dried over magnesium sulfate, and concentrated in vacuo. The crude material was chromatographed on silica gel prep plates (2 x 1 mm, ethyl acetate-hexanes (15:85)). The material from the prep plate was recrystallized from dichloromethane-hexanes-ether to afford 14 mg of the title compound.

Example 43: Synthesis of l-[2-difluoromethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4- methylpentyl] -lH-quinolin-4-one

To a solution of the 4-fluorophenol (25.3 g) and dimethylacryloyl chloride (25.9 g) in dusopropyl ether (500 mL) cooled in an ice bath was added friethylamine (35 mL) dropwise over a period of 20 minutes. After 1 hour, the reaction mixture was washed with water and brine, dried over sodium sulfate, and the organic solvent was evaporated in vacuo to give crude ester. Distillation under vacuum gave dimethylacrylate 4-fluorophenyl ester (38.20 g, 87%).

To a stirred suspension of aluminum trichloride (18.0 g) in carbon disulfide (30 mL) was added dimethylacrylate 4-fluorophenyl ester (18.0 g, 92.7 mmol) dropwise over a 0.5 hour period. The reaction mixture was stirred at room temperature for 14.0 hours. The reaction was poured onto ice and extracted with ethyl acetate-hexanes (1:10, 200 mL). The organic phase was washed with saturated sodium bicarbonate, dried over anhydrous sodium sulfate, and evaporated in vacuo. Trituration of the residue with cold hexane gave a colorless crystalline 6- fluoro-4,4-dimethylchroman-2-one (13.9 g, 77%).

To a solution of 6-fluoro-4,4-dimethylclιroman-2-one (5.40 g) dissolved in DMSO (20.0 mL) was added a solution of potassium hydroxide (6.00 g) dissolved in water (10.0 mL) over 5 minutes. After 20 minutes, methyl iodide (4.0 mL) was added portionwise over 15 minutes and the mixture was stirred at room temperature for 14.0 hours. The mixture was diluted with hexanes, washed with water, dried, filtered, and evaporated in vacuo. Distillation yielded the methyl 3-methyl-3-(2-methoxy-5-fluorophenyl)butanoate (4.2 g, 63%).

To a suspension of lithium aluminum hydride (0.75 g) in THF (20 mL) stirred under nitrogen was added dropwise a solution of methyl 3-methyl-3-(2-methoxy-5-fluorophenyl)butanoate (4.2 g) dissolved in THF (10 mL). The rnixture was stirred at room temperature for 4 hours. The reaction was quenched by cautious addition of water (1 mL) and diluted with ether (100 mL). The mixture was filtered through FLORISIL® selective adsorbent and evaporated to dryness in vacuo to give 3-methyl-3-(2-methoxy-5-fluorophenyl)butan-l-ol as an oil (3.30 g, 89%).

To a solution of 3-methyl-3-(2-methoxy-5-fluorophenyl)butan-l-ol (3.30 g) in methylene chloride (40 mL) stirred at room temperature was added pyridinium chlorochromate (4.2 g) portionwise over 5 minutes. The mixture was stirred for 3 hours and then filtered through CELITE® filter aid. The solvent was evaporated in vacuo and the residue was fractionated by chromatography over silica gel (methylene chloride-hexane (1:3 to 1:1 gradient)) to give 3- methyl-3-(2-methoxy-5-fluorophenyl)butyraldehyde an oil (2.5 g, 76%).

To a solution of the difluoromethylphosphonic acid diethyl ester (1.35 g) in THF (5.0 mL) cooled in a dry ice/acetone bath was added LDA (5.0 mL, 1.5M in cyclohexane) dropwise over 5.0 minutes. After 10.0 minutes, a solution of 3-methyl-3-(2-methoxy-5- fluorophenyl)butyraldehyde (0.94 g) in THF (5.0 L) was added dropwise. After an additional 20.0 minutes, acetic acid (1 mL) was added and the mixture was warmed to room temperature. The mixture was diluted with ethyl acetate, washed with water, dried, filtered, and evaporated in vacuo. Fractionation of the residue over silica gel (eluent: methylene chloride-ethyl acetate (1:4)) gave the desired [l,l-difluoro-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4- methylpentyl]phosphonic acid diethyl ester (1.15 g, 40%) as an oil that crystallized on freatment with hexanes.

A solution of oxalyl chloride (2.2 mL, 2.0M in dichloromethane) was diluted with dichloromethane (3.0 mL) and cooled in a dry ice/acetone bath. To this solution was added a solution of DMSO (0.7 mL) in dichloromethane (2.5 mL) dropwise. After 10 minutes, a solution of the [l,l-difluoro-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4- methylpentyl]phosphonic acid diethyl ester (1.10 g) in dichloromethane (3 mL) was added and the mixture was stirred for 15 minutes. Triethylamine (4.0 mL) was added, the cooling bath was removed, the reaction mixture was allowed to warm to room temperature and quenched with water and diluted with hexanes. The organic layer was separated, washed with water, dried, filtered, and concentrated in vacuo. The residue was purified by chromatography over silica gel (eluent: hexanes to hexanes-ethyl acetate (2:1) gradient) to give [l,l-difluoro-4-(5- fluoro-2-methoxyphenyl)-4-methyl-2-oxopentyl]phosphonic acid diethyl ester as an oil (1.0 g, 91%).

To a solution of [l,l-difluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxopentyl]phosphonic acid diethyl ester (1.0 g) in methanol (12.0 mL) was added a solution of sodium hydroxide (0.04 g) in water (1 mL). The mixture was stirred at room temperature for 30 minutes. The mixture was diluted with hexanes (50 mL) and water (50 mL) and the organic phase was separated, dried, filtered, and evaporated in vacuo to give l,l,-difluoro-4-methyl-4-(2-methoxy- 5-fluorophenyl)pentan-2-one (0.63 g) as an oil which was used without additional purification.

To suspension of frimethylsulfoxonium iodide (0.22 g) in DMSO (0.5 mL) and THF (0.5 mL) stirred under nitrogen and cooled on ice was added sodium hexamethyldisilazide (1.0 mL, 1.0M in THF) dropwise over 5 minutes. After 15 minutes, a solution of l,l,-difluoro-4-methyl-4-(2- methoxy-5-fluorophenyl)pentan-2-one (0.23 g) in THF (0.6 mL) was added dropwise and the mixture was allowed to come to room temperature over 2 hours. The mixture was diluted with hexane, washed with water, dried, filtered, and evaporated in vacuo to give 2-[2-(5-fluoro-2- methoxyphenyl)-2-methylpropyl]-2-difluoromethyloxirane as an oil (0.25 g).

To a solution of the 4-hydroxyquinoline and 2-[2-(5-fluoro-2-methoxyphenyl)-2- methylpropyl]-2-difluoromethyloxhane in DMSO (1.0 mL) stirred under nitrogen was added NaHMDS (1.2 mL, l.OM in THF) dropwise. The mixture was stirred at room temperature for 15 days. The mixture was diluted with ethyl acetate, washed with water, dried, filtered, and evaporated in vacuo. Trituration of the residue with diethyl ether gave the product l-[2- difluoromethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin-4-one as a crystalline solid that was collected by filtration and air dried (77.7 mg, 20%).

Example 44: Synthesis of l,l,l-Trifluoro-4-(2-methoxy-5-methylphenyl)-4-methylpentan- 2-one

To a yellow solution of 20 g of 4-methylanisole and 1.7 mL of concentrated sulfuric acid was added dropwise 19.17 mL of 3-chloro-2-methylpropene. The reaction became warm and turned dark puφle and after 20 minutes a precipitate formed. The reactions was monitored by TLC indicating a new less polar product. After 18 hours, the reaction was poured onto ice and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated in vacuo to leave an oil. The residue was diluted with hexanes, cooled to -78°C, and the solids collected by filtration to afford 14 g of 2-(2-chloro-l,l- dimethylethyl)-l-methoxy-4-methylbenzene which melted upon warming to room temperature. The filtrate was concentrated in vacuo to afford 15.5 g of product and starting anisole (4:1 mixture).

To a suspension of 1.87 g of Mg turnings in 30 mL of dry diethyl ether under argon in a water bath was added 1.62 mL of dibromoethane slowly by syringe while maintaining the temperature below 27°C. A solution of 4 g of 2-(2-chloro-l,l-dimethylethyl)-l-methoxy-4- methylbenzene and additional dibromoethane (1.62 mL) in 20 mL of diethyl ether was added by addition funnel at a rate that kept the internal temp below 25 °C The reaction became green and a fine precipitate formed. After 1 hour, the reaction was cooled to -78°C, solids formed on the bottom, stirring stopped, and a solution of 3.98 mL of trifluoroacetic anhydride in 4 mL diethyl ether was added by addition funnel while swirling the reaction by hand. The reaction was warmed to room temperature and stirring resumed above -40°C. The reaction was monitored by TLC indicating a new slightly more polar product and starting material. The reaction was poured onto cold IN aqueous HCl and extracted with diethyl ether. The combined organic layers were dried over magnesium sulfate and concentrated in vacuo. The residue was purified on silica gel column eluting with ethyl acetate-hexanes (0%-5%) to afford 1.7 g of l,l,l-trifluoro-4-(2-methoxy-5-methylphenyl)-4-methylpentan-2-one as a clear oil.

Example 45: Synthesis of {4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3,4-dihydro-2H-quinoxalin-l-yl}furan-2-ylmethanone

To a solution of 2-(3,4-dihydro-2H-quinoxalin-l -ylmethyl)- 1,1,1 -frifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol (0.50 g, 0.117 mmol) in dichloromethane (10 mL) was added pyridine (0.24 mL, 0.129 mmol) and 2-furoyl chloride (0.012 mL, 0.129 mmol). The reaction was stirred at room temperature for 14 hours. The reaction mixture was diluted with dichloromethane, washed with two 25 mL portions of a saturated aqueous sodium bicarbonate, dried over sodium sulfate, filtered, and the solvent was evaporated in vacuo. Purification by flash column chromatography (5% MeOΗ/CΗ₂Cl₂) yielded the title compound as a white solid (14.5 mg).

Assessment of Biological Properties

Compounds of the invention were evaluated for binding to the steroid receptor by a fluorescence polarization competitive binding assay. Detailed descriptions for preparation of recombinant glucocorticoid receptor (GR) complex used in the assay is described in U.S. Patent Application Publication No. 2003/00175503 and incoφorated herein by reference in its entirety. Preparation of the tetramethyl rhodamine (TAMRA)-labeled dexamethasone probe was accomplished using a standard literature procedure (M. Pons et al, J. Steroid Biochem., 1985, 22, pp. 267-273). A. Glucocorticoid Receptor Competitive Binding Assay Step 1. Characterization of the Fluorescent Probe

The wavelengths for maximum excitation and emission of the fluorescent probe should first be measured. An example of such a probe is rhodamine (TAMRA)-labeled dexamethasone.

The affinity of the probe for the steroid receptor was then determined in a titration experiment. The fluorescence polarization value of the probe in assay buffer was measured on an SLM- 8100 fluorometer using the excitation and emission maximum values described above. Aliquots of expression vector lysate were added and fluorescence polarization was measured after each addition until no further change in polarization value was observed. Non-linear least squares regression analysis was used to calculate the dissociation constant of the probe from the polarization values obtained for lysate binding to the probe.

Step 2. Screening for Inhibitors of Probe Binding This assay uses fluorescence polarization (FP) to quantitate the ability of test compounds to compete with tetramethyl rhodamine (TAMRA)-labeled dexamethasone for binding to a human glucocorticoid receptor (GR) complex prepared from an insect expression system. The assay buffer was: 10 mM TES, 50 mM KC1, 20 mM Na₂Mo0₄ ^»2H₂0, 1.5 mM EDTA, 0.04% w/v CHAPS, 10% v/v glycerol, 1 mM dithiothreitol, pH 7.4. Test compounds were dissolved to 1 mM in neat DMSO and then further diluted to lOx assay concenfration in assay buffer supplemented with 10% v/v DMSO. Test compounds were serially diluted at lOx assay concentrations in 10% DMSO-containing buffer in 96-well polypropylene plates. Binding reaction mixtures were prepared in 96-well black Dynex microtiter plates by sequential addition of the following assay components to each well: 15 μL of lOx test compound solution, 85 μL of GR-containing baculovirus lysate diluted 1:170 in assay buffer, and 50 μL of 15 nM TAMRA- labeled dexamethasone. Positive controls were reaction mixtures containing no test compound; negative controls (blanks) were reaction mixtures containing 0.7 μM to 2 μM dexamethasone. The binding reactions were incubated for 1 hour at room temperature and then read for fluorescence polarization in the LJL Analyst set to 550 nm excitation and 580 nm emission, with the Rhodamine 561 dichroic mirror installed. IC₅o values were determined by iterative non-linear curve fitting of the FP signal data to a 4-parameter logistic equation. Compounds found to bind to the glucocorticoid receptor may be evaluated for binding to the progesterone receptor (PR), estrogen receptor (ER), and mineralocorticoid receptors to evaluate the compound's selectivity for GR. The protocols for PR and MR are identical to the above GR method, with the following exceptions: PR insect cell lysate is diluted 1:7.1 and MR lysate diluted 1 :9.4. PR probe is TAMRA-labeled mifepristone, used at a final concentration of 5 nM in the assay, and the negative controls (blanks) were reactions containing mifepristone at 0.7 μM to 2 μM.

The ER protocol is similar to the above protocols, but uses PanNera kit receptor, fluorescein- labeled probe. The assay components are made in the same volumes as above, to produce final assay concentrations for ER of 15 nM and ES2 probe of 1 nM. In addition, the component order of addition is modified from the above assays: probe is added to the plate first, followed by receptor and test compound. The plates are read in the LJL Analyst set to 485 nm excitation and 530 nm emission, with the Fluorescein 505 dichroic mirror installed.

Compounds found to bind to the glucocorticoid receptor may be evaluated for dissociation of transactivation and transrepression by assays cited in the Background of the Invention (CM. Bamberger and H.M. Schulte, Eur. J. Clin. Invest., 2000, 30 (suppl. 3) 6-9) or by the assays described below.

B. Glucocorticoid Receptor Cell Assays

1. Induction ofAromatase in Fibroblasts (Cell Assay for Transactivation) Dexamethasone, a synthetic ligand to the glucocorticoid receptor (GR), induces expression of aromatase in human foreskin fibroblast cells. The activity of aromatase is measured by the conversion of testosterone to esfradiol in culture media. Compounds that exhibit binding to GR are evaluated for their ability to induce aromatase activity in human foreskin fibroblasts.

Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429, designation CCD112SK) are plated on 96 well plates at 50,000 cells per well 5 days before use, in Iscove's Modified Dulbecco's Media (GibcoBRL Life Technologies Cat No. 12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No. 15710-064). On the day of the experiment, the media in the wells is replaced with fresh media. Cells are treated with test compounds to final concentrations of 10^"5 M to 10^"8 M, and testosterone to a final concentration of 300 ng/mL. Each well has a total volume of 100 μL. Samples are made in duplicates. Control wells include: (a) wells that receive testosterone only, and (b) wells that receive testosterone plus 2 μM of dexamethasone to provide maximum induction of aromatase. Plates are incubated at 37°C overnight (15 to 18 hours), and supematants are harvested at the end of incubation. Esfradiol in the supernatant is measured using ELISA kits for esfradiol (made by ALPCO, obtained from American Laboratory Products Cat. No. 020-DR-2693) according to the manufacture's instruction. The amount of esfradiol is inversely proportional to the ELISA signals in each well. The extent of aromatase induction by test compounds is expressed as a relative percentage to dexamethasone. EC₅₀ values of test compounds are derived by non-linear curve fitting.

2. Inhibition of IL-6 Production in Fibroblasts (Cell Assay for Transrepression) Human foreskin fibroblast cells produce IL-6 in response to stimulation by pro-inflammatory cytokine IL-1. This inflammatory response, as measured by the production of IL-6, can be effectively inhibited by dexamethasone, a synthetic ligand to the glucocorticoid receptor (GR). Compounds that exhibit binding to GR are evaluated for their ability to inhibit IL-6 production in human foreskin fibroblasts.

Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429) are plated on 96 well plates at 5,000 cells per well the day before use, in Iscove's Modified Dulbecco's Media (GibcoBRL Life Technologies Cat. No. 12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat. No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No. 15710- 064). On the next day, media in the wells is replaced with fresh media. Cells are treated with IL-1 (rhIL-lα, R&D Systems Cat. No. 200-LA) to a final concentration of 1 ng/mL, and with test compounds to final concentrations of 10^"5 M to 10^"8 M, in a total volume of 200 μL per well. Samples are done in duplicates. Background control wells do not receive test compounds or IL-1. Positive control wells receive IL-1 only and represent maximum (or 100%) amount of IL-6 production. Plates are incubated at 37°C overnight (15 to 18 hours), and supematants are harvested at the end of incubation. IL-6 levels in the supematants are determined by the ELISA kits for IL-6 (MedSystems Diagnostics GmbH, Vienna, Austria, Cat. No. BMS213TEN) according to manufacture's instructions. The extent of inhibition of IL-6 by test compounds is expressed in percentage relative to positive controls. IC₅₀ values of test compounds are derived by non-linear curve fitting.

Evaluation of agonist or antagonist activity of compounds binding to the glucocorticoid receptor may be determined by any of the assays.

3. Modulation ofTyrosine Aminotransferase (TAT) Induction in Rat Hepatoma Cells

Testing of compounds for agonist or antagonist activity in induction of tyrosine aminotransferase (TAT) in rat hepatoma cells.

H4-II-E-C3 cells were incubated overnight in 96 well plates (20,000 cells/100 μL/well) in MEM medium containing 10% heat inactivated FBS and 1% nonessential amino acids. On the next day, cells were stimulated with the indicated concentrations of dexamethasone or test compound (dissolved in DMSO, final DMSO concentration 0.2%) for 18 hours. Control cells were treated with 0.2% DMSO. After 18 hours, the cells were lysed in a buffer containing 0.1% Triton X-100 and the TAT activity was measured in a photometric assay using tyrosine and alpha-ketoglutarate as substrates.

For measuring antagonist activity, the hepatoma cells were pre-stimulated by addition of dexamethasone (concentration ranges from 3 x 10^"9 M to 3 x 10^"8 M) shortly before the test compound was applied to the cells. The steroidal non-selective GR PR antagonist mifepristone was used as control.

4. Modulation ofMMTV-Luc Induction in HeLa Cells Testing of compounds for agonist or antagonist activity in stimulation of MMTV-(mouse mammary tumor virus) promoter in HeLa cells.

HeLa cells were stably co-transfected with the pHHLuc-plasmid containing a fragment of the MMTV-LTR (-200 to +100 relative to the transcription start site) cloned in front of the luciferase gene (Norden, 1988) and the pcDNA3.1 plasmid (Invifrogen) constitutively expressing the resistance for the selective antibiotic GENETICIN®. Clones with best induction of the MMTV-promoter were selected and used for further experiments. Cells were cultured overnight in DMEM medium without phenol red, supplemented with 3% CCS (charcoal treated calf serum) and then transferred to 96 well plates (15,000 cells/100 μL/well). On the next day, activation of the MMTV-promoter was stimulated by addition of test compound or dexamethasone dissolved in DMSO (final concenfration 0.2%). Control cells were treated with DMSO only. After 18 hours, the cells were lysed with cell lysis reagent (Promega, Cat. No. E1531), luciferase assay reagent (Promega, Cat. No. E1501) was added and the glow luminescence was measured using a luminometer (BMG, Offenburg).

For measuring antagonist activity, the MMTV-promoter was pre-stimulated by adding dexamethasone (3 x 10^"9 M to 3 x 10^"8 M) shortly before the test compound was applied to the cells. The steroidal non-selective GR/PR antagonist mifepristone was used as control.

5. Modulation of IL-8 Production in U937 Cells Testing of compounds for agonist or antagonist activity in GR-mediated inhibition of LPS- induced IL-8 secretion in U-937 cells.

U-937 cells were incubated for 2 to 4 days in RPMI1640 medium containing 10% CCS (charcoal treated calf serum). The cells were transferred to 96 well plates (40,000 cells/100 μL/well) and stimulated with 1 μg/mL LPS (dissolved in PBS) in the presence or absence of dexamethasone or test compound (dissolved in DMSO, final concentration 0.2%). Control cells were treated with 0.2% DMSO. After 18 hours, the IL-8 concenfration in the cell supernatant was measured by ELISA, using the "OptEIA human IL-8 set" (Pharmingen, Cat. No. 2654KI).

For measuring antagonist activity, the LPS-induced IL-8 secretion was inhibited by adding dexamethasone (3 x 10^"9 M to 3 x 10^"8 M) shortly before the test compound was applied to the cells. The steroidal non-selective GR/PR antagonist mifepristone was used as control.

6. Modulation oflCAM-Luc Expression in HeLa Cells

Testing of compounds for agonist or antagonist activity in inhibition of TNF-alpha-induced activation of the ICAM-promoter in HeLa cells. HeLa cells were stably co-fransfected with a plasmid containing a 1.3 kb fragment of the human ICAM-promoter (-1353 to -9 relative to the transcription start site, Ledebur and Parks, 1995) cloned in front of the luciferase gene and the pcDNA3.1 plasmid (Invifrogen) which constitutively expresses the resistance for the antibiotic GENETICIN®. Clones with best induction of the ICAM-promoter were selected and used for further experiments. Cells were transferred to 96 well plates (15,000 cells/ 100 μL/well) in DMEM medium supplemented with 3%_> CCS. On the following day the activation of the ICAM-promoter was induced by addition of 10 ng/mL recombinant TNF-alpha (R&D System, Cat. No. 210-TA). Simultaneously the cells were treated with the test compound or dexamethasone (dissolved in DMSO, final concenfration 0.2%). Control cells were treated with DMSO only. After 18 hours, the cells were lysed with cell lysis reagent (Promega, Cat. No. E1531), luciferase assay reagent (Promega, Cat. No. E1501) was added and glow luminescence was measured using a luminometer (BMG, Offenburg).

For measuring antagonist activity, the TNF-alpha-induced activation of the ICAM-promoter was inhibited by adding dexamethasone (3 x 10^"9 M to 3 x 10^"8 M) shortly before the test compound was applied to the cells. The steroidal non-selective GR/PR antagonist mifepristone was used as control.

Representative compounds of the invention have been tested and have shown activity as modulators of the glucocorticoid receptor function in one or more of the above assays. For example, the following compounds of the invention of Formula (IA) and Formula (IB) have demonstrated potent activity in the GR binding assay:

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2,6- dimethylpiperazine- 1 -carbaldehyde;

2-(l , 1 -Dioxo-2,3 -dihydro- IH- lλ⁶-benzo[ 1 ,4]thiazin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol; 2-(2,6-Dimethylmoφholin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-(2,3-Dihydrobenzo[ 1 ,4]oxazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3,5- dimethylpiperidin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-cinnolin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2,3-dihydro- lH-quinolin-4-one;

l-[4-(3-Fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Fluoro-4-methylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(4-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-Phenyl-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one; l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Chloro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin- 4-one;

l,l,l-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(l-oxo-2,3-dihydro-lH-lλ⁴- benzo[ 1 ,4]thiazin-4-ylmethyl)pentan-2-ol;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-2-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(6-Bromobenzo[l,3]dioxol-4-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

1 -[2-Ηydroxy-4-(4-hydroxybiphenyl-3 -yl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4- one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-hydroxyphenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl}-lH-quinolin-4-one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-methoxyphenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl}-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [l,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- frifluoromethylpentyl]- lH-[ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-moφholin-4-ylmethylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one; l-[2-Hydroxy-4-(5-hydroxymethyl-2-methoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -[4-(5-[l ,3]Dioxan-2-yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylρentyl]- 1H- quinolin-4-one;

1 -[2-Ηydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[4-(5-Furan-3-yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinazolin- 4-one;

1 -[3 ,3 ,3-Trifluoro-2-(6-fluoro-4-methylchroman-4-ylmethyl)-2-hydroxypropyl]- lH-quinolin-4- one;

l-(4- {3-[ 1 -(Benzyloxyirnino)ethyl]phenyl} -2-hydroxy-4-methyl-2-trifluoromethylpentyl)- IH- quinolin-4-one;

l-[4-(3-Cyclopropanecarbonylρhenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(5-Acetyl-2-me oxyρhenyl)-2-hydroxy-4-methyl-2-ttifluoromethylpentyl]-lH-qu olin- 4-one;

l-[4-(5-Bromo-2-hydroxyphenyl)-2-hyαj^,oxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

1 -(2-Ηydroxy-4- { 3 -[ 1 -(hydroxyimino)ethyl]phenyl } -4-methyl-2 -trifluoromethylpentyl)- 1H- quinolin-4-one; l-[4-(5-Bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-

4-one;

1 -[4-(3 ,5 -Difluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl] - lH-quinolin-4-one;

1 -[4-(3 ,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

1 - {2-Ηydroxy-4-methyl-4-[3-(2-methyl-[ 1 ,3]dioxolan-2-yl)phenyl]-2-trifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(2,3-Dihyαj^,obenzofin-an-7-yl)-2-hyάr'oxy-4-memyl-2-frifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(3-hydroxymethylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one; l-[4-(3-[l,3]Dioxan-2-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(3-Acetylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hyαroxy-4-methyl-2-frifluoromethylpentyl]-3,5-dimethyl- lH-pyridin-4-one;

l-{2-Ηydroxy-4-[3-(l-hydroxyethyl)phenyl]-4-methyl-2-trifϊuoromethylpentyl}-lH-quinolin- 4-one;

l-[4-(2,3-Dihydiobenzofuran-7-yl)-2-hydι^,oxy-4-methyl-2-frifluoromethylpentyl]-3,5-dimethyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-teifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

3-[4,4,4-Trifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin-l- ylmethyl)butyl]benzaldehyde;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(3-Bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one; l-[4-(5-Fluoro-2-hyαi'θxyphenyl)-2-hyαj-oxy-4-methyl-2-frifluoromethylpentyl]-7-hydroxy-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2'hydroxy-4-methyl-2-trifluoromethylpentyl]-3- hydroxymethyl- lH-quinolin-4-one;

6-Chloro- 1 -[4-(5-fluoro-2 -hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- IH- quinolin-4-one;

l-[-4-(2-Difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

6-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[2-Ηyo^oxy-4-(2-hydroxy-5-methylphenyl)-4-methyl-2-frifluoromethylpentyl]-lH-qumolin- 4-one;

1 - {2-Ηydroxy-4-methyl-4-[3 -(2-oxopropoxy)phenyl]-2-trifluoromethylpentyl } - lH-quinolin-4- one;

l-[2-Ηydroxy-4-(2-methoxy-5-methylphenyl)-4-methyl-2-xrifluoromethylpentyl]-lH-quinolin- 4-one; l-[4-(2,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[2-Ηydroxy-4-(3 -hydroxyphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-l,2- dihydroindazol-3-one;

7-Fluoro- 1 -[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-ttifluoromethylpentyl]-3,5-dimethyl- lH-pyridin-4-one;

7-Fluoro-l-[4-(5-fluoro-2-memoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-(2-Ηydroxy-4-methyl-4-phenyl-2-trifluoromethylhexyl)-lH-quinolin-4-one;

l-[4-(4-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(3,4-Dimethylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

8-Fluoro-l-[4-(5-fluoro-2-hyα^oxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-{4-[5-Fluoro-2-(2-oxopropoxy)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-lH- quinolin-4-one;

7-Chloro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2-Benzyloxy-5-fluorophenyl)-2-hyάj'θxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

8-Fluoro-l-[4-(5-fluoro-2-mexhoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

6-Fluoro- 1 -[4-(5 -fluoro-2 -methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[2-Ηydroxy-4-(5-mexhanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfinyl-2,3-d ydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7-yl)-2- frifluoromethylpentyl]-lH-quinolin-4-one;

7-Chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; 1 -[4-(3 -Fluoro-4-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-nitro-5- trifluoromethyl- lH-pyridin-2 -one;

2-(2,3-Dihydroindol- 1 -ylmethyl)- 1,1,1 -frifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-[2-Ηydroxy-4-methyl-4-(3-moφholin-4-ylmethylphenyl)-2-frifluoromethylpentyl]-lH- quinolin-4-one;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]piperazin-l- yl } furan-2-ylmethanone;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-αuhydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-3-methyl-lH-quinolin-4-one;

2-[4-(3 -Chloro-5-trifluoromethylpyridin-2-yl)piperazin- 1 -ylmethyl]- 1 ,1,1 -trifluoro-4-(5-fluoro- 2-methoxyphenyl)-4-methylpentan-2-ol;

{4-[4-(5-Fluoro-2-memoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]piperazin-l- yl} furan-2-ylmethanone;

l-[2-Ηydroxy-4-(2-methoxy-5-pyridin-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[2-Hydroxy-4-(2-hydroxy-3,5-dimethylphenyl)-4-methyl-2-trifluoroιnethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4- one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(2,4-dimethylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(4-Fluoro-2-methoxyphenyl)-2-hydr'oxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(3-Fluoro-4-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydrOxy-4-methyl-2-trifluoromethylpentyl]-l,2- dihydroindazol-3-one;

2-(3,4-Dihydro-2H-quinoxalin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol; l,l,l-Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-methyl-3,4-dihydro-2H- quinoxalin- 1 -ylmethyl)pentan-2-ol;

2-(2,3-Dihydrobenzo[ 1 ,4]thiazin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-{4-[4-(5-Fluoro-2-methox3φhenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin-l-yl}ethanone;

l-[2-Ηydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- IH- quinolin-4-one;

l-[2-Hydroxy-4-(2-hydroxy-5-pyridin-3-ylphenyl)-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

Carbonic acid 4-fluoro-2-[4,4,4-frifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin-l- ylmethyl)butyl]phenyl ester methyl ester;

l-[2-Difluoromethyl-4-(5-fluoro-2-rnethoxyphenyl)-2-hydiOxy-4-methylpentyl]-lH-quinolin-4- one. 7. Inhibition of Osteocalcin Production from Osteoblast Cell Line MG-63 Human osteosarcoma MG-63 cells (ATCC, Cat. No. CRL-1427) are plated on 96 well plates at 20,000 cells per well the day before use in 200 μL media of 99% D-MEM F-12 (Gibco- Invifrogen, Cat. No. 11039-021), supplemented with 1% penicillin and streptomycin (Gibco- Invitrogen, Cat. No. 15140-122), 10 μg mL Vitamin C (Sigma, Cat. No. A-4544), and 1% charcoal filtered Fetal Bovine Serum (HyClone, Cat. No. SH30068.02). The next day, wells are replaced with fresh media. Cells are treated with Vitamin D (Sigma, Cat. No. D1530) to a final concentration of 10 nM, and with the test compounds in concentrations of 10^"6 M to 10^"9 M, in a total volume of 200 μL per well. Samples are done in duplicates. Background control wells do not receive Vitamin D or compounds. Positive control wells receive Vitamin D only, without compounds, and represent maximum (100%) amount of osteocalcin production. Plates are incubated at 37°C incubator for 48 hours and supematants are harvested at the end of incubation. Amounts of osteocalcin in the supematants are determined by the Glype osteocalcin ELISA kit (Zymed, Cat. No. 99-0054) according to manufacture's protocol. Inhibition of osteocalcin by test compounds is expressed in percentage relative to positive controls. IC₅₀ values of the test compounds are derived by non-lineal curve fitting.

The following compounds of Formula (IA) inhibit the vitamin D stimulated production of osteocalcin:

1 -[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-Bromo-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-(4-Biphenyl-3-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-lH-quinolin-4-one; and

l-[4-(5-Fluoro-2-hydroxyρhenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [l,5]naphthyridin-4-one.

The invention also provides methods of modulating the glucocorticoid receptor function in a patient comprising administering to the patient a compound according to the invention. If the puφose of modulating the glucocorticoid receptor function in a patient is to treat a disease-state or condition, the administration preferably comprises a therapeutically or pharmaceutically effective amount of a pharmaceutically acceptable compound according to the invention. If the puφose of modulating the glucocorticoid receptor function in a patient is for a diagnostic or other puφose (e.g., to determine tlie patient's suitability for therapy or sensitivity to various sub-therapeutic doses of the compounds according to the invention), the administration preferably comprises an effective amount of a compound according to the invention, that is, the amount necessary to obtain the desired effect or degree of modulation.

Methods of Therapeutic Use

As pointed out above, the compounds of the invention are useful in modulating the glucocorticoid receptor function. In doing so, these compounds have therapeutic use in treating disease-states and conditions mediated by the glucocorticoid receptor function or that would benefit from modulation of the glucocorticoid receptor function.

As the compounds of the invention modulate the glucocorticoid receptor function, they have very useful anti-inflammatory and antiallergic, immune-suppressive, and anti-proliferative activity and they can be used in patients as drugs, particularly in the form of pharmaceutical compositions as set forth below, for the treatment of disease-states and conditions.

The agonist compounds according to the invention can be used in patients as drugs for the treatment of the following disease-states or indications that are accompanied by inflammatory, allergic, and/or proliferative processes: (i) Lung diseases: chronic, obstructive lung diseases of any genesis, particularly bronchial asthma and chronic obstructive pulmonary disease (COPD); adult respiratory distress syndrome (ARDS); bronchiectasis; bronchitis of various genesis; all forms of restrictive lung diseases, particularly allergic alveolitis; all forms of lung edema, particularly toxic lung edema; all forms of interstitial lung diseases of any genesis, e.g., radiation pneumonitis; and sarcoidosis and granulomatoses, particularly Boeck disease.

(ii) Rheumatic diseases or autoimmune diseases or joint diseases: all forms of rheumatic diseases, especially rheumatoid arthritis, acute rheumatic fever, and polymyalgia rheumatica; reactive arthritis; rheumatic soft tissue diseases; inflammatory soft tissue diseases of other genesis; arthritic symptoms in degenerative joint diseases (arthroses); traumatic arthritis; collagenoses of any genesis, e.g., systemic lupus erythematosus, scleroderma, polymyositis, dermatomyositis, Sjδgren syndrome, Still disease, and Felty syndrome;

(iii) Allergic diseases: all forms of allergic reactions, e.g., angioneurotic edema, hay fever, insect bites, allergic reactions to drugs, blood derivatives, contrast agents, etc., anaphylactic shock (anaphylaxis), urticaria, angioneurotic edema, and contact dermatitis;

(iv) Vasculitis diseases: panarteritis nodosa, polyarteritis nodosa, arteritis temporalis,

Wegner granulomatosis, giant cell arthritis, and erythema nodosum; (v) Dermatological diseases: atopic dermatitis, particularly in children; psoriasis; pityriasis rubra pilaris; erythematous diseases triggered by various noxa, e.g., rays, chemicals, bums, etc.; bullous dermatoses; diseases of the lichenoid complex; pruritus (e.g., of allergic genesis); seborrheic dermatitis; rosacea; pemphigus vulgaris; erythema multiforme exudativum; balanitis; vulvitis; hair loss, such as occurs in alopecia areata; and cutaneous T cell lymphomas;

(vi) Renal diseases: nephrotic syndrome; and all types of nephritis, e.g., glomerulonephritis; (vii) Hepatic diseases: acute liver cell disintegration; acute hepatitis of various genesis, e.g., viral, toxic, drug-induced; and chronically aggressive and/or chronically intermittent hepatitis; (viii) Gastrointestinal diseases: inflammatory bowel diseases, e.g., regional enteritis (Crohn disease), colitis ulcerosa; gastritis; peptic esophagitis (refluxoesophagitis); and gastroenteritis of other genesis, e.g., nontropical sprue; (ix) Proctological diseases: anal eczema; fissures; hemorrhoids; and idiopathic proctitis; (x) Eye diseases: allergic keratitis, uveitis, or iritis; conjunctivitis; blepharitis; neuritis nervi optici; choroiditis; and sympathetic ophthalmia; (xi) Diseases of the ear, nose, and throat (ENT) area: allergic rhinitis or hay fever; otitis externa, e.g., caused by contact eczema, infection, etc.; and otitis media;

(xii) Neurological diseases: brain edema, particularly tumor-related brain edema; multiple sclerosis; acute encephalomyelitis; meningitis; acute spinal cord injury; stroke; and various forms of seizures, e.g., nodding spasms; (xiii) Blood diseases: acquired hemolytic anemia; and idiopathic thrombocytopenia; (xiv) Tumor diseases: acute lymphatic leukemia; malignant lymphoma; lymphogranulomatoses; lymphosarcoma; extensive metastases, particularly in mammary, bronchial, and prostatic carcinoma; (xv) Endocrine diseases: endocrine ophthalmopathy; endocrine orbitopathia; thyrotoxic crisis; Thyroiditis de Quervain; Hashimoto thyroiditis; Morbus Basedow; granulomatous thyroiditis; struma lymphomatosa; and Grave disease;

(xvi) Organ and tissue transplantations and graft- versus-host diseases; (xvii) Severe states of shock, e.g., septic shock, anaphylactic shock, and systemic inflammatory response syndrome (SIRS); (xviii) Substitution therapy in: congenital primary adrenal insufficiency, e.g., adrenogenital syndrome; acquired primary adrenal insufficiency, e.g., Addison disease, autoimmune adrenalitis, post-infection, tumors, metastases, etc.; congenital secondary adrenal insufficiency, e.g., congenital hypopituitarism; and acquired secondary adrenal insufficiency, e.g., post-infection, tumors, metastases, etc.; (xix) Pain of inflammatory genesis, e.g., lumbago; and (xx) various other disease-states or conditions including type I diabetes (insulin-dependent diabetes), osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone resoφtion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion. In addition, the compounds according to the invention can be used for the treatment of any other disease-states or conditions not mentioned above which have been treated, are treated, or will be treated with synthetic glucocorticoids (see, e.g., H.J. Hatz, Glucocorticoide: Immunologische Grundlagen. Pharmakologie und Therapierichtlinien [Glucocorticoids: Immunological Fundamentals, Pharmacology, and Therapeutic Guidelines], Stuttgart: Verlagsgesellschaft mbH, 1998, which is hereby incoφorated by reference in its entirety). Most or all of the indications (i) through (xx) mentioned above are described in detail in H.J. Hatz, Glucocorticoide: Immunologische Grundlagen. Pharmakologie und Therapierichtlinien. Furthermore, the compounds of the invention can also be used to treat disorders other than those listed above or mentioned or discussed herein, including in the Background of the Invention.

The invention include use of a compound according to the invention for the preparation of a pharmaceutical composition. The invention also includes use of a compound according to the invention in combination with a pharmaceutically acceptable glucocorticoid for the preparation of a pharmaceutical composition. The invention additionally includes use of a compound according to the invention in combination with other pharmaceutically acceptable excipients and ingredients as set forth herein for the preparation of a pharmaceutical composition. The invention also includes the use of a compound according to the invention for the preparation of a pharmaceutical composition as described herein for the treatment of a disease-state or condition mediated by the glucocorticoid receptor function; type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma; a disease characterized by inflammatory, allergic, or proliferative processes, (i) lung diseases; (ii) rheumatic diseases/autoimmune diseases/joint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft-versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis. The antagonist compounds according to the invention, whether full antagonists or partial antagonists, can be used in patients as drugs for the treatment of the following disease-states or indications, without limitation: type II diabetes (non-insulin-dependent diabetes); obesity; cardiovascular diseases; hypertension; arteriosclerosis; neurological diseases, such as psychosis and depression; adrenal and pituitary tumors; glaucoma; and Cushing syndrome based on an ACTH secreting tumor like pituitary adenoma. In particular, the compounds of the invention are useful for treating obesity and all disease-states and indications related to a deregulated fatty acids metabolism such as hypertension, atherosclerosis, and other cardiovascular diseases. Using the compounds of the invention that are GR antagonists, it should be possible to antagonize both the carbohydrate metabolism and fatty acids metabolism. Thus, the antagonist compounds of the invention are useful in treating all disease-states and conditions that involve increased carbohydrate, protein, and lipid metabolism and would include disease-states and conditions leading to catabolism like muscle frailty (as an example of protein metabolism).

Methods of Diagnostic Use

The compounds of the invention may also be used in diagnostic applications and for commercial and other proposes as standards in competitive binding assays. In such uses, the compounds of the invention may be used in the form of the compounds themselves or they may be modified by attaching a radioisotope, luminescence, fluorescent label or the like in order to obtain a radioisotope, luminescence, or fluorescent probe, as would be known by one of skill in the art and as outlined in Handbook of Fluorescent Probes and Research Chemicals. 6th Edition, R.P. Haugland (ed.), Eugene: Molecular Probes, 1996; Fluorescence and Luminescence Probes for Biological Activity. W.T. Mason (ed.), San Diego: Academic Press, 1993; Receptor-Ligand Interaction. A Practical Approach. E.C Hulme (ed.), Oxford: IRL Press, 1992, each of which is hereby incoφorated by reference in their entireties.

General Administration and Pharmaceutical Compositions

When used as pharmaceuticals, the compounds of the invention are typically administered in the form of a pharmaceutical composition. Such compositions can be prepared using procedures well known in the pharmaceutical art and comprise at least one compound of the invention. The compounds of the invention may also be administered alone or in combination with adjuvants that enhance stability of the compounds of the invention, facilitate administration of pharmaceutical compositions containing them in certain embodiments, provide increased dissolution or dispersion, increased inhibitory activity, provide adjunct therapy, and the like. The compounds according to the invention may be used on their own or in conjunction with other active substances according to the invention, optionally also in conjunction with other pharmacologically active substances. In general, the compounds of this invention are administered in a therapeutically or pharmaceutically effective amount, but may be administered in lower amounts for diagnostic or other puφoses.

In particular, the compounds of the invention are useful in combination with glucocorticoids or corticosteroids. As pointed out above, standard therapy, for a variety of immune and inflammatory disorders includes administration of corticosteroids, which have the ability to suppress immunologic and inflammatory responses. (A.P. Truhan et al, Annals of Allergy,

1989, 62, pp. 375-391; J.D. Baxter, Hospital Practice, 1992, 27, pp. 111-134; R.P. Kimberly,

Curr. Opin. Rheumatol., 1992, 4, pp. 325-331; M.H. Weisman, Curr. Opin. Rheumatol., 1995, 7, pp. 183-190; W. Sterry, Arch. Dermatol. Res., 1992, 284 (Suppl), pp. S27-S29). While therapeutically beneficial, however, the use of corticosteroids is associated with a number of side effects, ranging from mild to possibly life threatening, especially with prolonged and/or high dose steroid usage. Accordingly, methods and compositions that enable the use of a lower effective dosage of corticosteroids (referred to as the "steroid sparing effect") would be highly desirable to avoid unwanted side effects. The compounds of the invention provide such a steroid sparing effect by achieving the desired therapeutic effect while allowing the use of lower doses and less frequent administration of glucocorticoids or corticosteroids.

Administration of the compounds of the invention, in pure form or in an appropriate pharmaceutical composition, can be carried out using any of the accepted modes of administration of pharmaceutical compositions. Thus, administration can be, for example, orally, buccally (e.g., sublingually), nasally, parenterally, topically, transdermally, vaginally, or rectally, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as, for example, tablets, suppositories, pills, soft elastic and hard gelatin capsules, powders, solutions, suspensions, or aerosols, or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The pharmaceutical compositions will generally include a conventional pharmaceutical carrier or excipient and a compound of the invention as the/an active agent, and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles, or combinations thereof. Such pharmaceutically acceptable excipients, carriers, or additives as well as methods of making pharmaceutical compositions for various modes or administration are well-known to those of skill in the art. The state of the art is evidenced, e.g., by Remington: The Science and Practice of Pharmacy. 20th Edition, A. Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook of Pharmaceutical Additives. Michael & Irene Ash (eds.), Gower, 1995; Handbook of Pharmaceutical Excipients. A.H. Kibbe (ed.), American Pharmaceutical Ass'n, 2000; H.C. Ansel and N.G. Popovish, Pharmaceutical Dosage Forms and Drug Delivery Systems. 5th ed., Lea and Febiger, 1990; each of which is incoφorated herein by reference in their entireties to better describe the state of the art.

As one of skill in the art would expect, the forms of the compounds of the invention utilized in a particular pharmaceutical formulation will be selected (e.g., salts) that possess suitable physical characteristics (e.g., water solubility) that is required for the formulation to be efficacious.

Pharmaceutical compositions suitable for buccal (sub-lingual) administration include lozenges comprising a compound of the present invention in a flavored base, usually sucrose, and acacia or tragacanth, and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Pharmaceutical compositions suitable for parenteral administration comprise sterile aqueous preparations of a compound of the present invention. These preparations are preferably administered infravenously, although administration can also be effected by means of subcutaneous, intramuscular, or intradermal injection. Injectable pharmaceutical formulations are commonly based upon injectable sterile saline, phosphate-buffered saline, oleaginous suspensions, or other injectable carriers known in the art and are generally rendered sterile and isotonic with the blood. The injectable pharmaceutical formulations may therefore be provided as a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, including 1,3-butanediol, water, Ringer's solution, isotonic sodium chloride solution, fixed oils such as synthetic mono- or diglycerides, fatty acids such as oleic acid, and the like. Such injectable pharmaceutical formulations are formulated according to the known art using suitable dispersing or setting agents and suspending agents. Injectable compositions will generally contain from 0.1 to 5% w/w of a compound of the invention.

Solid dosage forms for oral administration of the compounds include capsules, tablets, pills, powders, and granules. For such oral administration, a pharmaceutically acceptable composition containing a compound(s) of the invention is formed by the incoφoration of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, pregelatinized starch, magnesium stearate, sodium saccharine, talcum, cellulose ether derivatives, glucose, gelatin, sucrose, citrate, propyl gallate, and the like. Such solid pharmaceutical formulations may include formulations, as are well-known in the art, to provide prolonged or sustained delivery of the drug to the gastrointestinal tract by any number of mechanisms, which include, but are not limited to, pH sensitive release from the dosage form based on the changing pH of the small intestine, slow erosion of a tablet or capsule, retention in the stomach based on the physical properties of the formulation, bioadhesion of the dosage form to the mucosal lining of the intestinal tract, or enzymatic release of the active drug from the dosage form.

Liquid dosage forms for oral administration of the compounds include emulsions, microemulsions, solutions, suspensions, syrups, and elixirs, optionally containing pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like. These compositions can also contain additional adjuvants such as wetting, emulsifying, suspending, sweetening, flavoring, and perfuming agents.

Topical dosage forms of the compounds include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, eye ointments, eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. Topical application may be once or more than once per day depending upon the usual medical considerations. Furthermore, preferred compounds for the present invention can be administered in infranasal form via topical use of suitable infranasal vehicles. The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation, more usually they will form up to about 80% of the formulation.

Transdermal administration is also possible. Pharmaceutical compositions suitable for transdermal administration can be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. To be administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. Such patches suitably contain a compound of the invention in an optionally buffered, aqueous solution, dissolved and/or dispersed in an adhesive, or dispersed in a polymer. A suitable concenfration of the active compound is about 1% to 35%, preferably about 3% to 15%.

For administration by inhalation, the compounds of the invention are conveniently delivered in the form of an aerosol spray from a pump spray device not requiring a propellant gas or from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, frichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide, or other suitable gas. In any case, the aerosol spray dosage unit may be determined by providing a valve to deliver a metered amount so that the resulting metered dose inhaler (MDI) is used to administer the compounds of the invention in a reproducible and controlled way. Such inhaler, nebulizer, or atomizer devices are known in the prior art, for example, in PCT International Publication Nos. WO 97/12687 (particularly Figure 6 thereof, which is the basis for the commercial RESPEvlAT® nebulizer); WO 94/07607; WO 97/12683; and WO 97/20590, to which reference is hereby made and each of which is incoφorated herein by reference in their entireties.

Rectal administration can be effected utilizing unit dose suppositories in which the compound is admixed with low-melting water-soluble or insoluble solids such as fats, cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights, or fatty acid esters of polyethylene glycols, or the like. The active compound is usually a minor component, often from about 0.05 to 10% by weight, with the remainder being the base component. In all of the above pharmaceutical compositions, the compounds of the invention are formulated with an acceptable carrier or excipient. The carriers or excipients used must, of course, be acceptable in the sense of being compatible with the other ingredients of the composition and must not be deleterious to the patient. The carrier or excipient can be a solid or a liquid, or both, and is preferably formulated with the compound of the invention as a unit- dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compound. Such carriers or excipients include inert fillers or diluents, binders, lubricants, disintegrating agents, solution retardants, resoφtion accelerators, absoφtion agents, and coloring agents. Suitable binders include starch, gelatin, natural sugars such as glucose or β-lactose, com sweeteners, natural and synthetic gums such as acacia, fragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.

Generally, a therapeutically effective daily dose is from about 0.001 mg to about 15 mg/kg of body weight per day of a compound of the invention; preferably, from about 0.1 mg to about 10 mg/kg of body weight per day; and most preferably, from about 0.1 mg to about 1.5 mg/kg of body weight per day. For example, for administration to a 70 kg person, the dosage range would be from about 0.07 mg to about 1050 mg per day of a compound of the invention, preferably from about 7.0 mg to about 700 mg per day, and most preferably from about 7.0 mg to about 105 mg per day. Some degree of routine dose optimization may be required to determine an optimal dosing level and pattern.

Pharmaceutically acceptable carriers and excipients encompass all the foregoing additives and the like.

Examples of Pharmaceutical Formulations

The finely ground active substance, lactose, and some of the com starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining co starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.

The finely ground active substance, some of the com starch, lactose, microcrystalline cellulose, and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining com starch and water to form a granulate which is dried and screened. The sodium- carboxymefhyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.

The active substance, com starch, lactose, and polyvinylpyrrolidone are thoroughly mixed and moistened with water. The moist mass is pushed through a screen with a 1 mm mesh size, dried at about 45°C and the granules are then passed through the same screen. After the magnesium stearate has been mixed in, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are coated in known manner with a covering consisting essentially of sugar and talc. The finished coated tablets are polished with wax.

The substance and com starch are mixed and moistened with water. The moist mass is screened and dried. The dry granules are screened and mixed with magnesium stearate. The finished mixture is packed into size 1 hard gelatine capsules.

The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilized and sealed by fusion. The ampoules contain 5 mg, 25 mg, and 50 mg of active substance.

The hard fat is melted. At 40°C, the ground active substance is homogeneously dispersed therein. The mixture is cooled to 38°C and poured into slightly chilled suppository molds.

The suspension is transferred into a conventional aerosol container with a metering valve. Preferably, 50 μL of suspension are delivered per spray. The active substance may also be metered in higher doses if desired (e.g., 0.02% by weight).

In Examples H, I, J, and K, the powder for inhalation is produced in the usual way by mixing the individual ingredients together.

Claims

We claim:

1. A compound of Formula (LA)

wherein:

R¹ is an aryl, heteroaryl, or C5-C₁₅ cycloalkyl group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently C_-C₅ alkyl, C₂-C₅ alkenyl, G₂-C₅ alkynyl, C₃-Cs cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C5 alkoxy, C₂- C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C₁-C5 alkanoyloxy, C₁-C₅ alkanoyl, aroyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, Cj-C₅ dialkylaminocarbonyloxy, C₃-Cs cycloalkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C-C₅ alkylsulfonylamino, aminosulfonyl, C_-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, oxo, carboxy, cyano, trifluoromethyl, trifluoromethoxy, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl or C₃-Cs cycloalkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with one to four substituent groups selected from aryl or heterocyclyl wherein the heterocycle is optionally independently substituted with hydroxyl, halogen, methyl, or dialkyl amino; Cj-C₅ alkoxycarbonyl, methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl or C_rC₃ dialkylamines or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C1-C5 alkyl; aminosulfonyl, or oxime wherein the oxygen atom is optionally substituted by C₁-C₅ alkyl or benzyl; R² and R³ are each independently hydrogen, Cι-C₅ alkyl, or C₅-Cι₅ arylalkyl group, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-C₈ spiro cycloalkyl ring, or

R¹ and R² when taken together are a chromanyl or dihydrobenzofuranyl optionally substituted with Cj-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-Cg cycloalkyl, heterocyclyl, aryl, heteroaryl, Cj-C₅ alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C₁-C5 alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, Cj-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone;

R⁴ is carbonyl or methylene optionally independently substituted with one to two substituent groups selected from Cj-C₃ alkyl, hydroxy, and halogen;

R⁵ is a pyrrolidine, moφholine, thiomoφholine, piperazine, piperidine, lH-pyridin-4- one, lH-pyridin-2-one, lH-pyridin-4-ylideneamine, lH-quinolin-4-ylideneamine, pyran, tetrahydropyran, 1,4-diazepane, 2,5-diazabicyclo[2.2.1]heptane, 2,3,4,5- tetrahydrobenzo[b][l,4]diazepine, dihydroquinoline, tetrahydroquinoline, 5,6,7,8- tetrahydro-lH-quinolin-4-one, tetrahydroisoquinoline, decahydroisoquinoline, 2,3- dihydro-lH-isoindole, 2,3-dihydro-lH-indole, chroman, 1,2,3,4- tetrahydroquinoxaline, l,2-dihydroindazol-3-one, 3,4-dihydro-2H- benzo[l,4]oxazine, 4H-benzo[l,4]xhiazine, 3,4-dihydro-2H-benzo[l,4]thiazine, 1,2- dihydrobenzo[d][l,3]oxazin-4-one, 3,4-dihydrobenzo[l,4]oxazin-4-one, 3H- quinazolin-4-one, 3,4-dihydro-lH-quinoxalin-2-one, lH-cinnolin-4-one, 1H- quinazolin-4-one, lH-[l,5]naphthyridin-4-one, 5,6,7,8-tefrahydro-lH-

[l,5]naphthyridin-4-one, 2,3-dihydro-lH-[l,5]naphthyridin-4-one, 1,2- dihydropyrido[3,2- ][l,3]oxazin-4-one, pyrrolo[3,4-c]pyridine-l,3-dione, 1,2- dihydropyrrolo[3,4-e]pyridin-3-one, or tetrahydro[3][l,4]diazepinone, group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁵ is independently C C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-Cg cycloalkyl, heterocyclyl, aryl, heteroaryl, C_-C₅ alkoxy, C₂- C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C_rC₅ alkoxycarbonyl, C_-C₅ alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C1-C5 alkylaminocarbonyloxy, Cj-C₅ dialkylaminocarbonyloxy, C₁-C5 alkanoylamino, C₁-C₅ alkoxycarbonylamino, Cj- C₅ alkylsulfonylamino, C₁-C5 alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nifrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R⁵ is optionally independently substituted with one to three substituent groups selected from C C₃ alkyl, C_-C₃ alkoxy, Cι-C₃ alkoxycarbonyl, acyl, aryl, benzyl, heteroaryl, heterocyclyl, halogen, hydroxy, oxo, cyano, amino wherein the nifrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl;, or trifluoromethyl; and

or a tautomer, prodrug, solvate, or salt thereof.

2. The compound of Formula (IA) according to claim 1, wherein:

wherein each substituent group of R¹ is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cι-C₃ alkoxy, C₂-C₃ alkenyloxy, C_-C₃ alkanoyl, C_-C₃ alkoxycarbonyl, C_-C₃ alkanoyloxy, halogen, hydroxy, acyl, oxo, carboxy, cyano, trifluoromethyl, nitro, or C_-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with a substituent group selected from methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino;

R² and R³ are each independently hydrogen, Cj-C₃ alkyl, benzyl, or phenethyl, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-C₆ spiro cycloalkyl ring; and

R⁴ is CH₂,

or a tautomer, prodrug, solvate, or salt thereof.

3. The compound of Formula (IA) according to claim 1, wherein:

wherein each substituent group of R¹ is independently methyl, ethyl, methoxy, ethoxy, fluoro, chloro, bromo, hydroxy, trifluoromethyl, acyl, oxo, C_-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone, or cyano;

R⁴ is CH₂, or .a tautomer, prodrug, solvate, or salt thereof.

4. The compound of Foπnula (IA) according to claim 1, wherein:

wherein each substituent group of R¹ is independently C.-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cι-C₃ alkoxy, C₂-C₃ alkenyloxy, Cι-C₃ alkanoyl, C_-C₃ alkoxycarbonyl, Cι-C₃ alkanoyloxy, halogen, hydroxy, carboxy, cyano, trifluoromethyl, nitro, or Cj-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone; and

R² and R³ are each independently hydrogen or Cι-C₃ alkyl,

or a tautomer, prodrug, solvate, or salt thereof.

5. A compound selected from:

l-{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,6- dimethylpiperazin- 1 -yl} ethanone;

l-{5-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,5- diazabicyclo[2.2.1]hept-2-yl}ethanone;

4-[4-(5-Fluoro-2-memoxyphenyl)-2-hyα oxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxaline- 1 -carbaldehyde;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro- lH-quinoxalin-2-one; 4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperazine-2,6-dione;

2-(2,6-Dimethylthiomoφholin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)- 4-methylpentan-2-ol;

2-( 1 , 1 -Dioxo- IH- 1 λ⁶-benzo[ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

2-( 1 , 1 -Dioxo-2,3-dihydro- IH- 1 λ⁶-benzo[ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-ol;

l-{5-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 2,3 ,4,5 -tetrahydrobenzo [b] [ 1 ,4]diazepin- 1 -yl} ethanone;

5-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-l,3,4,5- tetrahydrobenzo[b][l,4]diazepin-2-one;

2-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-teifluoromethylpentyl]isoindole- 1,3-dione;

2-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- teifluoromethylpentyl]pyrrolo[3,4-c]pyridine-l,3-dione;

2-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-l,3- dioxo-2,3 -dihydro- lH-isoindole-5-carbonitrile;

2-(2,3-Dihydrobenzo[ 1 ,4]thiazin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(4-fluorophenyl)-4- methylpentan-2-ol;

4-(2,3-Dihydrobenzofuran-7-yl)- 1 ,1,1 -trifluoro-4-methyl-2-(4-methyl-3 ,4-dihydro-2H- quinoxalin- 1 -ylmethyl)pentan-2-ol;

l-{4-[4-(5-Bromo-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3,4-dihydro-2H-quinoxalin-l-yl}ethanone; 4-[4.(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3,4-dihydro-lH-quinoxalin-2-one;

1 - {4-[4-(3 -Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,6- dimethylpiperazin- 1 -yl} ethanone;

4-(2,3-Dihydrobenzofuran-7-yl)-2-(2,3-dihydrobenzo[l,4]thiazin-4-ylmethyl)-l , 1,1- frifluoro-4-methylpentan-2-ol;

2-(3 ,4-Dihydro-2H-quinoxalin- 1 -ylmethyl)- 1 ,1,1 -trifluoro-4-(4-fluorophenyl)-4- methylpentan-2-ol;

2-(2,6-Dimethylthiomoφholin-4-ylmethyl)-l,l,l-trifluoro-4-(4-fluorophenyl)-4- methylpentan-2-ol;

2-(l,l-Dioxo-2,3-dihydro-lH-lλ⁶-benzo[l,4]thiazin-4-ylmethyl)-l,l,l-trifluoro-4-(5- fluoro-2,3-dihydrobenzofuran-7-yl)-4-methylpentan-2-ol;

5-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2,5- diazabicyclo[2.2.1]heptan-3-one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-moφholin-4-ylmethylpentan- 2-ol;

2-(2,6-Dimethylmoφholin-4-ylmethyl)- 1 ,1,1 -frifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-(2,3-Dihydrobenzo[ 1 ,4]oxazin-4-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

2-(2,3-Dihydrobenzo[l,4]oxazin-4-ylmethyl)-l,l,l-trifluoro-4-(5-fluoro-2,3- dihydrobenzofuran-7-yl)-4-methylpentan-2-ol; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]piperidin- 4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methoxy- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-2,4-dimethylpentyl]-3,5-dimethyl-lH- pyridin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinazolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- cinnolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- isopropyl- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,3- dihydro- lH-quinolin-4-one;

l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]piperidin-4-one; l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(2-Fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Fluoro-4-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(4-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2-Methylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Cyanophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Carboxamidophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[4-(2,6-dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-Phenyl-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-Cyclohexyl-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(Thiophen-2-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(Pyridin-2-yl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(Pyridin-3-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(Pjτridin-4-yl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one; l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethylpiperidin-4-one;

l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinazolin-4- one;

l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-cinnolin-4-one;

1 -[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-tτifluoromethylpentyl]-3 -methyl- 1H- quinolin-4-one;

1 -[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3 -isopropyl- 1H- quinolin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Fluoro-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3 -methyl- lH-quinolin-4-one;

1 -[4-(5-Bromo-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Cyano-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Methyl-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Clιloro-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(5-Methoxy-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Fluoro-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl] -3 ,5 -dimethylpiperidin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinazolin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-cinnolin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-2,3-dihydro-lH-quinolin-4-one;

l-[4-(5-Bromo-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-2,3-dihydro-lH-quinolin-4-one;

1 -[4-(5-Cyano-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-2,3 -dihydro- lH-quinolin-4-one;

1 -[4-(4-Fluoro-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl] -2,3 -dihydro- lH-quinolin-4-one;

1 -[2,2,2-Trifluoro- 1 -hydroxy- 1 -(4-methylchroman-4-ylmethyl)ethyl]- lH-quinolin-4-one;

1 -[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1 ,2- dihydrobenzo[fi ][l,3]oxazin-4-one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl -2 -trifluoromethylpentyl]- 1 ,2- dihydrobenzo[cTI[l,3]oxazin-4-one;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3,4- dihydrobenzo[ 1 ,4]oxazin-2-one; 4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydrobenzo[ 1 ,4]oxazin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [l,5]naphthyridin-4-one;

l-[4-(5-Fluoro-2-hyάroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one ;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2,3- dihydro- lH-[ 1 ,5]naphthyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2,3- dihydro- lH-[ 1 ,5]naphthyridin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2,4-dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(4-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3-Fluoro-4-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-(4-Benzo[l,3]dioxol-4-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-lH-quinolin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-l,2- dihydroindazol-3 -one;

1,1,1 -Trifluoro-4-(5 -fluoro-2-methoxyphenyl)-4-methyl-2-piperazin- 1 -ylmethylpentan-2- ol: 1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-methylpiperazin-l - ylmethyl)pentan-2-ol;

l-{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperazin- 1 -yl} ethanone;

2-(3,5-Dimethylpiperazin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-metlιyl-2-(3 ,4,5-frimethylpiperazin- 1 - ylmethyl)pentan-2~ol;

2-(3 ,4-Dihydro-2H-quinoxalin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)- 4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-methyl-3,4-dihydro-2H- quinoxalin- 1 -ylmethyl)pentan-2-ol;

2-[ 1 ,4]Diazepan- 1 -ylmethyl- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-methyl-[ 1 ,4]diazepan- 1 - ylmethyl)pentan-2-ol;

l-{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydrOxy-4-methyl-2-trifluoromethylpentyl]- [ 1 ,4]diazepan- 1 -yl} ethanone;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydrOxy-4-methyl-2-trifluoromethylpentyl]- [ 1 ,4]diazepane- 1 -carbaldehyde;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-thiomoφholin-4- ylmethylpentan-2-ol; 1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-( 1 -oxo- 1 λ⁵-thiomoφholin-4- ylmethyl)pentan-2-ol;

2-(l , l-Dioxo-lλ⁶-thiomoφholin-4-ylmethyl)-l , 1 , 1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

2-(2,3-Dihydrobenzo[ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-( 1 -oxo-2,3-dihydro- IH- 1 λ⁴- benzo[ 1 ,4]thiazin-4-ylmethyl)pentan-2-ol;

l-{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } ethanone;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-2-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

1 -[4-(6-Bromobenzo[ 1 ,3]dioxol-4-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(4-hydroxybiphenyl-3-yl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-hydroxyphenyl]-2-hydroxy-4-methyl-2- frifluoromethylpentyl} - lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-methoxyphenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl}-lH-quinolin-4-one; l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [l,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-[l,5]naphthyridin-4-one;

l-[2-Ηy<froxy-4-methyl-4-(3-pyridm-3-ylphenyl)-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-moφholin-4-ylmethylphenyl)-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-moφholin-4-ylmethylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-hydroxymethyl-2-methoxyphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

4-Methoxy-3 -[4,4,4-frifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzaldehyde;

1 -[4-(5-[ 1 ,3]Dioxan-2-yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

1 -[4-(5-Furan-3 -yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- 1H- quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- frifluoromethylpentyl]-3,5-dimethyl-lH-pyridin-4-one; l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinazolin-4-one;

l-[2-Ηydroxy-4-(4-methoxybiphenyl-3-yl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Acetyl-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[3,3,3-Trifluoro-2-(6-fluoro-4-methylchroman-4-yhnethyl)-2-hydroxypropyl]-lH- quinolin-4-one;

l-(4-{3-[l-(Benzyloxyimino)ethyl]phenyl}-2-hydroxy-4-methyl-2- trifluoromethylpentyl)-lH-quinolin-4-one;

l-[4-(3-Cyclopropanecarbonylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Acetyl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-(2-Ηydroxy-4-{3-[l-(methoxyimino)ethyl]phenyl}-4-methyl-2 -trifluoromethylpentyl)- lH-quinolin-4-one;

l-[4-(5-Bromo-2-hyαrOxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -(2-Ηydroxy-4- {3 -[ 1 -(hydroxyimino)ethyl]phenyl} -4-methyl-2-trifluoromethylpentyl)- lH-quinolin-4-one;

l-[4-(5-Bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3,5-Difluorophenyl)-2-hydroxy-4-methyl-2-trifluoromexhylpentyl]-lH-quinolin-4- one; l-[4-(3,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-{2-Ηydroxy-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2-yl)phenyl]-2- trifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(2,3-Dihyαj^,obenzofuran-7-yl)-2-hyαi'oxy-4-methyl-2-frifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[2-Ηydroxy-4-(3-hydroxymethylphenyl)-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3-[l,3]Dioxan-2-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-{4-[3-(3,5-Dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethyl- lH-pyridin-4-one;

l-{2-Ηydroxy-4-[3-(l-hydroxyethyl)phenyl]-4-methyl-2-trifluoromethylpentyl}-lH- quinolin-4-one;

l-[4-(2,3-Dmydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one; 3-[4,4,4-Trifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin-l- ylmethyl)butyl]benzaldehyde;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-(4-imino-4H-quinolin- 1 -ylmethyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3- hydroxymethyl- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- hydroxy-2-methyl-lH-pyridin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3- methoxy-2-methyl-lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-6- hydroxy- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methoxymethyl- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-7- hydroxy- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-7- methoxy- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-6- methoxy- lH-quinolin-4-one; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-6- methyl- lH-quinolin-4-one;

6-Chloro-l-[4-(5-fluoro-2-hydroxyplιenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one;

l-[-4-(2-Difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

6-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-methylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-{2-ΗydjOxy-4-methyl-4-[3-(2-oxopropoxy)phenyl]-2-trifluoromethylpentyl}-lH- quinolin-4-one;

1 -[2-Ηydroxy-4-(3 -isopropoxyphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4- one;

l-[4-(3-Ethoxyphenyl)-2-hyάrOxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-methylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2,5-Dimethylphenyl)-2-hyα^oxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one: l-[2-Hydroxy-4-(3-hydroxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[2-Ηydroxy-4-(3-methoxyphenyl)-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1 ,2- dihydroindazol-3 -one;

7-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3,5- dimethyl- lH-pyridin-4-one;

7-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-(2-Ηydroxy-4-methyl-4-phenyl-2-trifluoromethylhexyl)-lH-quinolin-4-one;

2-(3 ,4-Dihydro-2H-quinolin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

\ l-[4-(4-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]piperidin- 4-ol;

l-[4-(3,4-Dimethylphenyl)-2-hydroxy-4-methyl-2-frifluoromexhylpentyl]-lH-quinolin-4- one;

8-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one; 6-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-{4-[5-Fluoro-2-(2-hydroxypropoxy)phenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl} - lH-quinolin-4-one;

l-{4-[5-Fluoro-2-(2-oxopropoxy)phenyl]-2-hydroxy-4-methyl-2 -trifluoromethylpentyl} - lH-quinolin-4-one;

7-Chloro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(2-Benzyloxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2-Ethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

8-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydrOxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfinyl-2,3-dihy(frobenzofuran-7-yl)-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7-yl)-2- frifluoromethylpentyl]-lH-quinolin-4-one; 7-Chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperidine-4-carboxylic acid amide;

l-[4-(2,3-Dihydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- IH-quinolin- 4-one;

l-[4-(3-Fluoro-4-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

3-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3H- quinazolin-4-one;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-l- methyl-3 ,4-dihydro- lH-quinoxalin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydrOxy-4-methyl-2-trifluoromethylpentyl]-lH- pyridin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-4,6- dimexhyl-2-oxo-l,2-dihydropyridine-3-carbonitrile;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-4- methyl- lH-quinolin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3-nitro- 5-trifluoromethyl-lH-pyridin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-nitro- lH-pyridin-2-one; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-5-nitro- lH-pyridin-2-one;

3-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-5-frifluoromethyl-lH-pyridin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-4- methyl- lH-pyridin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-4- methyl-3 -nitro- lH-pyridin-2-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-4- methyl-5-nifro- lH-pyridin-2-one;

2-(3 ,4-Dihydro- lH-isoquinolin-2-ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

2-( 1 ,3 -Dihydroisoindol-2 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-(2,3-Dihydroindol- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-l,3- dihydroindol-2-one;

l-[4-(3-Dimethylaminomethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3-Diethylaminomethylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(3-{[(2-Dimethylannnoe yl)methylammo]methyl}phenyl)-2-hy(froxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

1 - {2-Ηydroxy-4-[3 -(3 -hydroxypyrrolidin- 1 -ylmethyl)phenyl] -4-methyl-2- trifluoromethylpentyl}-lH-quinolin-4-one;

l-[4-(3-Ethylaminomethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(3-pyrrolidin-l-ylmethylphenyl)-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(3-piperidin-l-ylmethylphenyl)-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-{2-Ηydroxy-4-methyl-4-[3-(4-methylpiperazin-l-ylmethyl)phenyl]-2- trifluoromethylpentyl} - lH-quinolin-4-one;

l-{4-[3-(3-Dimethylaminopyrrolidin-l-ylmethyl)phenyl]-2-hydroxy-4-methyl-2- trifluoromethylpentyl}-lH-quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(3-methylaminomexhylphenyl)-2-frifluoromethylpentyl]-lH- quinolin-4-one;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperazin- 1-yl} furan-2-ylmethanone;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-mexhyl-2- frifluoromethylpentyl]-3-methyl-lH-quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one; l-[4-(5-Chloro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-3-methyl-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl- lH-quinolin-4-one;

7-[4,4,4-Trifluoro-3-hydroxy- 1 , 1 -dimethyl-3-(3-methyl-4-oxo-4H-quinolin- 1- ylmethyl)butyl]-2,3-dihydrobenzofuran-5-sulfonic acid amide;

l-[2-Ηydroxy-4-(2-methoxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[4-(3-Acetyl-2-hydrOxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3-Acetyl-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[4-(3-Bromo-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxybiphenyl-3-yl)-4-methyl-2-trifluoromexhylpentyl]-lH- quinolin-4-one;

l-(4-Chroman-8-yl-2-hydroxy-4-methyl-2-frifluoromethylpentyl)-lH-quinolin-4-one;

1 -(4-Chroman-8-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-3 -methyl- lH-quinolin- 4-one; l-[4-(2-Acetyl-5-fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methanesulfonylphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

4-Fluoro-2-[4,4,4-trifluoro-3-hydroxy-l , 1 -dimethyl-3-(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzenesulfonamide;

4-Fluoro-2-[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3-(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzamide;

4-Fluoro-NN-dimethyl-2-[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 -ylmethyl)butyl]benzamide;

l-[4-(5-Fluoro-2-oxazol-2-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-oxazol-5-ylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -[2-Ηydroxy-4-(2-hydroxy-3 -oxazol-2-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-3-oxazol-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl} furan-2-ylmethanone;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } thiophen-2-ylmethanone;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } phenylmethanone; {4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } -(4-fluorophenyl)methanone;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydjOxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } -(2-fluorophenyl)methanone;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin-l-yl}-(3-fluorophenyl)methanone;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl} furan-2-ylmethanone;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin-l-yl}thiophen-2-ylmethanone;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl }phenylmethanone;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } -(4-fluorophenyl)methanone;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin-l-yl}-(2-fluorophenyl)methanone;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin- 1 -yl } -(3 -fluorophenyl)methanone;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-5,6,7,8- tetrahydro- lH-quinolin-4-one;

l-[2-Ηyάi'oxy-4-(5-me1hanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-5,6,7,8-tetrahydro-lH-quinolin-4-one; l-[4-(2,3-Dmydrobenzo&ran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-5- methyl-5,6,7,8-tefrahydro- lH-[ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzoftιran-7-yl)-4-methyl-2- trifluoromethylpentyl]-5,6,7,8-tefrahydro-lH-[l,5]naphthyridin-4-one;

l-[4-(4-Fluoro-3-moφholin-4-ylmethylphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Fluoro-4-moφholin-4-ylmethylphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(2- { [Ethyl-(2-methoxyethyl)amino]methyl}phenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

2-[4-(3-Chloro-5-trifluoromethylpyridin-2-yl)piperazin- 1 -ylmethyl]- 1 ,1,1 -trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-ol;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperazin- 1 -yl} furan-2-ylmexhanone;

1 -(4- {4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperazin-l-yl}phenyl)ethanone;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[4-(4-fluorophenyl)piperazin- 1 - ylmethyl]-4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-phenylpiperazin- 1 - ylmethyl)pentan-2-ol;

2-[4-(2,4-Difluorophenyl)piperazin-l -ylmethyl]- 1 ,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperazine-l -carboxylic acid ethyl ester; {4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyljpiperazin- 1 -yl} -(tetrahydrofuran-2-yl)methanone;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperazine-l -carboxylic acid benzyl ester;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-pyrimidin-2-ylpiperazin- 1 - ylmethyl)pentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperidine-3 -carboxylic acid amide;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- [l,4]diazepane-l-carboxylic acid benzyl ester;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-[4-(5-pyrazin-2-yl- [ 1 ,3,4]oxadiazol-2-yl)piperidin- 1 -ylmethyl]pentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-pyridin-2-ylpiperazin- 1 - ylmethyl)pentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperidine-4-carboxylic acid methyl ester;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperazin-2-one;

l-{l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperidin-4-yl}-l,3-dihydrόbenzoirnidazol-2-one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(octahydroisoquinolin-2- ylmethyl)pentan-2-ol; {4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperazin-l-yl} acetic acid ethyl ester;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3,3- dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3,3- dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-3,3-dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-3,3-dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[4-(2,3-Dmydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,3- dimethyl-2,3 -dihydro- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,3- dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[4-(2-Acetyl-5-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,3- dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-3,3- dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-3,3- dimethyl-2,3-dihydro-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- 3 ,3 -dimethyl-2,3 -dihydro- lH-quinolin-4-one;

l-[4-(3-Ethoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,3-dimethyl-2,3- dihydro- lH-quinolin-4-one; 7-[4,4,4-Trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(3 -methyl-4-oxo-4H-quinolin- 1 - ylmethyl)butyl]-2,3-dihydrobenzofuran-5-sulfonic acid dimethylamide;

l-[4-(4-Bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-methyl-lH- quinolin-4-one;

4-[4,4,4-Trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(3 -methyl-4-oxo-4H-quinolui- 1 - ylmethyl)butyl]benzonitrile;

7-[4,4,4-Trifluoro-3-hydroxy- 1 , 1 -dimethyl-3-(4-oxo-4H-quinolin- 1 -ylmethyl)butyl]-2,3- dihydrobenzofuran-5-sulfonic acid dimethylamide;

l-[4-(4-Bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

4-[4,4,4-Trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzonitrile;

3-Methyl-l-[3,3,3-frifluoro-2-(6-fluoro-4-methylchroman-4-ylmethyl)-2-hydroxypropyl]- lH-quinolin-4-one;

3-Methyl-l-[3,3,3-frifluoro-2-(6-fluoro-4-methylchroman-4-ylmethyl)-2 -hydroxypropyl]- 1H-[1 ,5]naphthyridin-4-one;

l-[3,3,3-Trifluoro-2-(6-fluoro-4-me ylchroman-4-ylmethyl)-2-hydroxypropyl]-lH- [ 1 ,5]naphthyridin-4-one;

2-(4-Benzylpiperazin-l-ylmethyl)-l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-(4-Benzo[ 1 ,3]dioxol-5-ylmethylpiperazin- 1 -ylmethyl)-l , 1 , 1 -frifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(2-methylpiperidin- 1 - ylmethyl)pentan-2-ol; 1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-frifluoromethylpiperidin- 1 - ylmethyl)pentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[4-(4-fluorophenyl)piperidin- 1 - ylmethyl]-4-methylpentan-2-ol;

2-[4-(4-Bromophenyl)piperidin- 1 -ylmethyl]- 1 ,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-methylpiperidin- 1 - ylmethyl)pentan-2-ol;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- [l,4]diazepane-l -carboxylic acid tert-butyl ester;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperazine-l -carboxylic acid tert-butyl ester;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[4-(2-methoxyphenyl)piperazin- 1 - ylmethyl]-4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-pyrrolidin- 1 -ylpiperidin- 1 - ylmethyl)pentan-2-ol;

2-[l,4']Bipiperidinyl- -ylmethyl-l,l,l-trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-[4-(2-Ethoxyethyl)piperazin- 1 -ylmethyl]- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)- 4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[4-(2-methoxyethyl)piperazin- 1 - ylmethyl]-4-methylpentan-2-ol; 2-(4-Benzylpiperidin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperidine-3 -carboxylic acid diethylamide;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperidine-3 -carboxylic acid ethyl ester;

1 - { 1 -[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperidin-4-yl}-l,3-dihydroindol-2-one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-(4-phenylpiperidin- 1 - ylmethyl)pentan-2-ol;

2-(4-Benzylpiperidin- 1 -ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-2-[4-( lH-indol-2-yl)piperidin- 1 -ylmethyl]- 4-methylpentan-2-ol;

5-Chloro- 1 - { 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]piperidin-4-yl}-l,3-dihydrobenzoimidazol-2-one;

{ 1 -[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperidin-4-yl} acetic acid ethyl ester;

2-[4-(2,4-Dimethylphenyl)piperazin- 1 -ylmethyl]- 1 ,1,1 -frifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

2-(4-Benzyl-[ 1 ,4]diazepan-l -ylmethyl)- 1,1,1 -frifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]piperazine- 1 -carbaldehyde; 4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methoxycarbonylmethylpiperazine-1 -carboxylic acid tert-butyl ester;

2-(4-tert-Butylpiperazin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

2-(3-Dimethylaminopyrrolidin- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-pyrrolidin- 1 -ylmethylpentan- 2-ol;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-piperidin- 1 -ylmethylpentan-2- ol;

Carbonic acid ethyl ester 4-fluoro-2-[4,4,4-trifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo- 4H-quinolin- 1 -ylmethyl)butyl]phenyl ester;

Ethylcarbamic acid 4-fluoro-2-[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H- quinolin- 1 -ylmethyl)butyl]phenyl ester;

Ethylcarbamic acid 4-fluoro-2-[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(3 -methyl-4- oxo-4H-quinolin- 1 -ylmethyl)butyl]phenyl ester;

Ethylcarbamic acid 2-[3-(3,3-dimethyl-4-oxo-3,4-dihydro-2H-quinolin-l-ylmethyl)-4,4,4- trifluoro-3 -hydroxy- 1 , 1 -dimethylbutyl]-4-fluorophenyl ester;

Methylcarbamic acid 2-[4,4,4-frifluoro-3 -hydroxy- 1 , 1 -dimethyl-3-(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]phenyl ester;

Carbonic acid 2-[3-(3,5-dimethyl-4-oxo-4H-pyridin-l-ylmethyl)-4,4,4-frifluoro-3- hydroxy-l,l-dimethylbutyl]-4-fluorophenyl ester methyl ester; Methylcarbamic acid 2-[3-(3,5-dimethyl-4-oxo-4H-pyridin-l-ylmethyl)-4,4,4-trifluoro-3- hydroxy- 1 , 1 -dimethylbutyl]-4-fluorophenyl ester;

Cyclopropylcarbamic acid 2-[4,4,4-frifluoro-3-hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H- quinolin- 1 -ylmethyl)butyl]phenyl ester;

l-Cyclopropyl-3- {2-[4,4,4-frifluoro-3-hydroxy- 1 , 1 -dimethyl-3-(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]phenyl} urea;

l-Cyclopropyl-3-{2-[4,4,4-trifluoro-3-hydroxy-l,l-dimethyl-3-(3-methyl-4-oxo-4H- quinolin- 1 -ylmethyl)butyl]phenyl}urea;

1 -Methyl-3- {2-[4,4,4-trifluoro-3-hydroxy- 1 , 1 -dimethyl-3 -(3 -methyl-4-oxo-4H-quinolin- 1 -ylmethyl)butyl]phenyl } urea;

l-{2-[3-(3,3-Dimethyl-4-oxo-3,4-dihydro-2H-quinolin-l-ylmethyl)-4,4,4-frifluoro-3- hydroxy- 1 , 1 -dimethylbutyl]phenyl} -3-methylurea;

l-(2,2,3,3-Tetramethylcyclopropyl)-3-{2-[4,4,4-trifluoro-3-hydroxy-l,l-dimethyl-3-(4- oxo-4H-quinolin-l-ylmethyl)butyl]phenyl}urea;

(2,2,3,3-Tetramethylcyclopropyl)carbamic acid 2-[4,4,4-trifluoro-3 -hydroxy- 1,1- dimethyl-3 -(4-oxo-4H-quinolin- 1 -ylmethyl)butyl]phenyl ester;

Dimethylcarbamic acid 2-[4,4,4-trifluoro-3-hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- l-ylmethyl)butyl]phenyl ester;

Dimethylcarbamic acid 2-[4,4,4-trifluoro-3-hydroxy-l,l-dimeιhyl-3-(3-methyl-4-oxo-4H- quinolin- 1 -ylmethyl)butyl]phenyl ester;

Pyrrolidine- 1 -carboxylic acid 2-[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3-(4-oxo-4H- quinolin- 1 -ylmethyl)butyl]phenyl ester; Pyrrolidine- 1 -carboxylic acid 2-[3 -(3 ,3 -dimethyl-4-oxo-3 ,4-dihydro-2H-quinolin- 1 - ylmethyl)-4,4,4-trifluoro-3-hydroxy-l,l-dimethylbutyl]phenyl ester;

l-[2-Ηydroxy-4-(2-methoxy-5-pyridin-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(3-[l,3]Dioxan-2-yl-4-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-pyrirnidin-5-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(4-[l,3]Dioxan-2-yl-3-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyridin-3-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηyάroxy-4-(2-hydroxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one;

Carbonic acid 4-fluoro-2-[4,4,4-frifluoro-3-hydroxy- 1 , 1 -dimethyl-3-(4-oxo-4H-quinolin- l-ylmethyl)butyl]phenyl ester methyl ester;

l-[4-(2,3-Dmydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-[ 1 ,5]naphthyridin-4-one; and

1 -(4-Benzo[ 1 ,3]dioxol-4-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)-3 -methyl- 1H- [ 1 ,5]naphthyridin-4-one,

or a tautomer, prodrug, solvate, or salt thereof.

6. A compound according to claim 5, the compound selected from:

Preferred compounds of Formula (IA) include the following:

2-( 1 , 1 -Dioxo-2,3-dihydro- IH- lλ⁶-benzo[ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethylpiperidin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpenxyl]-lH- cinnolin-4-one;

l-[4-(4-Fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(3-Fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one; l-[4-(3-Fluoro-4-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(4-Fluoro-2-hyάroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-Phenyl-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Bromo-2,3-dmydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- teifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Methyl-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Chloro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- [1 ,5]naphthyridin-4-one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyh2-( 1 -oxo-2,3-dihydro- IH- lλ⁴- benzo[l,4]thiazin-4-ylmethyl)pentan-2-ol; l-[2-Hydroxy-4-(2-methoxy-5-thiophen-2-ylphenyl)-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one;

1 -[4-(6-Bromobenzo[ 1 ,3]dioxol-4-yl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- 1H- quinolin-4-one;

l-[2-Ηydroxy-4-(4-hydroxybiphenyl-3-yl)-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηyώoxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]- lH-[ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-methyl-4-(3-pyridin-3-ylphenyl)-2-trifluoromethylpentyl]-lH-quinolin- 4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-moφholin-4-ylmethylphenyl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one; l-[2-Hydroxy-4-(5-hydroxymethyl-2-methoxyphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-[l,3]Dioxan-2-yl-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hyQroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinazolin-4-one;

1 -[2-Ηydroxy-4-(4-methoxybiphenyl-3 -yl)-4-methyl-2-frifluoromethylpentyl]- 1H- quinolin-4-one;

l-[3,3,3-Trifluoro-2-(6-fluoro-4-methylchroman-4-ylmethyl)-2-hydroxypropyl]-lH- quinolin-4-one;

l-[4-(3-Cyclopropanecarbonylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(5-Acetyl-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

1 -(2-Ηydroxy-4- {3-[ 1 -(methoxyimino)ethyl]phenyl} -4-methyl-2-frifluoromethylpentyl)- lH-quinolin-4-one;

l-[4-(5-Bromo-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

1 -(2-Ηydroxy-4- {3-[ 1 -(hydroxyimino)ethyl]phenyl} -4-methyl-2-frifluoromethylpentyl)- lH-quinolin-4-one;

l-[4-(5-Bromo-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-qne;

l-[4-(3,5-Difluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(3,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-{2-Ηydroxy-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2-yl)phenyl]-2- frifluoromethylpentyl} - lH-quinolin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3 ,5-dimethyl- lH-pyridin-4-one;

l-[4-(2,3-Dmydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(3-hydroxymethylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3-[l,3]Dioxan-2-ylphenyl)-2-hydJOxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(3-Acetylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4-one;

l-{4-[3-(3,5-Dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2- frifluoromethylpentyl} - lH-quinolin-4-one;

1- {2-Ηydroxy-4-[3-(l -hydroxyethyl)phenyl]-4-methyl-2-trifluoromethylpentyl} - 1H- quinolin-4-one;

l-[4-(2,3-DihyQrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-7- hydroxy- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromexhylpentyl]-6- methyl- lH-quinolin-4-one; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3- hydroxymethyl-lH-quinolin-4-one;

6-Chloro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[-4-(2-Difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl] - lH-quinolin-4-one;

l-{2-Ηydroxy-4-methyl-4-[3-(2-oxopropoxy)phenyl]-2-trifluoromethylpentyl}-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(3-isopropoxyphenyl)-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(2,5-Dimemylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[2-Ηydroxy-4-(3-hydroxyphenyl)-4-methyl-2-frifluoromethylpentyl]-lH-quinolin-4- one; l-[2-Hydroxy-4-(3-methoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- 1 ,2- dihydroindazol-3 -one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethyl- lH-pyridin-4-one;

l-(2-Ηydroxy-4-methyl-4-phenyl-2-trifluoromethylhexyl)-lH-quinolin-4-one;

l-[4-(4-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(3,4-Dimemylphenyl)-2-hydroxy-4-metJιyl-2-ttifluoromethylpentyl]-lH-quinolin-4- one;

8-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydiOxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-hy(froxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

1 - {4-[5-Fluoro-2-(2-oxopropoxy)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl} - lH-quinolin-4-one;

7-Chloro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- lH-quinolin-4-one; l-[4-(5-Fluoro-2-isopropoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

8-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl] - lH-quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- xrifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(5-methanesulfinyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-methyl-4-(5-methylsulfanyl-2,3-dihydrobenzofuran-7-yl)-2- trifluoromethylpentyl]-lH-quinolin-4-one;

7-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl] - lH-quinolin-4-one;

l-[4-(3-Fluoro-4-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3-nitro- 5-trifluoromethyl-lH-pyridin-2-one;

3-Chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-5-trifluoromethyl-lH-pyridin-2-one; 2-(2,3-Dihydroindol- 1 -ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-mexhoxyphenyl)-4- methylpentan-2-ol;

l-[2-Hydroxy-4-methyl-4-(3-moφholin-4-ylmethylphenyl)-2-teifluoromethylpentyl]-lH- quinolin-4-one;

{4-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-- ttifluoromethylpentyl]piperazin-l-yl}furan-2-ylmethanone;

l-[2-Ηydroxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- frifluoromethylpentyl]-3-methyl-lH-quinolin-4-one;

2-[4-(3-Chloro-5-trifluoromexhylpyridin-2-yl)piperazin-l -ylmethyl]- 1 , 1 , 1 -trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-ol;

{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- teifluoromethylpentyl]piperazin- 1 -yl} furan-2-ylmethanone;

l-[2-Ηydroxy-4-(2-methoxy-5-pyrimidin-5-ylphenyl)-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(5-Fluoro-2-methylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(4-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

1 -(4-Benzo[ 1 ,3]dioxol-4-yl-2-hydroxy-4-methyl-2-trifluoromethylpentyl)- lH-quinolin-4- one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-l,2- dihydroindazol-3 -one;

2-(3 ,4-Dihydro-2H-quinoxalin- 1 -ylmethyl)- 1 ,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)- 4-methylpentan-2-ol;

l-{4-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,4- dihydro-2H-quinoxalin-l-yl}ethanone;

l-[2-Ηydroxy-4-(2-hydroxy-5-thiophen-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(2,3-Dmyαjobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one; l-[2-Hydroxy-4-(2-methoxy-3,5-dimethylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyridin-3-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hyαj^,oxy-5-pyrinrndin-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one; and

Carbonic acid 4-fluoro-2-[4,4,4-frifluoro-3-hydroxy-l,l-dimethyl-3-(4-oxo-4H-quinolin- l-ylmethyl)butyl]phenyl ester methyl ester,

or a tautomer, prodrug, solvate, or salt thereof.

7. A compound according to claim 6, the compound selected from:

2-(2,6-Dimethylmoφholin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2-methoxyphenyl)-4- methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimexhylpiperidin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-2,3- dihydro- lH-quinolin-4-one;

l-[4-(3-Fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one; l-[4-(4-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-Phenyl-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2,3-dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Bromo-2,3 -dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

1 -[4-(5-Chloro-2,3 -d ydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2- frifluoromethylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- [ 1 ,5]naphthyridin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-thiophen-2-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

l-[4-(5-Fluoro-2-hy(froxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one; l-[2-Hydroxy-4-(4-hydroxybiphenyl-3-yl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-{4-[5-(3,5-Dimethylisoxazol-4-yl)-2-hydroxyphenyl]-2-hydroxy-4-methyl-2- frifluoromexhylpentyl}-lH-quinolin-4-one;

4-Methoxy-3-[4,4,4-trifluoro-3 -hydroxy- 1 , 1 -dimethyl-3 -(4-oxo-4H-quinolin- 1 - ylmethyl)butyl]benzaldehyde;

l-[4-(5-Furan-3-yl-2-mexhoxyphenyl)-2-hydroxy-4-methyI-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(5-Acetyl-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-ttifluoromethylpentyl]-lH- quinolin-4-one;

l-[3,3,3-Trifluoro-2-(6-fluoro-4-me ylchroman-4-ylmethyl)-2-hydroxypropyl]-lH- quinolin-4-one; l-(4-{3-[l-(Benzyloxyimino)ethyl]phenyl}-2-hydroxy-4-methyl-2- trifluoromethylpentyl)-lH-quinolin-4-one;

l-(2-Ηydroxy-4-{3-[l-(methoxyimino)ethyl]phenyl}-4-methyl-2-frifluoromethylpentyl)- lH-quinolin-4-one;

1 -(2-Ηydroxy-4- {3-[l -(hydroxyimino)ethyl]phenyl} -4-methyl-2-frifluoromethylpentyI)- lH-quinolin-4-one;

l-[4-(3,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-{2-Ηydroxy-4-methyl-4-[3-(2-methyl-[l,3]dioxolan-2-yl)phenyl]-2- trifluoromethylpentyl}-lH-quinolin-4-one;

l-[4-(3-[l,3]Dioxan-2-ylphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-{4-[3-(3,5-Dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2- frifluoromexhylpentyl}-lH-quinolin-4-one; l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3,5- dimethyl- lH-pyridin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyI-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-6- methyl- lH-quinolin-4-one;

6-Chloro-l-[4-(5-fluoro-2-hydrox3φhenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[-4-(2-Difluoromethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-methylphenyl)-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

l-[2-Ηydroxy-4-(3-isopropoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[4-(3-Ethoxyphenyl)-2-hydroxy-4-methyl-2-xrifluoromethylpentyl]-lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-methoxy-5-methylphenyl)-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one; l-[4-(2,5-Dimethylphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

l-[2-Hydroxy-4-(3-methoxyphenyl)-4-methyl-2-trifluoromethylpentyl]-lH-quinolin-4- one;

1 -[4-(5-Fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]- 1 ,2- dihydroindazol-3 -one;

7-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-(2-Ηydroxy-4-methyl-4-phenyl-2-trifluoromethylhexyl)-lH-quinolin-4-one;

1 -[4-(3 ,4-Dimethylphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4- one;

8-Fluoro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-hyάrOxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one;

7-Chloro-l-[4-(5-fluoro-2-hydroxyphenyl)-2-hydroxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one; l-[4-(5-Fluoro-2-isopropoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-lH- quinolin-4-one;

l-[4-(2-Ethoxy-5-fluorophenyl)-2-hydroxy-4-methyl-2-frifluoromethylpentyl]-lH- quinolin-4-one;

6-Fluoro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hychOxy-4-methyl-2 -trifluoromethylpentyl]- lH-quinolin-4-one;

l-[2-Ηy(froxy-4-(5-methanesulfonyl-2,3-dihy(frobenzofuran-7-yl)-4-methyl-2- trifluoromethylpentyl]-lH-quinolin-4-one;

7-Chloro- 1 -[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl] - lH-quinolin-4-one ;

3-Chloro-l-[4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2- trifluoromethylpentyl]-5-trifluoromethyl-lH-pyridin-2-one;

l-[2-Hyaj-oxy-4-(5-methanesulfonyl-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- teifluoromethylpentyl]-3-methyl-lH-quinolin-4-one;

1 -[4-(3-[ 1 ,3]Dioxan-2-yl-4-fluorophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one; 2-( 1 , 1 -Dioxo-2,3 -dihydro- IH- lλ⁶-benzo[ 1 ,4]thiazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5- fluoro-2-methoxyphenyl)-4-methylpentan-2-ol;

2-(2,3-Dihydrobenzo[ 1 ,4]oxazin-4-ylmethyl)- 1,1,1 -trifluoro-4-(5-fluoro-2- methoxyphenyl)-4-methylpentan-2-ol;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hyάrOxy-4-methyl-2-frifluoromethylpentyl]-l,2- dihydroindazol-3 -one;

1,1,1 -Trifluoro-4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-( 1 -oxo-2,3-dihydro- IH- lλ⁴- benzo[ 1 ,4]thiazin-4-ylmethyl)pentan-2-ol; l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-2- hydroxymethyl-3,5-dimethyl-lH-pyridin-4-one;

l-[4-(2,3-Dihydrobenzofuran-7-yl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-3- methyl- lH-quinolin-4-one;

l-[2-Ηydroxy-4-(2-hydroxy-5-pyridin-3-ylphenyl)-4-methyl-2 -trifluoromethylpentyl] - lH-quinolin-4-one; and

l-[2-Ηydroxy-4-(2-hydroxy-5-pyrimidin-5-ylphenyl)-4-methyl-2-trifluoromethylpentyl]- lH-quinolin-4-one,

or a tautomer, prodrug, solvate, or salt thereof.

8. A pharmaceutical composition comprising an effective amount of a compound according to one of claims 1 to 7, or a tautomer, prodrug, solvate, or salt thereof, and a pharmaceutically acceptable excipient or carrier.

9. A method of modulating the glucocorticoid receptor function in a patient, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 1 to 7, or a tautomer, prodrug, solvate, or salt thereof.

10. A method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 1 to 7, or a tautomer, prodrug, solvate, or salt thereof.

11. A method of treating a disease-state or condition selected from: type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma, in a patient in need of such freatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 1 to 7, or a tautomer, prodrug, solvate, or salt thereof.

12. A method of treating a disease characterized by inflammatory, allergic, or proliferative processes, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 1 to 7, or a tautomer, prodrug, solvate, or salt thereof.

13. The method according to claim 12, wherein the disease is selected from: type I diabetes (insulin-dependent diabetes), osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone resoφtion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute purulent meningitis, necrotizing enterocolitis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.

14. The method according to claim 12, wherein the disease is selected from: (i) lung diseases; (ii) rheumatic diseases/autoimmune diseases/joint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft-versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis.

15. A method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising sequentially or simultaneously administering to the patient: (a) an effective amount of a pharmaceutically acceptable compound according to one of claims 1 to 7 or a tautomer, prodrug, solvate, or salt thereof; and (b) a pharmaceutically acceptable glucocorticoid.

16. A compound of Formula (IB)

wherein:

wherein each substituent group of R¹ is independently C₁-C₅ alkyl, C₂-Cs alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C - C₅ alkenyloxy, C₂-C5 alkynyloxy, aryloxy, acyl, C₁-C5 alkoxycarbonyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkanoyl, aroyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, - C5 alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, oxo, carboxy, cyano, trifluoromethyl, trifluoromethoxy, nifro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C_.-C₅ alkyl or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with one to three substituent groups selected from aryl or heterocyclyl wherein the heterocycle is optionally independently substituted with hydroxyl, halogen, methyl, dialkyl amino; methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino wherein the nitrogen atom is optionally independently mono- or di- substituted by C₁-C5 alkyl or Cj-C₃ dialkylamines or aryl; or ureido wherein either nitrogen atom is optionally independently substituted with C_-C₅ alkyl; aminosulfonyl, oxime wherein the oxygen atom is optionally substituted by C C₅ alkyl or benzyl. R² and R³ are each independently hydrogen, C_-C₅ alkyl, or C₅-C₁₅ arylalkyl group, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-Cg spiro cycloalkyl ring, or

R¹ and R² when taken together are a chromanyl or dihydrobenzofuranyl optionally substituted with C_.-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, C₁-C₅ alkoxy, C₂-C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, C₁-C5 alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C_.-C5 alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C5 alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nifrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with Cι-C₃ alkyl; or C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone;

R⁴ is carbonyl or methylene optionally independently substituted with one to two substituent groups selected from C_-C₃ alkyl, hydroxy, and halogen;

R⁵ is a pyrrolidine, moφholine, thiomoφholine, piperazine, piperidine, lH-pyridin-4- one, lH-pyridin-2-one, lH-pyridin-4-ylideneamine, lH-quinolin-4-ylideneamine, pyran, tefrahydropyran, 1,4-diazepane, 2,5-diazabicyclo[2.2.1]heptane, 2,3,4,5- tefrahydrobenzo[b][l,4]diazepine, dihydroquinoline, tefrahydroquinoline, 5,6,7,8- tefrahydro-lH-quinolin-4-one, tetrahydroisoquinoline, decahydroisoquinoline, 2,3- dihydro-lH-isoindole, 2,3-dihydro-lH-indole, chroman, 1,2,3,4- tetrahydroquinoxaline, l,2-dihydroindazol-3-one, 3,4-dihydro-2H- benzo[l,4]oxazine, 4H-benzo[l,4]thiazine, 3,4-dihydro-2H-benzo[l,4]xhiazine, 1,2- dihydrobenzo[<i][ 1 ,3]oxazin-4-one, 3,4-dihydrobenzo[l ,4]oxazin-4-one, 3H- quinazolin-4-one, 3,4-dihydro-lH-quinoxalin-2-one, lH-cinnolin-4-one, 1H- quinazolin-4-one, lH-[l,5]naphthyridin-4-one, 5,6,7,8-tefrahydro-lH-

[l,5]naphthyridin-4-one, 2,3-dihydro-lH-[l,5]naphthyridin-4-one, 1,2- dihydropyrido[3,2-d][l,3]oxazin-4-one, pyrrolo[3,4-c]pyridine-l,3-dione, 1,2- dihydropyπrolo[3,4-c]pyridin-3-one, or tefrahydro[b][l,4]diazepinone, group, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁵ is independently C_-C₅ alkyl, C₂-C5 alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, heterocyclyl, aryl, heteroaryl, Cj-C₅ alkoxy, C₂- C₅ alkenyloxy, C₂-C₅ alkynyloxy, aryloxy, acyl, C₁-C₅ alkoxycarbonyl, Cj-C₅ alkanoyloxy, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, Cj- C₅ alkylsulfonylamino, C₁-C₅ alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, oxo, cyano, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, nitro, or amino wherein the nitrogen atom is optionally independently mono- or di-substituted by C₁-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl; or C₁-C5 alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R⁵ is optionally independently substituted with one to three substituent groups selected from C-C₃ alkyl, Cι-C₃ alkoxy, C₁-C₃ alkoxy carbonyl, acyl, benzyl, heteroaryl, heterocyclyl, halogen, hydroxy, oxo, cyano, amino wherein the nitrogen atom is optionally independently mono- or di-substituted by Q-C₅ alkyl; or ureido wherein either nitrogen atom is optionally independently substituted with C₁-C₅ alkyl, or trifluoromethyl; and

is hydrogen, Cj-Cs alkyl, C₂-C₈ alkenyl, C₂-Cg alkynyl, carbocycle, heterocyclyl, aryl, heteroaryl, carbocycle-Ci-Cg alkyl, carboxy, alkoxycarbonyl, aryl-Q-Cg alkyl, aryl-Cj-Cg -haloalkyl, heterocyclyl-Cj-Cg alkyl, heteroaryl-Q-Cg alkyl, carbocycle- C₂-Cg alkenyl, aryl-C₂-Cg alkenyl, heterocyclyl-C₂-Cg alkenyl, or heteroaryl-C₂-C₈ alkenyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁶ is independently C₁-C₅ alkyl, C₂-C₅ alkenyl, C₂-C₅ alkynyl, C₃-C₈ cycloalkyl, phenyl, C₁-C₅ alkoxy, phenoxy, C₁-C₅ alkanoyl, aroyl, C1-C5 alkoxycarbonyl, C.-C5 alkanoyloxy, aminocarbonyloxy, Cj-C₅ alkylaminocarbonyloxy, C_.-C₅ dialkylaminocarbonyloxy, aminocarbonyl, Cj-C₅ alkylaminocarbonyl, C₁-C5 dialkylaminocarbonyl, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C5 alkylsulfonylamino, C₁-C₅ alkylaminosulfonyl, C_- C₅ dialkylaminosulfonyl, halogen, hydroxy, carboxy, cyano, oxo, trifluoromethyl, nitro, amino wherein the nitrogen atom is optionally independently mono- or di- substituted by C₁-C₅ alkyl; or ureido wherein either nifrogen atom is optionally independently substituted with C₁-C5 alkyl; or C_-C₅ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein R⁶ cannot be trifluoromethyl, and

or a tautomer, prodrug, solvate, or salt thereof.

17. The compound of Formula (IB) according to claim 16, wherein:

R¹ is phenyl, dihydrobenzofuranyl, benzofuranyl, dihydroindolyl, indolyl, benzo[l,3]dioxole, dihydrobenzothienyl, benzothienyl, benzoxazole, benzisoxazole, benzpyrazole, benzimidazole, thienyl, quinolinyl, tefrahydroquinolinone, tetrahydronaphthyridinone, dihydrochromene, pyridinyl, pyrimidinyl, or pyrazinyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R¹ is independently C_-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cj-C₃ alkoxy, C₂-C₃ alkenyloxy, Cj-C₃ alkanoyl, Cι-C₃ alkoxycarbonyl, C₁-C₃ alkanoyloxy, halogen, hydroxy, acyl, oxo, carboxy, cyano, trifluoromethyl, nitro, or C₁-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein each substituent group of R¹ is optionally independently substituted with a substituent group selected from methyl, methoxy, halogen, hydroxy, oxo, cyano, or amino; R² and R³ are each independently hydrogen, Q-C₃ alkyl, benzyl, or phenethyl, or R² and R³ together with the carbon atom they are commonly attached to form a C₃-C₆ spiro cycloalkyl ring;

R⁴ is CH₂; and

R⁶ is C_.-C₅ alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl, phenyl, C₃-C₆ cycloalkyl-C]-C₃ alkyl, phenyl-C_-C₃ alkyl, phenyl-C_-C₃ haloalkyl, C₃-C₆ cycloalkyl-C₂-C₃ alkenyl, phenyl-C₂-C₃ alkenyl, each optionally independently substituted with one to three substituent groups,

wherein each substituent group of R⁶ is independently Cι-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cj-C₃ alkoxy, aminocarbonyl, Cι-C₃ alkylaminocarbonyl, Cι-C₃ dialkylaminocarbonyl, halogen, hydroxy, oxo, carboxy, cyano, trifluoromethyl, nitro, or Q-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone,

wherein R⁶ cannot be trifluoromethyl,

or a tautomer, prodrug, solvate, or salt thereof.

18. The compound of Formula (IB) according to claim 16, wherein:

R⁴ is CH₂, or a tautomer, prodrug, solvate, or salt thereof.

19. The compound of Formula (IB) according to claim 16, wherein:

wherein each substituent group of R¹ is independently Cι-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, Cj-C₃ alkoxy, C₂-C₃ alkenyloxy, C_-C₃ alkanoyl, Cj-C₃ alkoxycarbonyl, C₁-C₃ alkanoyloxy, halogen, hydroxy, carboxy, cyano, trifluoromethyl, nifro, or Cj-C₃ alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxide or sulfone; and

R² and R³ are each independently hydrogen or Q-C₃ alkyl,

or a tautomer, prodrug, solvate, or salt thereof.

20. A compound selected from:

l-[2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH- quinolin-4-one;

l-[2-Difluoromethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH- quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin-4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-2-isopropyl-4-methylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-mexhoxyphenyl)-2-fluoromethyl-2-hydroxy-4-methylpentyl]-lH- quinolin-4-one; l-[2-Cyclobutyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin- 4-one;

l-[4-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-2,4-dimethylpentyl]-lH-quinolin-4-one; and

l-[2-Ethyl-4-(5-fluoro-2-methoxyphenyl)-2-hydroxy-4-methylpentyl]-lH-quinolin-4-one,

or a tautomer, prodrug, solvate, or salt thereof.

21. A pharmaceutical composition comprising an effective amount of a compound according to one of claims 16 to 20, or a tautomer, prodrug, solvate, or salt thereof, and a pharmaceutically acceptable excipient or carrier.

22. A method of modulating the glucocorticoid receptor function in a patient, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 16 to 20, or a tautomer, prodrug, solvate, or salt thereof.

23. A method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 16 to 20, or a tautomer, prodrug, solvate, or salt thereof.

24. A method of treating a disease-state or condition selected from: type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma, in a patient in need of such freatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 16 to 20, or a tautomer, prodrug, solvate, or salt thereof.

25. A method of treating a disease characterized by inflammatory, allergic, or proliferative processes, in a patient in need of such treatment, the method comprising administering to the patient an effective amount of a pharmaceutically acceptable compound according to one of claims 16 to 20, or a tautomer, prodrug, solvate, or salt thereof.

26. The method according to clahn 25, wherein the disease is selected from: type I diabetes (insulin-dependent diabetes), osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone resoφtion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to trauma, acute pumlent meningitis, necrotizing enterocohtis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.

27. The method according to claim 25, wherein the disease is selected from: (i) lung diseases; (ii) rheumatic diseases/autoimmune diseases/joint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft-versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis.

28. A method of treating a disease-state or condition mediated by the glucocorticoid receptor function in a patient in need of such treatment, the method comprising sequentially or simultaneously administering to the patient: (a) an effective amount of a pharmaceutically acceptable compound according to one of claims 16 to 20 or a tautomer, prodrug, solvate, or salt thereof; and (b) a pharmaceutically acceptable glucocorticoid.

29. Use of a compound according to claims 1 or 16 for the preparation of a pharmaceutical composition.

30. Use of a compound according to claims 1 or 16 in combination with a pharmaceutically acceptable glucocorticoid for the preparation of a pharmaceutical composition.

31. Use according to claims 27 and 28 to prepare a pharmaceutical composition for the treatment of a disease-state or condition mediated by the glucocorticoid receptor function; type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma; a disease characterized by inflammatory, allergic, or proliferative processes, (i) lung diseases; (ii) rheumatic diseases/autoimmune diseases/joint diseases; (iii) allergic diseases; (iv) vasculitis diseases; (v) dermatological diseases; (vi) renal diseases; (vii) hepatic diseases; (viii) gastrointestinal diseases; (ix) proctological diseases; (x) eye diseases; (xi) diseases of the ear, nose, and throat (ENT) area; (xii) neurological diseases; (xiii) blood diseases; (xiv) tumor diseases; (xv) endocrine diseases; (xvi) organ and tissue transplantations and graft- versus-host diseases; (xvii) severe states of shock; (xviii) substitution therapy; and (xix) pain of inflammatory genesis.

32. Use according to claims 27 and 28 to prepare a pharmaceutical composition for the treatment of: type I diabetes (insulin-dependent diabetes), osteoarthritis, Guillain-Barre syndrome, restenosis following percutaneous transluminal coronary angioplasty, Alzheimer disease, acute and chronic pain, atherosclerosis, reperfusion injury, bone resoφtion diseases, congestive heart failure, myocardial infarction, thermal injury, multiple organ injury secondary to frauma, acute pumlent meningitis, necrotizing enterocohtis and syndromes associated with hemodialysis, leukopheresis, and granulocyte transfusion.